{"meta":{"query_hash":"abc7a7fb8bc6","filters":{"venue":"European Urology Oncology"},"cohort_total":180,"direct_labels_cover":0,"predictions_cover":180,"exported":180,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/abc7a7fb8bc6","api":"https://metacan.xera.ac/api/v1/cohort?venue=European+Urology+Oncology"},"results":[{"id":"W2793748657","doi":"10.1016/j.euo.2019.03.007","title":"Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; Sunnybrook Hospital; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Janssen Biotech; National Cancer Institute; Foundation Medicine; Pfizer Canada; Novartis Pharmaceuticals Canada; Bristol-Myers Squibb Canada; Eisai; National Comprehensive Cancer Network; Ipsen; Astellas Pharma Canada; Genentech; AstraZeneca Canada; Novartis; GlaxoSmithKline; Merck; Exelixis; Bayer; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Celldex Therapeutics; Pfizer","keywords":"Medicine; Renal cell carcinoma; Nephrectomy; Papillary renal cell carcinomas; Carcinoma; Oncology; Internal medicine; Kidney; Database; Pathology; Urology","score_opus":0.0301147906641542,"score_gpt":0.26762377117072317,"score_spread":0.23750898050656896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793748657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92119306,0.001702936,0.0000470637,0.004102917,0.0011406839,0.0013158128,0.00054354937,0.000060812712,0.06989318],"genre_scores_gemma":[0.9887029,0.00006222421,0.0029577026,0.0037236249,0.0005255857,0.000056154207,0.0018115897,0.0001124781,0.0020477239],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9929553,0.0029772515,0.0012835204,0.0013978964,0.0005369548,0.0008490333],"domain_scores_gemma":[0.99526596,0.0021939366,0.0006658138,0.0013445533,0.00021061621,0.00031914646],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016141477,0.00060513517,0.0010484558,0.00037363105,0.00011495587,0.00003291331,0.0007991945,0.00013359517,0.00085090677],"category_scores_gemma":[0.00035741887,0.0004490617,0.00027175024,0.0003534835,0.0005307989,0.00016664872,0.0005825337,0.0012953317,0.0016659789],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040318213,0.0073595694,0.30546397,0.00021553332,0.0017619763,0.0897275,0.013694479,0.0012522583,0.45158687,0.00037382028,0.08386333,0.0043825037],"study_design_scores_gemma":[0.048465405,0.010187758,0.7596459,0.00004843934,0.0023704541,0.0025077087,0.0023034045,0.0011259696,0.03794114,0.00017527962,0.1342099,0.0010186735],"about_ca_topic_score_codex":0.0008995538,"about_ca_topic_score_gemma":0.0002058848,"teacher_disagreement_score":0.4541819,"about_ca_system_score_codex":0.00058662455,"about_ca_system_score_gemma":0.00081481814,"threshold_uncertainty_score":0.9997961},"labels":[],"label_agreement":null},{"id":"W2793980325","doi":"10.1016/j.euo.2018.02.009","title":"Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Prostate Cancer UK; GlaxoSmithKline; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Voting; Delphi method; Biomarker; Consensus conference; Clinical trial; MEDLINE; Intensive care medicine; Cancer; Medical physics; Oncology; Pathology; Internal medicine; Computer science; Political science","score_opus":0.11904081778682665,"score_gpt":0.4557216727429578,"score_spread":0.3366808549561311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793980325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039084352,0.9737749,0.000010096249,0.0017741193,0.0013281283,0.0053916713,0.0003615702,0.00013718756,0.016831446],"genre_scores_gemma":[0.000104558,0.99071383,0.0006514232,0.00095782086,0.00074074866,0.0010725049,0.00072528835,0.00023343248,0.004800371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541074,0.0012203841,0.001041776,0.0011088628,0.000214615,0.0010036132],"domain_scores_gemma":[0.9972641,0.00088268064,0.00071714685,0.00057419506,0.00026532655,0.0002965841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012025569,0.0006220034,0.002063145,0.00041442268,0.000229155,0.000015455862,0.00025075127,0.00033083637,0.00019665206],"category_scores_gemma":[0.0002970887,0.00045123242,0.0004949079,0.00026632054,0.00065763644,0.000017981187,0.00016061218,0.0006262332,0.0004376132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021582285,0.00028185945,0.00003057281,0.00563609,0.0018378664,0.0014313629,0.00015255011,0.000003105859,0.000013303571,0.000035568595,0.025420913,0.96299857],"study_design_scores_gemma":[0.005445732,0.0076597687,0.000029442124,0.001955487,0.001676975,0.00028282552,0.00002831086,0.0000136385925,0.000005234736,0.000021457401,0.9825354,0.0003456776],"about_ca_topic_score_codex":0.000007960333,"about_ca_topic_score_gemma":0.000011150438,"teacher_disagreement_score":0.9626529,"about_ca_system_score_codex":0.0010894594,"about_ca_system_score_gemma":0.0017672202,"threshold_uncertainty_score":0.99979395},"labels":[],"label_agreement":null},{"id":"W2801612425","doi":"10.1016/j.euo.2018.04.013","title":"Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Rochester Epidemiology Project; Epidemiology; Surveillance, Epidemiology, and End Results; Odds ratio; Confidence interval; Cohort; Incidence (geometry); Internal medicine; Population; Logistic regression; Cancer; Prostate; Cancer registry","score_opus":0.05876208115487862,"score_gpt":0.37008032226869425,"score_spread":0.3113182411138156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801612425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97511613,0.0030520929,0.00000786119,0.0126435105,0.0001227584,0.00080597703,0.0012598268,0.000010742468,0.0069810697],"genre_scores_gemma":[0.99467456,0.0015416672,0.0000873233,0.0031255751,0.000073379,0.000042297434,0.00021877671,0.000016103375,0.00022028637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9896074,0.008653962,0.00081058015,0.00043263653,0.00011284135,0.00038257483],"domain_scores_gemma":[0.9944896,0.0040503787,0.00051959284,0.0006086846,0.0002309399,0.00010078424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067513934,0.00017725662,0.00095900666,0.0003555879,0.000078356185,0.0000024288875,0.00029763207,0.000063545536,0.000039600898],"category_scores_gemma":[0.002559958,0.00009347078,0.000115811155,0.0010031292,0.0023557274,0.00005018966,0.00023143544,0.00035055575,0.000004624456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015442751,0.0006661928,0.95609176,0.00007936102,0.0019731044,0.0010828222,0.006470443,0.000045723173,0.0010147312,0.00030056486,0.0099813,0.0068512387],"study_design_scores_gemma":[0.008859992,0.0028787302,0.96436226,0.00001926165,0.00069544616,0.00004647528,0.000573442,0.0002596737,0.00009571823,0.00006975722,0.022055088,0.0000841766],"about_ca_topic_score_codex":0.0024781954,"about_ca_topic_score_gemma":0.0030752379,"teacher_disagreement_score":0.01955843,"about_ca_system_score_codex":0.000044621538,"about_ca_system_score_gemma":0.0004939824,"threshold_uncertainty_score":0.8679776},"labels":[],"label_agreement":null},{"id":"W2805171356","doi":"10.1016/j.euo.2018.05.008","title":"Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Leiomyosarcoma; Hazard ratio; Sarcoma; Liposarcoma; Confidence interval; Internal medicine; Epidemiology; Radiation therapy; Proportional hazards model; Surgery; Oncology; Gastroenterology; Pathology","score_opus":0.041686899165674945,"score_gpt":0.33368052075052274,"score_spread":0.29199362158484776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805171356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525642,0.00024877346,0.00015112142,0.0032770936,0.00017108423,0.00027295892,0.000012781179,0.00020656647,0.04309544],"genre_scores_gemma":[0.9935608,0.00001534517,0.0017214149,0.0036918672,0.00047277982,0.00001845082,0.00034300916,0.000048741793,0.00012758776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968366,0.0013473768,0.0005521939,0.0006037569,0.0001759575,0.00048408887],"domain_scores_gemma":[0.9983012,0.0005225389,0.00022580945,0.00051613187,0.00019922711,0.00023509497],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062492565,0.00026228707,0.00080838543,0.00043672734,0.0002345393,0.00001565263,0.00015479194,0.00016238636,0.0012723394],"category_scores_gemma":[0.00021208156,0.00021295073,0.00032022924,0.0007283071,0.00032168056,0.00002578601,0.000076943594,0.00028302177,0.00070279336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073091825,0.0011200984,0.9850648,0.0000043552213,0.00091472233,0.0024644374,0.000085422165,0.000062205996,0.00019510777,0.00011267692,0.00038110817,0.008864165],"study_design_scores_gemma":[0.003952061,0.0032813824,0.9599903,0.000005462934,0.0022083742,0.00017819462,0.000018610745,0.0022603017,0.00008164792,0.0000069985567,0.027851336,0.00016530433],"about_ca_topic_score_codex":0.00051620614,"about_ca_topic_score_gemma":0.00034860458,"teacher_disagreement_score":0.042967852,"about_ca_system_score_codex":0.00019923678,"about_ca_system_score_gemma":0.000088643785,"threshold_uncertainty_score":0.99964064},"labels":[],"label_agreement":null},{"id":"W2805215598","doi":"10.1016/j.euo.2018.02.001","title":"Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cystectomy; Medicine; Bladder cancer; Cancer; Oncology; Bladder Neoplasm; General surgery; Urology; Internal medicine","score_opus":0.020059077603888316,"score_gpt":0.34007945176971327,"score_spread":0.32002037416582496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805215598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993146,0.0008981342,0.00010747654,0.000664172,0.0003737563,0.00042621052,0.00001027633,0.00001607145,0.007572468],"genre_scores_gemma":[0.99831545,0.000055842625,0.00028636446,0.0009471397,0.00017182798,0.000055307573,0.0000052908285,0.000028080149,0.00013466805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983327,0.00045150568,0.00051027746,0.0003072727,0.00013944479,0.0002587993],"domain_scores_gemma":[0.9991212,0.00007419704,0.00020660486,0.00029866488,0.00020859353,0.00009072348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031731295,0.00015205074,0.0005302335,0.00014254842,0.000017468095,0.0000013057064,0.00010926652,0.00008217603,0.0005971482],"category_scores_gemma":[0.00012150713,0.00012442969,0.00006985762,0.00023935312,0.0008290412,0.000036550453,0.00006317882,0.00016786592,0.000091774724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00869349,0.0062699174,0.91609395,0.0006105866,0.0018052126,0.0045503653,0.009261549,0.000015922698,0.009827656,0.00029576797,0.0010299389,0.041545633],"study_design_scores_gemma":[0.005971016,0.013069537,0.9703417,0.000061683655,0.00067889184,0.00019699991,0.000074354735,0.00006107653,0.003524567,0.00010619163,0.0057847,0.00012931119],"about_ca_topic_score_codex":0.00046357556,"about_ca_topic_score_gemma":0.00039712293,"teacher_disagreement_score":0.05424771,"about_ca_system_score_codex":0.00008353215,"about_ca_system_score_gemma":0.00044451136,"threshold_uncertainty_score":0.6538354},"labels":[],"label_agreement":null},{"id":"W2805244703","doi":"10.1016/j.euo.2018.05.001","title":"Role of Active Surveillance for Localized Small Renal Masses","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Interquartile range; Kidney cancer; MEDLINE; Cancer; Surgery; Internal medicine","score_opus":0.07044376850108269,"score_gpt":0.3449440507820464,"score_spread":0.2745002822809637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805244703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038490244,0.9457628,0.00014703756,0.0001010239,0.0003757639,0.002070291,0.0001442681,0.00007303698,0.05094088],"genre_scores_gemma":[0.0003597672,0.9927661,0.0032148976,0.0002725363,0.0009881882,0.00019041168,0.000612829,0.00020388105,0.0013914043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951686,0.0021793519,0.0010703529,0.0008732755,0.00013330822,0.0005750801],"domain_scores_gemma":[0.99625945,0.0013881571,0.0010832016,0.0007742306,0.0002924373,0.00020253648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089992717,0.00058764074,0.0035828797,0.00031492842,0.000060752885,0.0000046532,0.00039055315,0.00053388363,0.00016935906],"category_scores_gemma":[0.0004589252,0.00044741508,0.0008767677,0.00020158745,0.0006238113,0.00001585098,0.00021831667,0.00050382083,0.0003557517],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016331902,0.00047060396,0.00006720685,0.0039330325,0.0015139848,0.0005604905,0.000104417675,5.172501e-7,0.0000537493,0.000105009036,0.0028111169,0.9887467],"study_design_scores_gemma":[0.0022762315,0.009019594,0.00029926884,0.0004562179,0.0023963416,0.0011986356,0.000012666367,0.0000040570962,0.000040599443,0.00004631921,0.9839846,0.0002655056],"about_ca_topic_score_codex":0.000012035695,"about_ca_topic_score_gemma":0.000039102815,"teacher_disagreement_score":0.98848116,"about_ca_system_score_codex":0.00031616742,"about_ca_system_score_gemma":0.0008555841,"threshold_uncertainty_score":0.99979776},"labels":[],"label_agreement":null},{"id":"W2805258017","doi":"10.1016/j.euo.2018.03.005","title":"Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; Institute of Clinical and Translational Sciences; University of Texas Medical Branch","keywords":"Comorbidity; Medicine; Cystectomy; Bladder cancer; MEDLINE; Perioperative; Intensive care medicine; Risk assessment; Systematic review; Internal medicine; Cancer; Surgery","score_opus":0.05377424198456397,"score_gpt":0.39814201089946516,"score_spread":0.3443677689149012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805258017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81358135,0.05257361,0.000906285,0.004951381,0.0029981367,0.01163485,0.00045013812,0.00020389032,0.11270039],"genre_scores_gemma":[0.9817957,0.0046200817,0.0006048562,0.012133464,0.0002770311,0.0001586639,0.00006138456,0.00004872358,0.00030008444],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9981481,0.00060738623,0.0005548346,0.00031196003,0.00012484827,0.00025288004],"domain_scores_gemma":[0.99865115,0.00022707735,0.0003716055,0.0002672693,0.00037213217,0.00011075422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060090417,0.0001745585,0.00087030645,0.000060825114,0.000080154154,0.0000031738973,0.00011473137,0.00007512106,0.00021458545],"category_scores_gemma":[0.00029087465,0.00013537084,0.000087858665,0.00007863641,0.00033402737,0.000027566883,0.00008503654,0.00012772522,0.00004100013],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040253666,0.006462735,0.28643468,0.6213328,0.006987583,0.00021600511,0.0024449772,8.54803e-7,0.0013236902,0.0006867851,0.053723156,0.016361356],"study_design_scores_gemma":[0.05172889,0.09579627,0.6476327,0.07885215,0.025004499,0.00054375886,0.0002592884,0.00031629694,0.0011357112,0.00026450233,0.09708174,0.0013842009],"about_ca_topic_score_codex":0.000036143818,"about_ca_topic_score_gemma":0.000019463394,"teacher_disagreement_score":0.5424807,"about_ca_system_score_codex":0.00006960158,"about_ca_system_score_gemma":0.00013403478,"threshold_uncertainty_score":0.5520263},"labels":[],"label_agreement":null},{"id":"W2806535129","doi":"10.1016/j.euo.2018.04.010","title":"Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cystoscopy; Urinary system; Bladder cancer; Randomized controlled trial; Clinical trial; Urology; Cancer; Internal medicine; Oncology","score_opus":0.12933062305410345,"score_gpt":0.42197412263934186,"score_spread":0.2926434995852384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806535129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001302315,0.97394526,0.00014575591,0.0006896804,0.0015381306,0.014686628,0.00015509526,0.00007814816,0.008748274],"genre_scores_gemma":[0.000006742017,0.98719627,0.0024113723,0.0031162673,0.001726823,0.0040468713,0.00017522491,0.00022287757,0.0010975584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99154097,0.0048553534,0.0014241787,0.001196642,0.0001886537,0.0007942272],"domain_scores_gemma":[0.99704045,0.0010829062,0.0007981336,0.0006078787,0.00024348339,0.0002271263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022259282,0.0007878155,0.004275967,0.00037746804,0.00013061489,0.0000119552815,0.00041915243,0.0004921941,0.00053051446],"category_scores_gemma":[0.00040911592,0.0006274496,0.0005897548,0.00062150724,0.00039231885,0.000051230883,0.00019540348,0.0008023274,0.00026479384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052756976,0.0017744089,0.000007973572,0.015743097,0.0030570158,0.0027347119,0.00027356792,0.0000034893035,2.0284288e-7,0.000010094935,0.113905944,0.8097325],"study_design_scores_gemma":[0.036743212,0.034095585,0.000012291206,0.0070327595,0.007552373,0.0004902188,0.000021235719,0.0000038271382,1.1921342e-7,0.000004031029,0.9136523,0.00039207403],"about_ca_topic_score_codex":0.000012284446,"about_ca_topic_score_gemma":0.000012771835,"teacher_disagreement_score":0.8093405,"about_ca_system_score_codex":0.0007489044,"about_ca_system_score_gemma":0.0038805387,"threshold_uncertainty_score":0.9996177},"labels":[],"label_agreement":null},{"id":"W2806910229","doi":"10.1016/j.euo.2018.05.003","title":"Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Interquartile range; Androgen deprivation therapy; Biochemical recurrence; Radiation therapy; Urology; Stage (stratigraphy); Metastasis; Biopsy; Concomitant; Cancer; Prostate; Prostate-specific antigen; Internal medicine; Perineural invasion; Oncology","score_opus":0.02501038793937871,"score_gpt":0.30309944216885065,"score_spread":0.27808905422947194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806910229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98388547,0.003633382,0.000038144684,0.004387161,0.0008857572,0.0010171698,0.00011694329,0.0001325541,0.005903422],"genre_scores_gemma":[0.9849629,0.0077942535,0.0010296929,0.0037426064,0.0004935594,0.000211536,0.00009315937,0.000084842504,0.0015874824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971501,0.0005659374,0.00059643877,0.0008027769,0.00015049886,0.00073419727],"domain_scores_gemma":[0.9984698,0.00029940673,0.00028648836,0.0005026045,0.00021978734,0.00022185978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005945725,0.00035083183,0.0007823108,0.0002652165,0.00016190376,0.00001422744,0.00015000382,0.00015175603,0.0004385217],"category_scores_gemma":[0.00020433142,0.00027624457,0.000088938905,0.00029612207,0.00086053426,0.00008571576,0.00013813218,0.0004081985,0.00054845226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008624948,0.002097321,0.69715565,0.000096458294,0.0004361384,0.0077553918,0.003020112,0.0001412605,0.00685062,0.0003193589,0.014752308,0.25875044],"study_design_scores_gemma":[0.01675553,0.015548214,0.8798085,0.00012482185,0.0005460381,0.0003841104,0.00023945759,0.0004913137,0.0024742144,0.00053258846,0.082711115,0.00038412667],"about_ca_topic_score_codex":0.0015574378,"about_ca_topic_score_gemma":0.0014233466,"teacher_disagreement_score":0.25836632,"about_ca_system_score_codex":0.00036757748,"about_ca_system_score_gemma":0.00036435237,"threshold_uncertainty_score":0.99996895},"labels":[],"label_agreement":null},{"id":"W2807009771","doi":"10.1016/j.euo.2018.03.006","title":"Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Stage (stratigraphy); Adverse effect; Urology; Prostate; Oncology; Cancer; Internal medicine","score_opus":0.014382548418915408,"score_gpt":0.28928467068598257,"score_spread":0.2749021222670672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807009771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490285,0.00013738853,0.000029970213,0.000864723,0.000107185006,0.0018483377,0.00017937075,0.00003887708,0.0018912794],"genre_scores_gemma":[0.9974692,0.00013865186,0.00048296564,0.0007659279,0.000079660946,0.00032367514,0.00032522928,0.000045033365,0.00036965025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984398,0.00026748254,0.00042157908,0.0004051826,0.00010710143,0.00035889322],"domain_scores_gemma":[0.9992116,0.00008873254,0.0002411803,0.00020402881,0.00014149849,0.000112941794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022131793,0.00019511713,0.0004906042,0.00017555455,0.000044234974,0.000001891688,0.000065372915,0.00008552579,0.00010999459],"category_scores_gemma":[0.000043142987,0.00014087088,0.000057087673,0.00020999125,0.0005282415,0.000048498678,0.000028572884,0.0001267997,0.000011605031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021330463,0.0017581073,0.95526946,0.00007653049,0.00020517696,0.00017941889,0.0011437895,0.00003273091,0.00035174526,0.00005881928,0.0008995405,0.01869422],"study_design_scores_gemma":[0.0403778,0.04176523,0.78246194,0.000063887645,0.00027737863,0.000011149417,0.00005592972,0.00018912564,0.0029008046,0.000010293211,0.13171646,0.00016997954],"about_ca_topic_score_codex":0.00012903035,"about_ca_topic_score_gemma":0.0010160556,"teacher_disagreement_score":0.1728075,"about_ca_system_score_codex":0.00023052198,"about_ca_system_score_gemma":0.00018384686,"threshold_uncertainty_score":0.5744548},"labels":[],"label_agreement":null},{"id":"W2807167984","doi":"10.1016/j.euo.2018.03.007","title":"The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Logistic regression; Brachytherapy; Radiation therapy; Internal medicine; Odds ratio; Proportional hazards model; Cancer; Epidemiology; Hazard ratio; Oncology; Urology; Surgery; Confidence interval","score_opus":0.037231248731797284,"score_gpt":0.3735573927117167,"score_spread":0.3363261439799194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807167984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884219,0.00016711772,0.000040357743,0.0027167245,0.00064290315,0.0037943472,0.00030872368,0.0000409488,0.0038669442],"genre_scores_gemma":[0.99455386,0.0003308056,0.000041452586,0.0022258998,0.00034465725,0.0021386135,0.000035639194,0.000058078036,0.00027097773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975245,0.0008517402,0.00042843854,0.00052520557,0.00017310934,0.000497016],"domain_scores_gemma":[0.9980167,0.0007078265,0.0004018333,0.00046192372,0.0002094779,0.00020224205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036713848,0.0003155684,0.0006951136,0.00009575473,0.00016398421,0.000014680176,0.00022686421,0.0000402639,0.000034383876],"category_scores_gemma":[0.00012673067,0.00018016007,0.00014650078,0.00015245118,0.001033466,0.000038249647,0.00011051697,0.000092007685,0.000023971348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016554927,0.0012144553,0.7899772,0.00003724022,0.0025316945,0.00004979824,0.0035105136,0.00021668541,0.000048613576,0.00012568671,0.0024018525,0.18333136],"study_design_scores_gemma":[0.011531638,0.14978732,0.72897184,0.000038402337,0.0010125147,0.0000022053143,0.00008336724,0.00012260927,0.009459763,0.000034273427,0.098761246,0.00019481455],"about_ca_topic_score_codex":0.0013249811,"about_ca_topic_score_gemma":0.0009131842,"teacher_disagreement_score":0.18313655,"about_ca_system_score_codex":0.0007020541,"about_ca_system_score_gemma":0.00011043388,"threshold_uncertainty_score":0.7346714},"labels":[],"label_agreement":null},{"id":"W2807345550","doi":"10.1016/j.euo.2018.04.004","title":"Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Oncology; Internal medicine; Placebo; Androgen deprivation therapy; Randomized controlled trial; Confidence interval; Prostate-specific antigen; Cancer; Urology; Androgen receptor; Pathology","score_opus":0.03979434032370471,"score_gpt":0.3766406032830469,"score_spread":0.33684626295934217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807345550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911421,0.002649276,0.000008321169,0.00079137605,0.00012843117,0.0006931584,0.000042174666,0.000036936373,0.004508214],"genre_scores_gemma":[0.99785984,0.00041952997,0.00088411116,0.0003086928,0.000094369345,0.000042006366,0.00005131508,0.00003733112,0.00030282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767154,0.0007304723,0.0005305225,0.0004573339,0.00015897528,0.00045116327],"domain_scores_gemma":[0.99904925,0.00015752147,0.00021118767,0.00026642653,0.0001297303,0.0001858824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062424794,0.00019716601,0.00065711717,0.00028410114,0.00009147054,0.00000785601,0.0001192925,0.000085759624,0.00010196459],"category_scores_gemma":[0.00009489394,0.0001660774,0.00003664407,0.0002679418,0.000836114,0.00008374452,0.00008239533,0.0003067958,0.000022788645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012801379,0.0015973675,0.55473137,0.00019967732,0.0003627131,0.0017178116,0.013936718,0.000117430885,0.22034162,0.000112889626,0.00026393318,0.19381706],"study_design_scores_gemma":[0.016867142,0.028216964,0.8933725,0.00009512881,0.0003770174,0.00026697884,0.0013282784,0.0012367046,0.039517164,0.00019228441,0.018147998,0.00038187948],"about_ca_topic_score_codex":0.00013300739,"about_ca_topic_score_gemma":0.001955466,"teacher_disagreement_score":0.33864108,"about_ca_system_score_codex":0.0001354467,"about_ca_system_score_gemma":0.00031718705,"threshold_uncertainty_score":0.677244},"labels":[],"label_agreement":null},{"id":"W2810579527","doi":"10.1016/j.euo.2018.08.009","title":"Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2–4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Cystectomy; Medicine; Bladder cancer; Perioperative; Oncology; Nomogram; Neoadjuvant therapy; Internal medicine; Stage (stratigraphy); Chemotherapy; Proportional hazards model; Confidence interval; Urology; Clinical trial; Surgery; Cancer; Breast cancer","score_opus":0.04498250182132508,"score_gpt":0.35564242784721484,"score_spread":0.31065992602588977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810579527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003196,0.00022454876,0.0016285061,0.0018598953,0.00095824525,0.0020607403,0.00013198936,0.00007331007,0.0030307833],"genre_scores_gemma":[0.99172527,0.00005358522,0.0024026684,0.003538346,0.0018139266,0.000107631124,0.000054447373,0.00013657726,0.00016752949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951516,0.001822358,0.001186954,0.00091809,0.00025139746,0.000669637],"domain_scores_gemma":[0.998062,0.00054607005,0.0002332257,0.0006175689,0.00020384986,0.00033727693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002534837,0.00040596962,0.0014259793,0.00021251496,0.000101869155,0.000015952171,0.00023613434,0.00033788904,0.0003139312],"category_scores_gemma":[0.0007650936,0.0003024189,0.00019979288,0.0001286081,0.0007751371,0.00007798022,0.00013147286,0.0005297128,0.000069321344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32572073,0.008101516,0.5991666,0.000078346784,0.0014954003,0.0013051376,0.0021842003,0.000011037154,0.0002598106,0.00015871509,0.0029021814,0.05861635],"study_design_scores_gemma":[0.43502602,0.0849108,0.4373075,0.0000576663,0.0013904179,0.00018948746,0.000101224476,0.0014689787,0.000120351986,0.00034084683,0.038343858,0.00074283005],"about_ca_topic_score_codex":0.000036343117,"about_ca_topic_score_gemma":0.00009003912,"teacher_disagreement_score":0.16185907,"about_ca_system_score_codex":0.000108333974,"about_ca_system_score_gemma":0.000348865,"threshold_uncertainty_score":0.9999428},"labels":[],"label_agreement":null},{"id":"W2846016134","doi":"10.1016/j.euo.2018.06.008","title":"“Reverse Stage Migration”: What Can Population-based Data Tell Us About Trends in Prostate Cancer Presentation?","year":2018,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Presentation (obstetrics); Stage (stratigraphy); Population; Cancer; Data presentation; Oncology; Internal medicine; Environmental health; Surgery; Statistics; Data collection","score_opus":0.04622336113204339,"score_gpt":0.3496175459854732,"score_spread":0.3033941848534298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2846016134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.120130666,0.003993597,0.000006919362,0.8652065,0.002833892,0.001685125,0.0025869457,0.00015298095,0.0034034196],"genre_scores_gemma":[0.031620324,0.005329297,0.00039110266,0.87615633,0.0048671933,0.00045415253,0.06536376,0.00026729936,0.015550565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952739,0.0012958352,0.0008817463,0.0014437925,0.0003272517,0.00077750196],"domain_scores_gemma":[0.99716896,0.00032395587,0.00064388994,0.0015166529,0.00018514051,0.00016138633],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004884075,0.0005718588,0.0009658073,0.0007310762,0.00012220237,0.000076146025,0.00052493677,0.0004952121,0.0019404463],"category_scores_gemma":[0.00008741447,0.000519437,0.00012743552,0.0003969025,0.0003292531,0.00026217723,0.00023574456,0.0013765276,0.0001864351],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037116607,0.00032149273,0.24616377,0.0001103345,0.00024750043,0.00663156,0.00044765562,0.00021196526,0.0000064710835,0.0000022437148,0.7305509,0.014934929],"study_design_scores_gemma":[0.0035645235,0.0012805014,0.25235125,0.00009899969,0.0004280428,0.000041282645,0.000024355835,0.00033031366,0.000010380194,0.000003918152,0.7415713,0.00029511756],"about_ca_topic_score_codex":0.0039412784,"about_ca_topic_score_gemma":0.015842447,"teacher_disagreement_score":0.08851034,"about_ca_system_score_codex":0.0009163824,"about_ca_system_score_gemma":0.0007900814,"threshold_uncertainty_score":0.9997257},"labels":[],"label_agreement":null},{"id":"W2884540301","doi":"10.1016/j.euo.2018.06.007","title":"Systematic Review of the Management of Local Kidney Cancer Relapse","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nephrectomy; Kidney cancer; Renal cell carcinoma; Cancer; Radiation therapy; Meta-analysis; Surgery; Systematic review; Retrospective cohort study; CINAHL; MEDLINE; Kidney; General surgery; Oncology; Internal medicine; Psychological intervention","score_opus":0.04137451773879018,"score_gpt":0.3400570479144596,"score_spread":0.2986825301756694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884540301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004535423,0.94659775,0.000019490986,0.00043311232,0.0007266253,0.003977784,0.000035236095,0.000021767715,0.048183672],"genre_scores_gemma":[0.00003139421,0.994056,0.0001317676,0.0022901446,0.00013342379,0.0002480117,0.0000460086,0.00009706995,0.0029661888],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930448,0.003685247,0.0020862035,0.0005383575,0.00030954942,0.00033587322],"domain_scores_gemma":[0.9955888,0.00022904958,0.0021933035,0.0016169474,0.00019611836,0.00017580467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015186354,0.00047765492,0.0048425402,0.0001448716,0.00003802965,0.0000013738048,0.0006957985,0.0002507394,0.00031878048],"category_scores_gemma":[0.0001596289,0.00025712757,0.0010938362,0.00038206705,0.00078817597,0.000011022773,0.0005175494,0.0005009555,0.0003794113],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029482866,0.00019566747,0.0000020770879,0.9558281,0.0028119525,0.0006389198,0.000024708183,9.523061e-8,2.557566e-7,0.00015115886,0.010391381,0.029926248],"study_design_scores_gemma":[0.0003833917,0.00081285235,0.000015645093,0.45881706,0.027197827,0.0007289769,0.0000055506434,2.847774e-7,0.0000015647904,0.0000020512905,0.51193863,0.0000961361],"about_ca_topic_score_codex":0.0000080018535,"about_ca_topic_score_gemma":0.0000016723961,"teacher_disagreement_score":0.5015473,"about_ca_system_score_codex":0.00042769188,"about_ca_system_score_gemma":0.0006645537,"threshold_uncertainty_score":0.9999881},"labels":[],"label_agreement":null},{"id":"W2885280442","doi":"10.1016/j.euo.2018.07.002","title":"Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Joseph Brant Hospital; McMaster University","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation","keywords":"Aspirin; Medicine; Hazard ratio; Prostate cancer; Proportional hazards model; Confidence interval; Internal medicine; Cancer; Surgery; Oncology","score_opus":0.039439900897022206,"score_gpt":0.3684279539946468,"score_spread":0.3289880530976246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885280442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833907,0.00034711213,0.0000025740424,0.011907875,0.0011148646,0.0015256137,0.0000051210145,0.000038042315,0.0016680984],"genre_scores_gemma":[0.97854555,0.00004363243,0.000031585325,0.019970385,0.0006392102,0.0000829121,0.000005957326,0.000031404215,0.0006493762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517065,0.0034783878,0.00037039237,0.0003759078,0.00015343158,0.00045120955],"domain_scores_gemma":[0.9989436,0.0003939415,0.00015682232,0.0002934296,0.000080572434,0.00013160857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030251192,0.0001707701,0.00041348848,0.00013104017,0.00017549262,0.000010234616,0.00013295538,0.0000807651,0.000083408166],"category_scores_gemma":[0.00027601456,0.00010756697,0.000032522326,0.00015672855,0.0003422933,0.00005918033,0.00011997761,0.000520976,0.000113735136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003095138,0.0011665303,0.90468043,0.00006586111,0.00009578912,0.002923249,0.0393088,0.0000010766271,0.00047828504,0.0001424626,0.019285008,0.028757371],"study_design_scores_gemma":[0.00574698,0.012614117,0.8989123,0.000026291184,0.000047262543,0.0002583393,0.0008427564,0.000023421066,0.00001722998,0.000013566611,0.08139513,0.0001026141],"about_ca_topic_score_codex":0.0001310058,"about_ca_topic_score_gemma":0.0013304302,"teacher_disagreement_score":0.062110122,"about_ca_system_score_codex":0.000067883506,"about_ca_system_score_gemma":0.00034254295,"threshold_uncertainty_score":0.4386454},"labels":[],"label_agreement":null},{"id":"W2886065680","doi":"10.1016/j.euo.2018.07.003","title":"Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Carboplatin; Medicine; Gemcitabine; Oncology; Internal medicine; Cisplatin; Hazard ratio; Chemotherapy; Metastatic Urothelial Carcinoma; Cancer; Bladder cancer; Urothelial carcinoma; Nivolumab; Confidence interval; Immunotherapy","score_opus":0.07254437410222264,"score_gpt":0.41245632057114395,"score_spread":0.3399119464689213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886065680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303967,0.00010554986,0.0003965315,0.0003669195,0.00039368117,0.004084267,0.00014518696,0.000019008956,0.0014492108],"genre_scores_gemma":[0.9987604,0.0000077635,0.00013017908,0.000470445,0.00015911552,0.00024827028,0.00017931307,0.00003144928,0.000013086535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960538,0.0025466576,0.00053410296,0.00039480897,0.00014847361,0.00032214847],"domain_scores_gemma":[0.99809647,0.0010804421,0.00026613558,0.00029669105,0.00018876605,0.000071526214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010439355,0.0002509042,0.0007958271,0.00014179431,0.0001557017,0.0000068602117,0.00016545322,0.00005166388,0.000033740365],"category_scores_gemma":[0.00007755818,0.0001732993,0.00009501706,0.00020790844,0.0003145232,0.00004410874,0.000024765543,0.00018258831,0.000019858486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33390763,0.049928933,0.50615346,0.00037678736,0.0023706062,0.00053488126,0.08035934,0.00004196787,0.0017862514,0.00008260102,0.0005194623,0.023938108],"study_design_scores_gemma":[0.08384993,0.23210354,0.6809677,0.000015895075,0.00044210136,0.000022055316,0.00059706747,0.0001658497,0.0005583275,0.000013362232,0.0011496968,0.00011447938],"about_ca_topic_score_codex":0.00029373766,"about_ca_topic_score_gemma":0.0013866712,"teacher_disagreement_score":0.2500577,"about_ca_system_score_codex":0.00012886368,"about_ca_system_score_gemma":0.0002626784,"threshold_uncertainty_score":0.706694},"labels":[],"label_agreement":null},{"id":"W2886529900","doi":"10.1016/j.euo.2018.07.006","title":"Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of British Columbia","funders":"National Center for Advancing Translational Sciences; DOD Peer Reviewed Cancer Research Program; National Cancer Institute; National Institutes of Health; Institute of Clinical and Translational Sciences; University of Texas Medical Branch; U.S. Department of Defense","keywords":"Medicine; Psychological intervention; Comorbidity; Cystectomy; Socioeconomic status; Corpectomy; Marital status; Receipt; Bladder cancer; MEDLINE; Systematic review; Cancer; Family medicine; Emergency medicine; Gerontology; Environmental health; Internal medicine; Surgery; Psychiatry; Population","score_opus":0.1034561736754374,"score_gpt":0.39005715634427907,"score_spread":0.28660098266884165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886529900","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023540491,0.9913198,0.00010641936,0.000236451,0.00024544186,0.005313857,0.00021870217,0.000030882045,0.0025049248],"genre_scores_gemma":[0.00026750405,0.99729675,0.000019464367,0.0009539037,0.00015691158,0.00043268336,0.00031635255,0.00010748648,0.00044891922],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99553734,0.0023527914,0.001202068,0.00039508208,0.00022098556,0.00029173392],"domain_scores_gemma":[0.9958999,0.0011705399,0.0019126574,0.0005390334,0.00039639533,0.00008146962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010670203,0.00040474767,0.0040619737,0.0001295296,0.000059255533,0.0000023071684,0.00032538042,0.0002904698,0.00018396588],"category_scores_gemma":[0.00089083903,0.00019664488,0.0005399335,0.00033428345,0.00061366626,0.00001664443,0.000059078004,0.00029800876,0.000012317181],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012847874,0.00035094595,0.000028846349,0.9764944,0.0066281315,0.000028415006,0.00019431737,1.1476248e-7,6.7780377e-7,0.000042874603,0.0069220853,0.009180756],"study_design_scores_gemma":[0.0020235705,0.004672288,0.00006347159,0.31079376,0.044563092,0.00009849975,0.00001686586,0.0000017990184,0.0000030033184,0.000002317644,0.63757116,0.00019015853],"about_ca_topic_score_codex":0.000008969854,"about_ca_topic_score_gemma":0.000021202386,"teacher_disagreement_score":0.6657006,"about_ca_system_score_codex":0.00018733382,"about_ca_system_score_gemma":0.0009790538,"threshold_uncertainty_score":0.80189455},"labels":[],"label_agreement":null},{"id":"W2888744124","doi":"10.1016/j.euo.2018.08.001","title":"Individual Comparison of Cholesterol Metabolism in Normal and Tumour Areas in Radical Prostatectomy Specimens from Patients with Prostate Cancer: Results of the CHOMECAP Study","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Association pour la Recherche sur les Tumeurs de la Prostate; Fonds pour la Formation de Chercheurs et l'Aide à la Recherche","keywords":"Prostate cancer; Prostatectomy; Prostate; Cholesterol; Medicine; Pathology; Cancer; Immunohistochemistry; Internal medicine; Endocrinology","score_opus":0.010232621292633848,"score_gpt":0.26050403909763997,"score_spread":0.2502714178050061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888744124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964422,0.0006170739,0.0000027321523,0.0001430231,0.0011799666,0.0007944216,0.00023897242,0.0000047549315,0.0005768433],"genre_scores_gemma":[0.9984893,0.00007192475,0.000059866336,0.000203178,0.0010236227,0.000028979715,0.00006365495,0.000026891952,0.000032555436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997383,0.0009838532,0.00064248143,0.00049770833,0.00016728326,0.00032568327],"domain_scores_gemma":[0.9990312,0.000039134844,0.000413594,0.0003382459,0.000109235574,0.000068629495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051555067,0.00020455137,0.000531596,0.000116946314,0.000042382093,0.0000061190262,0.00033069446,0.00011355325,0.000009016212],"category_scores_gemma":[0.00009135007,0.00014979437,0.000036049598,0.00018037825,0.00078195496,0.0000082900715,0.00034334548,0.00029161983,0.0000014932592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006268217,0.0013057371,0.9676405,0.000008345588,0.00011023048,0.0000014434582,0.005420027,0.00005221252,0.014343162,0.0000070748224,0.00064913154,0.004193893],"study_design_scores_gemma":[0.014428729,0.0026620652,0.9351682,0.000011549459,0.00007590158,0.0000027970214,0.00027043073,0.000006203854,0.0038466905,0.0000070283386,0.04338653,0.00013387993],"about_ca_topic_score_codex":0.000575319,"about_ca_topic_score_gemma":0.007075834,"teacher_disagreement_score":0.0427374,"about_ca_system_score_codex":0.000017451946,"about_ca_system_score_gemma":0.00015916313,"threshold_uncertainty_score":0.6108437},"labels":[],"label_agreement":null},{"id":"W2889240474","doi":"10.1016/j.euo.2018.08.003","title":"GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Prostate Cancer Canada","keywords":"Methylation; DNA methylation; Prostate cancer; Biochemical recurrence; Oncology; Epigenetics; Medicine; breakpoint cluster region; Cancer research; Cancer; Prostatectomy; Internal medicine; Biology; Genetics; Gene; Gene expression","score_opus":0.019729878792382964,"score_gpt":0.28836486595863975,"score_spread":0.2686349871662568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889240474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960585,0.00044796875,0.00026422786,0.0010861779,0.00010483111,0.0014948607,0.0002522348,0.000019951274,0.00027121222],"genre_scores_gemma":[0.99834585,0.000069418544,0.0010468619,0.00014396991,0.00011632053,0.00009206161,0.00010629301,0.000024281582,0.000054924705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989377,0.00009433391,0.0002143501,0.00039072664,0.00009936136,0.00026352756],"domain_scores_gemma":[0.9991566,0.0001563209,0.00014813153,0.00010784261,0.0003189251,0.00011218474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017970902,0.00015336178,0.0002570935,0.00012677835,0.00008219718,0.0000065172153,0.000045078614,0.00009085945,0.0000092885575],"category_scores_gemma":[0.00016590918,0.00010470979,0.00002302788,0.00013060246,0.0013542651,0.00006269068,0.00006599617,0.00017151472,5.852241e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012469303,0.00035910687,0.8589501,0.00021202576,0.00029050547,0.000009942323,0.004813627,2.499514e-7,0.045153666,0.000011984076,0.00043407016,0.07729546],"study_design_scores_gemma":[0.006944345,0.01126496,0.9723117,0.000041772924,0.00022188107,0.00002895301,0.000055414366,0.0004133685,0.007776283,0.00008523064,0.0007674533,0.00008864806],"about_ca_topic_score_codex":0.000035385518,"about_ca_topic_score_gemma":0.00001642329,"teacher_disagreement_score":0.113361634,"about_ca_system_score_codex":0.000052154654,"about_ca_system_score_gemma":0.00013152884,"threshold_uncertainty_score":0.49898463},"labels":[],"label_agreement":null},{"id":"W2890338448","doi":"10.1016/j.euo.2018.08.017","title":"Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; University Health Network; University of Toronto; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Health Sciences Centre","funders":"National Cancer Institute; Movember Foundation","keywords":"Medicine; Prostate cancer; Histopathology; Grading (engineering); Biopsy; Concordance; Prostatectomy; International agency; Cancer; Pathology; Internal medicine","score_opus":0.13266953195984751,"score_gpt":0.4189207318701253,"score_spread":0.2862511999102778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890338448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665086,0.0040105996,0.00013056227,0.021400534,0.0014985105,0.00094260916,0.00033581708,0.000075281685,0.005097488],"genre_scores_gemma":[0.99261373,0.00053520757,0.00037800017,0.0053162607,0.0009986921,0.00008037587,0.000047178248,0.00001450405,0.00001605048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779445,0.0009870699,0.00032793952,0.00047961302,0.000097851516,0.00031309397],"domain_scores_gemma":[0.99863666,0.00042501735,0.00033077563,0.00023293745,0.00026561506,0.00010897414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007445675,0.00022067755,0.00048931636,0.00002160593,0.0002964606,0.000013515849,0.00008728884,0.000099925914,0.00000919464],"category_scores_gemma":[0.0003388086,0.00014493034,0.0000764582,0.00013531379,0.00092916755,0.000052667237,0.00011284465,0.0001567744,0.000017750375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01315252,0.000689422,0.8986492,0.0001634578,0.0030721158,0.00039263695,0.006078393,0.0000043115037,0.00027730712,0.016260348,0.006655115,0.054605156],"study_design_scores_gemma":[0.004093685,0.00623047,0.9540558,0.000020355428,0.00025974534,0.0006648604,0.002604457,0.000021995067,0.00007567224,0.0012550553,0.030572325,0.00014559596],"about_ca_topic_score_codex":0.000023705212,"about_ca_topic_score_gemma":0.00047376886,"teacher_disagreement_score":0.055406567,"about_ca_system_score_codex":0.0005547065,"about_ca_system_score_gemma":0.00014147398,"threshold_uncertainty_score":0.5910088},"labels":[],"label_agreement":null},{"id":"W2895225151","doi":"10.1016/j.euo.2018.08.031","title":"Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; University of British Columbia; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Stage (stratigraphy); Nuclear medicine; Computed tomography; Radiology","score_opus":0.006326498858319275,"score_gpt":0.23850046015535176,"score_spread":0.2321739612970325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895225151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881026,0.00038775624,0.00039712645,0.00038346206,0.0003499902,0.0002212844,0.0000066365383,0.00007995529,0.010071181],"genre_scores_gemma":[0.9985456,0.000032946107,0.00016893279,0.0007841424,0.00019101871,0.000003437655,0.000018453617,0.00003565453,0.00021981818],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980435,0.0007305248,0.0004516093,0.00034815015,0.00010208669,0.00032414848],"domain_scores_gemma":[0.9990831,0.00016915986,0.00026949513,0.00027962393,0.00009615327,0.00010243667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006266396,0.00015057107,0.00037068845,0.00035480346,0.00006204115,0.000004836813,0.00012714975,0.00009194197,0.0000639745],"category_scores_gemma":[0.00021294902,0.00015327576,0.000066956956,0.0004233339,0.00034253538,0.000056142006,0.00006399261,0.00033925683,0.00009600465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073938066,0.00058254803,0.41674778,0.00007260609,0.000035474688,0.00079126965,0.00060088874,0.000125629,0.57558703,0.00000877464,0.00077474205,0.003933901],"study_design_scores_gemma":[0.0040349024,0.0017853306,0.94843966,0.000012081261,0.000026655398,0.00013566772,0.000039219416,0.0013863668,0.035354003,0.000004629365,0.00864536,0.00013612836],"about_ca_topic_score_codex":0.00002895776,"about_ca_topic_score_gemma":0.000029732175,"teacher_disagreement_score":0.540233,"about_ca_system_score_codex":0.0000630423,"about_ca_system_score_gemma":0.00005879128,"threshold_uncertainty_score":0.6250404},"labels":[],"label_agreement":null},{"id":"W2900345444","doi":"10.1016/j.euo.2018.10.003","title":"Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Radiation therapy; Hazard ratio; Internal medicine; Oncology; Meta-analysis; Adjuvant therapy; Adjuvant; Proportional hazards model; Randomized controlled trial; Kidney cancer; Surgery; Cancer; Kidney; Confidence interval","score_opus":0.03927091721695056,"score_gpt":0.29670798988080344,"score_spread":0.25743707266385285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900345444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011411736,0.99072134,0.000017525817,0.00019028863,0.000047952966,0.0067361,0.000042335807,0.000038802642,0.0010644696],"genre_scores_gemma":[0.0045585595,0.98976433,0.0003918109,0.00309403,0.00008249131,0.0010683419,0.0005182268,0.00015367783,0.0003685323],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98769337,0.008182068,0.0019263156,0.001245158,0.0003729577,0.00058011914],"domain_scores_gemma":[0.99658257,0.00048890966,0.0012950134,0.0011547321,0.00015637392,0.00032241357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001578688,0.0009588179,0.012701235,0.0008803852,0.000052315812,0.000016473448,0.00028852996,0.0004121892,0.00058953575],"category_scores_gemma":[0.000108838176,0.0005324132,0.0016720439,0.00091873854,0.00043022214,0.00004812681,0.00013606827,0.0007751181,0.0002536541],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026082138,0.0030098471,0.0051527256,0.7590341,0.20620145,0.008374751,0.00037497535,0.0000011123242,1.1309658e-7,0.0000055253463,0.0015747179,0.013662449],"study_design_scores_gemma":[0.0037253862,0.0046909577,0.0020767779,0.0014748812,0.6982416,0.00024606584,0.0000010982886,0.0000015049982,1.4675906e-7,6.2342133e-7,0.28918967,0.00035131266],"about_ca_topic_score_codex":0.000015640315,"about_ca_topic_score_gemma":0.000018288918,"teacher_disagreement_score":0.75755924,"about_ca_system_score_codex":0.00041674584,"about_ca_system_score_gemma":0.00036113666,"threshold_uncertainty_score":0.99971277},"labels":[],"label_agreement":null},{"id":"W2900751841","doi":"10.1016/j.euo.2018.10.010","title":"The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Lymph node; Dissection (medical); Oncology; Urology; Lymph; Internal medicine; Cancer; Surgery; Pathology","score_opus":0.012559255608214881,"score_gpt":0.29390614843341767,"score_spread":0.2813468928252028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900751841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965852,0.00055057177,0.0000037673412,0.0007231977,0.000075972304,0.0010249946,0.00006804106,0.000014894409,0.00095338526],"genre_scores_gemma":[0.99945813,0.00014001151,0.000022130525,0.00011880952,0.000010489162,0.0001291947,0.000043369284,0.000023502438,0.000054337037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756724,0.0012725857,0.00046392818,0.0003292833,0.00013371257,0.00023326723],"domain_scores_gemma":[0.998628,0.0006226389,0.00030179817,0.00018905205,0.00017840472,0.000080075486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005320446,0.00020104695,0.0009413017,0.0002459173,0.00007146381,0.0000060077496,0.000063917134,0.000043287444,0.00001128372],"category_scores_gemma":[0.00012085696,0.000104668376,0.000078690886,0.0004892141,0.0009309193,0.000045375946,0.00004567899,0.00012507987,0.0000017105573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009129003,0.000373131,0.9825995,0.000027792345,0.0024628253,0.00013988541,0.0012579998,0.00001136659,0.00021231559,0.000017374748,0.000014373709,0.0037544502],"study_design_scores_gemma":[0.011382708,0.02095552,0.9644426,0.000026471234,0.001548828,0.0000071422955,0.00005673143,0.000070089416,0.0012073918,0.0000020426673,0.00022070919,0.000079759295],"about_ca_topic_score_codex":0.00062330964,"about_ca_topic_score_gemma":0.00042802142,"teacher_disagreement_score":0.02058239,"about_ca_system_score_codex":0.000119011325,"about_ca_system_score_gemma":0.00013661924,"threshold_uncertainty_score":0.42682526},"labels":[],"label_agreement":null},{"id":"W2901127133","doi":"10.1016/j.euo.2018.10.008","title":"Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Meta-analysis of Oncologic, Perioperative, and Complication-related outcomes","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cystectomy; Medicine; Bladder cancer; Perioperative; Randomized controlled trial; Hazard ratio; Surgery; Confidence interval; Cancer; Internal medicine","score_opus":0.22061064428387933,"score_gpt":0.44183294748994956,"score_spread":0.22122230320607023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901127133","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022124572,0.94380665,0.00007343406,0.0017272814,0.0005327613,0.003644355,0.00030328575,0.00013888518,0.049552128],"genre_scores_gemma":[0.009258462,0.9765118,0.0037930682,0.002662296,0.0002888916,0.0010334069,0.0017297084,0.00031959426,0.0044027995],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.98879343,0.0062900833,0.0022254568,0.0016847948,0.0003515183,0.00065468514],"domain_scores_gemma":[0.9945175,0.0019268547,0.0014385127,0.0013553703,0.00028521082,0.000476544],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015944886,0.0010336775,0.012123352,0.0009268098,0.0002606234,0.000048936163,0.0011105927,0.0010052259,0.0031480398],"category_scores_gemma":[0.00049798534,0.0006805319,0.002695261,0.0013405195,0.0022284572,0.00008176538,0.0009365669,0.0011495767,0.00033703508],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026113817,0.0026351959,0.0003589298,0.0016888034,0.77854556,0.001980361,0.0005668877,0.0000050553494,0.000011725353,0.0008617144,0.0024578776,0.2082765],"study_design_scores_gemma":[0.0063240947,0.0046145995,0.0036057308,0.00004564588,0.40053442,0.00053025945,0.000013617478,0.000011863565,3.973274e-7,0.000003825337,0.5840085,0.00030705656],"about_ca_topic_score_codex":0.00012938955,"about_ca_topic_score_gemma":0.00013688332,"teacher_disagreement_score":0.5815506,"about_ca_system_score_codex":0.00047435416,"about_ca_system_score_gemma":0.0013397264,"threshold_uncertainty_score":0.9995646},"labels":[],"label_agreement":null},{"id":"W2902725138","doi":"10.1016/j.euo.2018.11.005","title":"Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Janssen Research and Development; Genentech; European Society for Medical Oncology; Astellas Pharma; Eisai; Bayer; Canada Millennium Scholarship Foundation; Phycological Society of America; Amgen; Boehringer Ingelheim; Gilead Sciences; AbbVie; Sanofi; Novartis; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Clinical trial; Randomized controlled trial; Prostate-specific antigen; Cabazitaxel; Prostate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.06802942518975472,"score_gpt":0.40857977959971103,"score_spread":0.3405503544099563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902725138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880523,0.00030139007,0.000031998177,0.0030272815,0.00011959632,0.0063081533,0.00003924749,0.000049950813,0.0020700495],"genre_scores_gemma":[0.995367,0.00094303826,0.0016187395,0.00031752107,0.00019739615,0.00048415214,0.000104136874,0.00007535412,0.0008926579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9896964,0.006214053,0.002096347,0.0008130232,0.000470446,0.00070975],"domain_scores_gemma":[0.9940342,0.003719901,0.0011078375,0.00036710725,0.0005641895,0.00020682262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007184417,0.0003782874,0.0024731415,0.0003963435,0.00007039379,0.000020146214,0.00017815978,0.00018451856,0.00007806328],"category_scores_gemma":[0.0013562476,0.00021102,0.00015639393,0.00063559035,0.0015936667,0.00010187431,0.00006964758,0.00077222695,0.000024404828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48469844,0.0015333154,0.5091861,0.000020348758,0.0007176731,0.0015437698,0.00046244985,0.000018757371,0.000058013,0.0000103431885,0.00007982834,0.0016709911],"study_design_scores_gemma":[0.45978618,0.025535023,0.51300496,0.00007577308,0.00044127973,0.00002892322,0.00011206299,0.00011594014,0.000032681728,0.000015717927,0.00070471334,0.00014676791],"about_ca_topic_score_codex":0.00038454344,"about_ca_topic_score_gemma":0.005813152,"teacher_disagreement_score":0.024912255,"about_ca_system_score_codex":0.00036077594,"about_ca_system_score_gemma":0.0015286652,"threshold_uncertainty_score":0.8605146},"labels":[],"label_agreement":null},{"id":"W2903023839","doi":"10.1016/j.euo.2018.11.006","title":"Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Cabozantinib; Docetaxel; Prostate cancer; Oncology; Abiraterone acetate; Internal medicine; Enzalutamide; Hazard ratio; Mitoxantrone; Prednisone; Cancer; Urology; Confidence interval; Chemotherapy; Androgen receptor; Androgen deprivation therapy","score_opus":0.11050460092748174,"score_gpt":0.4826046893328425,"score_spread":0.3721000884053608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903023839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877755,0.0021799644,0.00045964585,0.002589737,0.00054461136,0.0028096433,0.0003989523,0.00006659028,0.0031753627],"genre_scores_gemma":[0.99506754,0.00008057761,0.0021074007,0.00055199454,0.0002796631,0.00033587616,0.00041424282,0.000050027025,0.0011126924],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618185,0.0014581817,0.0010249439,0.000533112,0.00023403237,0.0005679098],"domain_scores_gemma":[0.99744016,0.0007817524,0.0006838751,0.00035531112,0.00054805056,0.00019085086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027319342,0.00025350295,0.0016187766,0.00057617674,0.0001811773,0.000016519458,0.00016820716,0.000066493434,0.00041729287],"category_scores_gemma":[0.00078614237,0.00018456028,0.0005332331,0.0008070131,0.0006066664,0.00006800263,0.00006339322,0.00019023487,0.000020275438],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1998396,0.012682442,0.039308578,0.00070572423,0.115658626,0.009585946,0.015149163,0.00025404565,0.46102983,0.0041520963,0.013076727,0.12855724],"study_design_scores_gemma":[0.42914695,0.16160312,0.047859628,0.0002524474,0.13958456,0.00020839386,0.0016532728,0.01136437,0.06912811,0.0010327084,0.13651769,0.0016487536],"about_ca_topic_score_codex":0.00006344024,"about_ca_topic_score_gemma":0.00018121388,"teacher_disagreement_score":0.3919017,"about_ca_system_score_codex":0.00010676172,"about_ca_system_score_gemma":0.00069589796,"threshold_uncertainty_score":0.752615},"labels":[],"label_agreement":null},{"id":"W2909961841","doi":"10.1016/j.euo.2018.12.007","title":"Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Vlaamse regering; Kom op tegen Kanker; Leonard D. Schaeffer Center for Health Policy and Economics; KU Leuven; Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Interquartile range; Prostate cancer; Odds ratio; Prostatectomy; Cohort; Internal medicine; Population; Oncology; DECIPHER; Logistic regression; Cancer; Metastasis; Cohort study; Surgery; Bioinformatics; Biology","score_opus":0.014951533781855294,"score_gpt":0.2694467555458495,"score_spread":0.2544952217639942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909961841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958561,0.0005900338,0.000030590585,0.0009730302,0.00025631365,0.0015866007,0.00019349546,0.000015216037,0.00049858465],"genre_scores_gemma":[0.9978975,0.00035471996,0.0005582406,0.00031504157,0.000038034894,0.00046043785,0.000044975313,0.000042070627,0.0002889447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982235,0.00048493574,0.0004563906,0.0003791224,0.0001391157,0.0003169265],"domain_scores_gemma":[0.99780506,0.0012979793,0.00042054988,0.00031542152,0.00010056025,0.000060458475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007860528,0.00016742609,0.0005011274,0.00009461725,0.000032604377,0.0000062008116,0.000093743736,0.000034948578,0.00019301045],"category_scores_gemma":[0.00030217835,0.00010741615,0.00007758078,0.0002180035,0.00016982474,0.000057147903,0.000058725367,0.00018385139,0.000027401737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017748448,0.0004292161,0.9836545,0.00010522691,0.00017595946,0.000111501926,0.00090223056,0.0003882119,0.00022222193,0.000009996354,0.000572132,0.011653956],"study_design_scores_gemma":[0.0045001637,0.0031150088,0.98451287,0.00016202834,0.0005891961,0.000025901232,0.00011492413,0.00023091129,0.0008747844,0.000076140146,0.005668792,0.00012928995],"about_ca_topic_score_codex":0.00011871871,"about_ca_topic_score_gemma":0.00016545266,"teacher_disagreement_score":0.011524666,"about_ca_system_score_codex":0.00017299605,"about_ca_system_score_gemma":0.0002945289,"threshold_uncertainty_score":0.43803033},"labels":[],"label_agreement":null},{"id":"W2913311442","doi":"10.1016/j.euo.2019.01.009","title":"Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Janssen Research and Development; Fonds de Recherche du Québec - Santé; AbbVie; Merck; Sanofi; Janssen Biotech; Astellas Pharma; Genzyme; Bayer; Netherlands Leprosy Relief; Amgen","keywords":"Medicine; Abiraterone acetate; Prednisone; Asymptomatic; Internal medicine; Prostate cancer; Proportional hazards model; Oncology; Survival analysis; Placebo; Retrospective cohort study; Predictive marker; Neutrophil to lymphocyte ratio; Lymphocyte; Gastroenterology; Cancer; Pathology; Androgen deprivation therapy","score_opus":0.008421583608822449,"score_gpt":0.2784300486536095,"score_spread":0.27000846504478704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913311442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865679,0.00005565167,0.00004752382,0.0017985718,0.000439293,0.00283821,0.000070200884,0.000052418094,0.008130187],"genre_scores_gemma":[0.9961176,0.0000048086813,0.00015358898,0.0026371668,0.00005528367,0.00008326553,0.000007674618,0.0000573158,0.00088327477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99405724,0.003514646,0.00084447605,0.0007456048,0.00041774442,0.00042031688],"domain_scores_gemma":[0.9970331,0.00044020306,0.00048794452,0.0012470155,0.0005496502,0.0002420401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024468563,0.00029427657,0.0011536569,0.0008287696,0.000073553165,0.0000063786,0.000518845,0.00013990227,0.0005272467],"category_scores_gemma":[0.0010987677,0.0002268682,0.00032249064,0.0017967696,0.00039270075,0.000045281697,0.00058829633,0.00029509078,0.00033348467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09030359,0.0012345992,0.8249731,0.000023233466,0.0056488654,0.00038084405,0.0050224727,0.0007564666,0.07058757,0.000046495756,0.0007232336,0.0002995025],"study_design_scores_gemma":[0.0048705693,0.01655638,0.9703721,0.000015853639,0.0038029857,0.000037269958,0.00062567176,0.00026770346,0.0013098522,0.00000760081,0.0019780619,0.00015598751],"about_ca_topic_score_codex":0.000022407947,"about_ca_topic_score_gemma":0.000030076984,"teacher_disagreement_score":0.14539893,"about_ca_system_score_codex":0.00042359048,"about_ca_system_score_gemma":0.00057851285,"threshold_uncertainty_score":0.92514163},"labels":[],"label_agreement":null},{"id":"W2921052390","doi":"10.1016/j.euo.2019.02.004","title":"Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"EMD Serono; MedImmune; Exelixis; Novartis; Merck; Bayer; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Hazard ratio; Proportional hazards model; Oncology; Taxane; Liquid biopsy; Carcinoma; Cancer; Confidence interval; Breast cancer","score_opus":0.03538344053251901,"score_gpt":0.33735410156659135,"score_spread":0.30197066103407233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921052390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794558,0.000036991438,0.00001679384,0.0010187739,0.00036211387,0.0012905088,0.000006623146,0.00005079648,0.017761568],"genre_scores_gemma":[0.9954616,0.0000044717194,0.00024412392,0.003400418,0.00014709898,0.000042673106,0.0000105586005,0.000041876596,0.00064720545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975104,0.001035906,0.0005038008,0.00049242895,0.00014660339,0.00031087114],"domain_scores_gemma":[0.9989181,0.0004348722,0.00021171366,0.00026098196,0.000067385554,0.00010693369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080268004,0.00018421818,0.0005894983,0.00011940172,0.000061501756,0.000010282961,0.0000735668,0.00005238581,0.00008877344],"category_scores_gemma":[0.00022702993,0.00014566515,0.00004138911,0.00011928058,0.00006309424,0.000064272484,0.00006028019,0.0004216773,0.00015428718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017228688,0.0015779971,0.9928747,0.000007108312,0.0001526937,0.00095294876,0.0007378396,0.00001753101,0.00047413463,0.000024203042,0.000027260525,0.0014307034],"study_design_scores_gemma":[0.018388238,0.032377474,0.94749117,0.0000065531594,0.00018220009,0.00018409072,0.00025388788,0.000056740977,0.0000055563128,0.000011582092,0.0009263127,0.000116221956],"about_ca_topic_score_codex":0.00009325089,"about_ca_topic_score_gemma":0.00033746293,"teacher_disagreement_score":0.04538357,"about_ca_system_score_codex":0.00019224902,"about_ca_system_score_gemma":0.00022485486,"threshold_uncertainty_score":0.5940052},"labels":[],"label_agreement":null},{"id":"W2925184412","doi":"10.1016/j.euo.2019.02.007","title":"Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ferring; Astellas Pharma Canada; Sanofi; Merck; Bayer","keywords":"Medicine; Prostate cancer; Radium-223; Denosumab; Zoledronic acid; Androgen deprivation therapy; Oncology; Abiraterone acetate; Cancer; Internal medicine; Abiraterone; Bone metastasis; Osteoporosis; Androgen receptor","score_opus":0.06879219085183638,"score_gpt":0.359064597872905,"score_spread":0.2902724070210686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925184412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8199161,0.020807404,0.0009584737,0.09523265,0.00372915,0.009358292,0.0005921999,0.00044320797,0.048962485],"genre_scores_gemma":[0.9834044,0.0016649562,0.0053800144,0.0021994216,0.00060350006,0.0005723512,0.00085619045,0.00011639875,0.005202775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662936,0.0015211818,0.00054515497,0.0006185718,0.00015383062,0.00053191924],"domain_scores_gemma":[0.99812627,0.00078946055,0.00027609232,0.00050424325,0.0001283907,0.00017555308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091318344,0.00029618753,0.00046357446,0.00014607265,0.00046350682,0.000057895653,0.00023346115,0.000052882893,0.00048492654],"category_scores_gemma":[0.00009108965,0.0001926931,0.00016862844,0.00021261063,0.00023938017,0.000094086085,0.0000932213,0.00032068667,0.00026807783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026294991,0.009816087,0.052443616,0.00022563056,0.011717058,0.004022964,0.08305591,0.0020927996,0.23359433,0.008802674,0.066048086,0.50188583],"study_design_scores_gemma":[0.028041504,0.011845098,0.04233953,0.00015677357,0.0012366967,0.00019596399,0.0039936113,0.0030119738,0.00066023634,0.00044225782,0.9074977,0.00057864166],"about_ca_topic_score_codex":0.00034503292,"about_ca_topic_score_gemma":0.00070894964,"teacher_disagreement_score":0.8414496,"about_ca_system_score_codex":0.0005852001,"about_ca_system_score_gemma":0.00036542577,"threshold_uncertainty_score":0.78577965},"labels":[],"label_agreement":null},{"id":"W2931461559","doi":"10.1016/j.euo.2019.03.003","title":"Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Receiver operating characteristic; Stage (stratigraphy); Prostate cancer; Prostate-specific antigen; Logistic regression; Cohort; Prostate; Oncology; Cancer; Internal medicine; Confidence interval; Statistics; Mathematics","score_opus":0.06270675657138075,"score_gpt":0.34705480117989096,"score_spread":0.2843480446085102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2931461559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926215,0.0021861808,0.00047004386,0.0012816216,0.0003382994,0.002806494,0.00011663243,0.000017467892,0.00016179601],"genre_scores_gemma":[0.9906675,0.0017164899,0.006501521,0.00060230284,0.000060275877,0.00024920137,0.000048228198,0.00003392573,0.00012055769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829495,0.00028169042,0.00065391365,0.0003992781,0.000120568686,0.000249574],"domain_scores_gemma":[0.9986015,0.0005808185,0.00037189462,0.00020227264,0.00014161397,0.0001018915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010893726,0.00015710309,0.0005312543,0.000093599294,0.000072773626,0.000008926251,0.0000702869,0.000037009373,0.00002013798],"category_scores_gemma":[0.00011381063,0.000110316716,0.00004367788,0.00012903575,0.00017266072,0.000059734248,0.000094757816,0.00012775732,0.000005020442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003948681,0.00086590706,0.8952232,0.00056833157,0.00085262116,0.000050116607,0.0046360404,0.00036464064,0.013063151,0.0009527293,0.00097005506,0.078504495],"study_design_scores_gemma":[0.010139812,0.011585592,0.80042404,0.00014786556,0.0005804535,0.00005795484,0.001405078,0.0006937079,0.012643635,0.00006614806,0.1620777,0.00017801028],"about_ca_topic_score_codex":0.000025913736,"about_ca_topic_score_gemma":0.000009461439,"teacher_disagreement_score":0.16110764,"about_ca_system_score_codex":0.00007530531,"about_ca_system_score_gemma":0.00021331373,"threshold_uncertainty_score":0.44985852},"labels":[],"label_agreement":null},{"id":"W2939883602","doi":"10.1016/j.euo.2019.03.008","title":"Salvage Local Treatments After Focal Therapy for Prostate Cancer","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"UCLH Biomedical Research Centre; National Health Research Institutes; National Institute for Health and Care Research","keywords":"Medicine; Prostatectomy; Prostate cancer; Salvage therapy; Retrospective cohort study; Radiation therapy; Ablation; Surgery; Sexual function; Prostate; Cancer; Internal medicine; Chemotherapy","score_opus":0.06258989109579838,"score_gpt":0.3876547859406349,"score_spread":0.3250648948448365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939883602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001236141,0.98629767,0.00007350881,0.00090637454,0.0014552522,0.0064032213,0.0005848763,0.00011794604,0.004037557],"genre_scores_gemma":[0.00028241452,0.98398095,0.00018270517,0.0039903517,0.0007612622,0.0053504347,0.0007885965,0.00029939582,0.0043638875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624413,0.00076755864,0.0008302536,0.0011698564,0.00014471654,0.000843476],"domain_scores_gemma":[0.9980201,0.0004344714,0.00047792672,0.00069323514,0.000110936206,0.0002633077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033211737,0.0008186682,0.0031098197,0.00022562132,0.000076026656,0.000015600444,0.00022881675,0.00049002125,0.00041652579],"category_scores_gemma":[0.00002358874,0.00055802666,0.0009176677,0.00015166245,0.000339739,0.00003946762,0.00012855622,0.00054648024,0.0010228554],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013915614,0.0009573405,0.00038347172,0.0024614444,0.0022807615,0.00153191,0.00013265685,0.0000013594369,3.7856387e-7,0.000018909817,0.007930937,0.98290926],"study_design_scores_gemma":[0.0070072967,0.013086353,0.00079797086,0.0009694552,0.004999504,0.00031508942,0.000006010264,0.000003711572,0.0000016994143,0.000012068823,0.97241455,0.0003863058],"about_ca_topic_score_codex":0.000020869735,"about_ca_topic_score_gemma":0.00001895084,"teacher_disagreement_score":0.98252296,"about_ca_system_score_codex":0.001013895,"about_ca_system_score_gemma":0.0011786831,"threshold_uncertainty_score":0.99975497},"labels":[],"label_agreement":null},{"id":"W2946628936","doi":"10.1016/j.euo.2019.04.007","title":"Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"European Organisation for Research and Treatment of Cancer; Medtronic","keywords":"Medicine; Nephrectomy; Intensive care medicine; MEDLINE; Urology; Internal medicine; Kidney","score_opus":0.10100723821200605,"score_gpt":0.38861430127581376,"score_spread":0.2876070630638077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946628936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00057550357,0.9665826,0.00012429034,0.0024804387,0.0012805074,0.005479775,0.00047100472,0.00012190957,0.022883983],"genre_scores_gemma":[0.0015677697,0.9832025,0.003014159,0.0018967547,0.0016886295,0.0012628727,0.0045294403,0.00033953405,0.0024983333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943311,0.0025853761,0.0010378779,0.0010700114,0.00020517908,0.0007704588],"domain_scores_gemma":[0.9955974,0.0016840581,0.00095627055,0.0012450321,0.00027803914,0.00023920232],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001215403,0.0007490182,0.0027477313,0.00046194193,0.00024889858,0.000035341396,0.0007204594,0.0005883381,0.00035687364],"category_scores_gemma":[0.0006013036,0.0004782734,0.0006495064,0.0005082129,0.00045815666,0.000048303886,0.00035631767,0.0011602947,0.0016682099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001399347,0.0014847006,0.00019341164,0.007056049,0.006856905,0.0010316663,0.0021721756,0.000007898835,0.000031958167,0.0014732258,0.10708045,0.8712122],"study_design_scores_gemma":[0.0022186674,0.0040391446,0.0007138528,0.0002801686,0.0097265225,0.0024786622,0.000033045282,0.000007656384,0.0000027323329,0.000018610948,0.980136,0.0003449312],"about_ca_topic_score_codex":0.000013671439,"about_ca_topic_score_gemma":0.000017392274,"teacher_disagreement_score":0.8730556,"about_ca_system_score_codex":0.0006058302,"about_ca_system_score_gemma":0.0021335154,"threshold_uncertainty_score":0.9997669},"labels":[],"label_agreement":null},{"id":"W2947253482","doi":"10.1016/j.euo.2019.05.001","title":"Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Neuropeptides and Animal Physiology","field":"Neuroscience","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Transcriptome; Identification (biology); Oncology; Neuropeptide; Cancer research; Internal medicine; Pathology; Gene expression; Biology; Gene; Receptor","score_opus":0.050242098600692696,"score_gpt":0.3534754279592582,"score_spread":0.3032333293585655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947253482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976604,0.00007261804,0.000092105845,0.00079589157,0.00024148005,0.0008645558,0.000118710625,0.000025201509,0.00012905325],"genre_scores_gemma":[0.9951839,0.0034678357,0.0001177261,0.0009830608,0.000035467794,0.00003492515,0.000014192946,0.000044999506,0.0001178874],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9959424,0.0016178924,0.0012739269,0.0007978939,0.0000915137,0.00027636046],"domain_scores_gemma":[0.9980774,0.00049946154,0.0009309458,0.00029956567,0.00009814352,0.00009449844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072353665,0.00019437591,0.0006503936,0.00013616195,0.00004863982,0.000010627159,0.0002235869,0.00007442733,0.000019028199],"category_scores_gemma":[0.00019060678,0.00015802839,0.0000541006,0.00025213158,0.0008832298,0.0001651349,0.00012763355,0.00037209457,0.000008465325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016937641,0.00041459478,0.12576355,0.000057739362,0.0000133294625,0.000011391948,0.00020592904,0.00008559096,0.86492234,0.00025463183,0.000008119617,0.006569033],"study_design_scores_gemma":[0.004807298,0.002784788,0.9645508,0.000044889424,0.0000821378,0.00004256838,0.00002001716,0.0009922413,0.023495018,0.000046168723,0.002955743,0.00017831936],"about_ca_topic_score_codex":0.000030246041,"about_ca_topic_score_gemma":0.000048322658,"teacher_disagreement_score":0.8414273,"about_ca_system_score_codex":0.0000143884035,"about_ca_system_score_gemma":0.00013729355,"threshold_uncertainty_score":0.6444211},"labels":[],"label_agreement":null},{"id":"W2949728994","doi":"10.1016/j.euo.2019.06.003","title":"Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Mitomycin C; Disease; Cancer; Urology; Carcinoma in situ; Surgery; Internal medicine; Oncology","score_opus":0.023462383481248718,"score_gpt":0.3043653441791391,"score_spread":0.28090296069789034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949728994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90212256,0.009900988,0.000031501095,0.043655105,0.0052777776,0.0016310826,0.000043547552,0.00014526867,0.0371922],"genre_scores_gemma":[0.9687141,0.007077515,0.00007501899,0.02042878,0.0010110462,0.00011662089,0.00004908367,0.00008388013,0.0024439183],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975209,0.0006973546,0.00038129388,0.00063254114,0.00019707167,0.00057080603],"domain_scores_gemma":[0.99840677,0.00029186194,0.0002486054,0.0007225771,0.00013397018,0.00019621963],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003427207,0.00031556917,0.0005459686,0.00011608675,0.00017067211,0.00003419394,0.00033906504,0.00016897562,0.001466128],"category_scores_gemma":[0.00006297506,0.0002173959,0.00019140846,0.00020625914,0.0003248875,0.0001377234,0.00018039336,0.00065245776,0.0030692879],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006252379,0.0077645774,0.23577523,0.0005266197,0.0056816135,0.0067222766,0.0125007685,0.00089949777,0.024039438,0.0012801664,0.21241914,0.48613828],"study_design_scores_gemma":[0.00930404,0.006675069,0.44041586,0.00017078362,0.0009250076,0.0005793774,0.001720995,0.00009442201,0.00047847527,0.00013267889,0.53905725,0.0004460493],"about_ca_topic_score_codex":0.000051070707,"about_ca_topic_score_gemma":0.00016694928,"teacher_disagreement_score":0.48569223,"about_ca_system_score_codex":0.00022967834,"about_ca_system_score_gemma":0.00041491058,"threshold_uncertainty_score":0.9994467},"labels":[],"label_agreement":null},{"id":"W2949821396","doi":"10.1016/j.euo.2019.01.013","title":"Re: Shusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2019;2:320–328","year":2019,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Overall survival; Cancer; Internal medicine; Gynecology","score_opus":0.07546158276393353,"score_gpt":0.3527123459148482,"score_spread":0.2772507631509147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949821396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51626116,0.0016722135,0.0024351515,0.45257998,0.0014712868,0.018189242,0.0024843004,0.00018525314,0.0047213957],"genre_scores_gemma":[0.51679057,0.00453398,0.023813704,0.3898716,0.0021322486,0.005792658,0.020781586,0.0012716638,0.035012025],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945606,0.0012644929,0.0012888942,0.0013353415,0.0004991726,0.0010515194],"domain_scores_gemma":[0.996189,0.001780405,0.000916612,0.00044923162,0.0005016477,0.00016311281],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001481528,0.0007767183,0.0016977207,0.00058037014,0.00013914931,0.000039759892,0.00020549294,0.00045382662,0.000024564435],"category_scores_gemma":[0.0003759922,0.0006641393,0.00018033785,0.00021949688,0.00035828515,0.00017147318,0.00017539765,0.0013942997,0.000022461467],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046311636,0.01061745,0.09617826,0.0069776485,0.01557512,0.023295522,0.07195532,0.035349216,0.014635131,0.00025708947,0.6423899,0.03645774],"study_design_scores_gemma":[0.1318097,0.038085654,0.029293926,0.0015597238,0.005875311,0.0011629348,0.0012319301,0.12084862,0.0027056613,0.00012328704,0.6642474,0.0030558384],"about_ca_topic_score_codex":0.00018574398,"about_ca_topic_score_gemma":0.00045338468,"teacher_disagreement_score":0.085499406,"about_ca_system_score_codex":0.0010706423,"about_ca_system_score_gemma":0.003285012,"threshold_uncertainty_score":0.999581},"labels":[],"label_agreement":null},{"id":"W2954147811","doi":"10.1016/j.euo.2019.06.002","title":"Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Roche; Merck","keywords":"Cystectomy; Medicine; Bladder cancer; Chemotherapy; Cisplatin; Oncology; Guideline; Cancer; Neoadjuvant therapy; Internal medicine; Clinical trial; DNA Damage Repair; DNA repair; Pathology; Gene; Breast cancer","score_opus":0.03674697873142426,"score_gpt":0.3119977905155355,"score_spread":0.27525081178411126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954147811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.927575,0.00089971453,0.0000148391855,0.028389875,0.00072557887,0.000892789,0.00003073696,0.000044928856,0.041426573],"genre_scores_gemma":[0.9751638,0.0006134705,0.00026338725,0.019892393,0.00015321885,0.000026766886,0.000015371297,0.00006010829,0.0038114502],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981675,0.0005406461,0.00042836263,0.00036321033,0.00012398112,0.00037630732],"domain_scores_gemma":[0.9989666,0.00021839108,0.00016870529,0.0004933711,0.000067668494,0.00008527491],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032693596,0.00019612252,0.00048002924,0.00013708559,0.000032119784,0.000004871967,0.0001996012,0.000114762384,0.0009980258],"category_scores_gemma":[0.00004959465,0.00013252132,0.00010313808,0.00021072345,0.00029485335,0.000035044235,0.00006957757,0.0002783031,0.00013115729],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005964007,0.0012626535,0.68439573,0.000059758702,0.0018295682,0.0011273114,0.004155837,0.00038223056,0.025019497,0.00032695103,0.062201925,0.21327455],"study_design_scores_gemma":[0.007471111,0.0024108232,0.39962295,0.00001732191,0.00014896152,0.00015403995,0.0000898091,0.0001291404,0.00057522807,0.000026961274,0.589224,0.00012965717],"about_ca_topic_score_codex":0.0014783336,"about_ca_topic_score_gemma":0.00076097884,"teacher_disagreement_score":0.52702206,"about_ca_system_score_codex":0.00016291159,"about_ca_system_score_gemma":0.00037683974,"threshold_uncertainty_score":0.9999152},"labels":[],"label_agreement":null},{"id":"W2957715479","doi":"10.1016/j.euo.2019.06.014","title":"Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Hazard ratio; Interquartile range; Cystectomy; Proportional hazards model; Chemotherapy; Primary tumor; Internal medicine; Confidence interval; Metastasis; Carboplatin; Oncology; Clinical endpoint; Cancer; Bladder cancer; Surgery; Cisplatin; Clinical trial","score_opus":0.04766636536898497,"score_gpt":0.36295574273882414,"score_spread":0.3152893773698392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957715479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525696,0.00025748648,0.000083470666,0.00069748826,0.00043744678,0.0009599722,0.0006107193,0.000013733705,0.0016827236],"genre_scores_gemma":[0.9963645,0.00012496309,0.0009381571,0.0015644794,0.00010239667,0.00005969499,0.0007386952,0.000029750534,0.000077398756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783134,0.00076730613,0.00061560335,0.0003777535,0.0001723742,0.00023562083],"domain_scores_gemma":[0.99770427,0.001278796,0.0003503643,0.00050141965,0.00010624269,0.00005888148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009870796,0.00016194544,0.00079467305,0.00049936114,0.000025320356,0.0000032503688,0.00027828015,0.00003598931,0.00022244606],"category_scores_gemma":[0.00016150852,0.00011697153,0.00026290823,0.00035287993,0.00016714395,0.000085853164,0.00009290214,0.00016295,0.000017167951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020026026,0.006918218,0.926009,0.0002440281,0.004113293,0.0006112876,0.0037079717,0.0011652169,0.024553545,0.000065527376,0.00032189963,0.0122639695],"study_design_scores_gemma":[0.010232113,0.0018091311,0.97681785,0.00002474274,0.0030817084,0.000037900736,0.0001571315,0.0028716095,0.00035010907,0.0000044974377,0.0045030867,0.00011011209],"about_ca_topic_score_codex":0.00024455742,"about_ca_topic_score_gemma":0.00019545705,"teacher_disagreement_score":0.05080884,"about_ca_system_score_codex":0.00007652834,"about_ca_system_score_gemma":0.00024406456,"threshold_uncertainty_score":0.47699606},"labels":[],"label_agreement":null},{"id":"W2958595932","doi":"10.1016/j.euo.2019.06.001","title":"Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Medical physics; Internal medicine; Radiology","score_opus":0.024791159646288065,"score_gpt":0.3455335534015078,"score_spread":0.32074239375521973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958595932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83874935,0.0024858494,0.00055628683,0.14507525,0.0027636373,0.004813135,0.00027645286,0.00001998223,0.005260041],"genre_scores_gemma":[0.9960031,0.00050443463,0.000019948338,0.0019767294,0.00034254437,0.0004105531,0.00005452216,0.000014741033,0.0006734651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990579,0.00031408356,0.0001842365,0.00019210739,0.00008009139,0.0001715874],"domain_scores_gemma":[0.9992662,0.00026237237,0.00013322796,0.00012757661,0.00019027597,0.000020346388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007484306,0.000073339164,0.00015082826,0.00006965714,0.000052216084,0.000005302099,0.00012388598,0.000037792484,0.000032052187],"category_scores_gemma":[0.0000751543,0.00004137181,0.00004043405,0.00006313537,0.0001873104,0.000040388302,0.00002678773,0.00014372407,0.0000021754538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057457136,0.00038000089,0.8042924,0.00019352676,0.00023695565,0.000012914795,0.0028885717,0.0001993069,0.03672616,0.0026790155,0.0167629,0.12988253],"study_design_scores_gemma":[0.012698047,0.0009502569,0.81308454,0.000029920498,0.00013291712,0.000022486942,0.0004561903,0.0061126594,0.00036664217,0.0004975252,0.16557454,0.00007424381],"about_ca_topic_score_codex":0.000060029957,"about_ca_topic_score_gemma":0.000108274355,"teacher_disagreement_score":0.1572537,"about_ca_system_score_codex":0.0001236978,"about_ca_system_score_gemma":0.00018720028,"threshold_uncertainty_score":0.16870935},"labels":[],"label_agreement":null},{"id":"W2960318035","doi":"10.1016/j.euo.2019.06.008","title":"Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Prostate-specific antigen; Oncology; Prostate; Internal medicine; Cancer; Urology; Androgen receptor","score_opus":0.021386679673091453,"score_gpt":0.335426463842839,"score_spread":0.31403978416974754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960318035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863395,0.004423146,0.000006149766,0.0036662435,0.0002797419,0.0028424521,0.000611679,0.00006600504,0.0017650669],"genre_scores_gemma":[0.9752952,0.014766055,0.000623064,0.00038661488,0.00013572825,0.00040439185,0.000869893,0.000062385756,0.0074566877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997641,0.00037305025,0.00037861287,0.00092647184,0.00014456309,0.00053624803],"domain_scores_gemma":[0.99865603,0.00016330852,0.00019994075,0.00034636562,0.0003447506,0.00028962275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024130357,0.00035775415,0.0007619548,0.00036222814,0.00019038668,0.00004071156,0.000102910875,0.000115073904,0.00017118228],"category_scores_gemma":[0.000015086089,0.00026142807,0.000099808756,0.0002566671,0.0003528316,0.00017590112,0.00010656145,0.00011734812,0.00005410611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041371297,0.0012751475,0.7153254,0.000038780992,0.00501957,0.0007164977,0.0123244,0.00017138754,0.09538753,0.00012699797,0.00009419366,0.12814876],"study_design_scores_gemma":[0.026792098,0.05955995,0.6792968,0.0000133660205,0.000930913,0.00007579268,0.00063231174,0.00026262147,0.004069477,0.000024702194,0.22800197,0.00034004071],"about_ca_topic_score_codex":0.00013737718,"about_ca_topic_score_gemma":0.00046866902,"teacher_disagreement_score":0.22790776,"about_ca_system_score_codex":0.0008753116,"about_ca_system_score_gemma":0.00025575171,"threshold_uncertainty_score":0.9999838},"labels":[],"label_agreement":null},{"id":"W2961998542","doi":"10.1016/j.euo.2019.05.007","title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"SABR volatility model; Ablative case; Medicine; Meta-analysis; Radiation therapy; Renal cell carcinoma; Oncology; Radiosurgery; Stereotactic radiation therapy; Internal medicine; Radiology; Medical physics","score_opus":0.2666787028741161,"score_gpt":0.4176423623246922,"score_spread":0.1509636594505761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961998542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016338679,0.98838264,0.000084290004,0.00021457762,0.00033364922,0.0041624615,0.00025188143,0.000039054867,0.004897573],"genre_scores_gemma":[0.012422077,0.9812126,0.0007789021,0.00062204496,0.00017437979,0.0005149396,0.0008775071,0.00019553576,0.0032019946],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9909985,0.004819129,0.0019949425,0.0012342632,0.00032383614,0.0006292982],"domain_scores_gemma":[0.99099874,0.0044895452,0.002655464,0.0012051072,0.00046925468,0.00018186492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017459274,0.0009673606,0.011955588,0.0018049917,0.00008628657,0.000010425902,0.0003894266,0.00036093176,0.00037352994],"category_scores_gemma":[0.0002981828,0.00063900335,0.0053397184,0.001085591,0.00038409134,0.000058247326,0.00015825446,0.0006175053,0.00021814258],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010445616,0.0011224073,0.00010176696,0.007926297,0.7805807,0.0009010987,0.0016363203,0.000057178113,0.000022908334,0.00007680489,0.0015848615,0.20494509],"study_design_scores_gemma":[0.0019213693,0.007820681,0.00037293564,0.000024529872,0.53049344,0.00011906606,0.000039400795,0.000016250007,0.000012854549,0.0000077457335,0.45891726,0.00025445657],"about_ca_topic_score_codex":0.000013915251,"about_ca_topic_score_gemma":0.000009114457,"teacher_disagreement_score":0.4573324,"about_ca_system_score_codex":0.00054744055,"about_ca_system_score_gemma":0.00072772073,"threshold_uncertainty_score":0.99960613},"labels":[],"label_agreement":null},{"id":"W2963065632","doi":"10.1016/j.euo.2019.06.018","title":"Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Meso Scale Diagnostics; Novartis Pharma; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; AstraZeneca; Ipsen; Bayer Schering; Novartis; Pfizer; Bristol-Myers Squibb","keywords":"Temsirolimus; Sunitinib; Medicine; Everolimus; Internal medicine; Renal cell carcinoma; Oncology; Discovery and development of mTOR inhibitors; Refractory (planetary science); Pazopanib; Sorafenib; Tyrosine-kinase inhibitor; Progressive disease; Cancer; Progression-free survival; Urology; PI3K/AKT/mTOR pathway; Chemotherapy","score_opus":0.030486559560012918,"score_gpt":0.29029199453445287,"score_spread":0.25980543497444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963065632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9186346,0.0020032313,0.000055831206,0.006133082,0.0008545986,0.0022148697,0.0000071214145,0.00010238934,0.069994256],"genre_scores_gemma":[0.9747337,0.00003428537,0.0033576759,0.017670123,0.00036214496,0.00010105399,0.000059679092,0.00013112421,0.0035501914],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.995728,0.0014320543,0.000615121,0.0009938384,0.00030757464,0.0009233949],"domain_scores_gemma":[0.99739325,0.00038506198,0.00021897319,0.0009542469,0.00024331312,0.0008051826],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00074551604,0.00045063687,0.0009197371,0.0004830744,0.00008912144,0.00006733123,0.00039412657,0.00012535123,0.0016858776],"category_scores_gemma":[0.00013940198,0.00038137852,0.00020178365,0.00040460963,0.00015505026,0.00018565022,0.00038804405,0.0005216371,0.015874712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023819089,0.0056307726,0.067301854,0.00063950254,0.0015117488,0.12868789,0.025717856,0.001214084,0.340244,0.0012994433,0.06573085,0.33820292],"study_design_scores_gemma":[0.01344336,0.07593579,0.24085301,0.00009499797,0.001146782,0.00541335,0.0028697462,0.000050663366,0.021032367,0.00006521375,0.63808256,0.0010121379],"about_ca_topic_score_codex":0.00001477767,"about_ca_topic_score_gemma":0.000008092056,"teacher_disagreement_score":0.57235175,"about_ca_system_score_codex":0.00036650716,"about_ca_system_score_gemma":0.00037388032,"threshold_uncertainty_score":0.9998638},"labels":[],"label_agreement":null},{"id":"W2975538531","doi":"10.1016/j.euo.2019.09.001","title":"Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute; Ipsen Biopharmaceuticals; Dana-Farber/Harvard Cancer Center; University of Rochester; Pfizer; Eisai; AbbVie; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Internal medicine; Cohort; Renal cell carcinoma; Oncology; Proportional hazards model; Antibiotics; Confidence interval","score_opus":0.017095364068757186,"score_gpt":0.2640910312807955,"score_spread":0.24699566721203828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975538531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98430485,0.00040422296,0.0000052626197,0.00024376117,0.00016344295,0.0011085281,0.0000046271343,0.00003412548,0.013731165],"genre_scores_gemma":[0.99829024,0.000017200673,0.00017336113,0.0004935817,0.000022838776,0.00000773497,0.000016164906,0.000063382926,0.00091552385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961078,0.0024201153,0.00044677826,0.00046331546,0.00018522129,0.0003767351],"domain_scores_gemma":[0.9976961,0.0013385229,0.00025707658,0.0005668085,0.00004777208,0.000093691284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077206397,0.00031291615,0.0011029667,0.00034998095,0.00001959374,0.000004976858,0.00014570853,0.00008096149,0.00006919644],"category_scores_gemma":[0.000067514615,0.00019060711,0.00012650911,0.00016711769,0.00018605405,0.000048880378,0.000054280346,0.0003523654,0.00043552343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005152557,0.0004725912,0.96142155,0.00031523657,0.00019374609,0.0045978026,0.0006168051,0.00018944523,0.026004832,0.0000536974,0.00004549705,0.0009362106],"study_design_scores_gemma":[0.012274161,0.06250661,0.9118654,0.00006266115,0.00045475955,0.0010528077,0.00007750583,0.000032558954,0.011155804,0.0000012906737,0.0003566002,0.00015983146],"about_ca_topic_score_codex":0.000055655404,"about_ca_topic_score_gemma":0.000015460852,"teacher_disagreement_score":0.062034015,"about_ca_system_score_codex":0.00016027436,"about_ca_system_score_gemma":0.00010029434,"threshold_uncertainty_score":0.77727324},"labels":[],"label_agreement":null},{"id":"W2977743112","doi":"10.1016/j.euo.2019.09.002","title":"First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Axitinib; Medicine; Oncology; Internal medicine; Renal cell carcinoma; Population; Clinical endpoint; Pembrolizumab; Adverse effect; Progression-free survival; Clinical trial; Meta-analysis; Atezolizumab; Avelumab; Cancer; Overall survival; Immunotherapy; Sunitinib","score_opus":0.1707180087076591,"score_gpt":0.35836265979127085,"score_spread":0.18764465108361175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977743112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013339149,0.9872023,0.000058325877,0.00030456088,0.00011148031,0.0072573707,0.000108350985,0.00003991737,0.004904377],"genre_scores_gemma":[0.0007098474,0.99232006,0.00075286644,0.0006793602,0.00012324045,0.00062488246,0.0004892726,0.00016101972,0.004139452],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9881252,0.0065935445,0.0030237206,0.0012741225,0.00029927067,0.0006841325],"domain_scores_gemma":[0.99272436,0.0019829383,0.0028100887,0.0019648448,0.00018245047,0.00033534612],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0016119109,0.0012271189,0.027541602,0.0006291955,0.00007773948,0.0000096669,0.0003480895,0.00029256134,0.00053729763],"category_scores_gemma":[0.00013561243,0.0007177708,0.006033465,0.00096935587,0.00027868006,0.000026967042,0.00020831214,0.00043620876,0.00048530143],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005221952,0.00081096403,0.000011154315,0.76313144,0.23023571,0.0029193216,0.00006564592,0.000040978397,1.2732956e-7,0.000019662588,0.00043127564,0.0022814923],"study_design_scores_gemma":[0.00096350274,0.00749733,0.000014835711,0.0029519373,0.7591463,0.0015871543,0.0000025047632,0.000008670817,2.5954674e-7,0.0000027409271,0.22753848,0.0002863174],"about_ca_topic_score_codex":0.00002807135,"about_ca_topic_score_gemma":0.000029891471,"teacher_disagreement_score":0.7601795,"about_ca_system_score_codex":0.00043344064,"about_ca_system_score_gemma":0.00044505813,"threshold_uncertainty_score":0.99952734},"labels":[],"label_agreement":null},{"id":"W2979377184","doi":"10.1016/j.euo.2019.09.003","title":"What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Oncology; Internal medicine; Cancer; Clinical trial; Meta-analysis","score_opus":0.09390410564921418,"score_gpt":0.384706383792036,"score_spread":0.2908022781428218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979377184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16444032,0.8247159,0.0000050655103,0.0016825866,0.0004923925,0.00787864,0.00064099964,0.000021499638,0.00012256691],"genre_scores_gemma":[0.071886815,0.9236106,0.00016807848,0.0033924507,0.00010509786,0.00057289907,0.00004446579,0.00012858643,0.00009098767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98592144,0.007424819,0.004025495,0.0013990562,0.00052343484,0.00070577994],"domain_scores_gemma":[0.98820996,0.0059686317,0.004373016,0.00061097305,0.0006114146,0.00022602157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003476776,0.00093947415,0.007067197,0.00036346543,0.00008226772,0.000022794382,0.00038729745,0.00042378344,0.00014253057],"category_scores_gemma":[0.0043620495,0.00056241016,0.00031888078,0.00043024812,0.0012380235,0.00017958054,0.00043799356,0.0011178488,0.0000042515862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010483941,0.0019182276,0.7675415,0.14175639,0.008476404,0.0006414178,0.002005343,0.000010058811,0.00000914841,0.00002331855,0.00023825112,0.076331526],"study_design_scores_gemma":[0.018738765,0.013354351,0.84225273,0.060427494,0.05928976,0.00030101722,0.00046235567,0.00007695681,9.000249e-7,0.00004982669,0.0040486515,0.0009972069],"about_ca_topic_score_codex":0.00034878546,"about_ca_topic_score_gemma":0.0019619123,"teacher_disagreement_score":0.09889469,"about_ca_system_score_codex":0.00029883388,"about_ca_system_score_gemma":0.0013978982,"threshold_uncertainty_score":0.9996827},"labels":[],"label_agreement":null},{"id":"W2980122297","doi":"10.1016/j.euo.2019.08.003","title":"Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Henry M. Jackson Foundation; Brigham Research Institute; Prostate Cancer Foundation","keywords":"Medicine; Androgen deprivation therapy; Dementia; Hazard ratio; Prostate cancer; Proportional hazards model; Depression (economics); Internal medicine; Cohort; Neurocognitive; Cohort study; Oncology; Cancer; Psychiatry; Confidence interval; Cognition","score_opus":0.012978189361594637,"score_gpt":0.2588309837939002,"score_spread":0.24585279443230554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980122297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335384,0.0017791179,0.000032186872,0.00019221207,0.000028156728,0.0011914521,0.0000092602595,0.00002538719,0.0033883853],"genre_scores_gemma":[0.99731904,0.002023839,0.000275459,0.00012805434,0.000020088273,0.000048524387,0.000014859067,0.000034525634,0.00013557798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984709,0.0005383379,0.00026557193,0.000373565,0.000104796985,0.00024682216],"domain_scores_gemma":[0.999252,0.00017659571,0.00029434473,0.00013294243,0.000092431066,0.000051678362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037791385,0.00017105679,0.00039965828,0.00016031184,0.000060999977,0.0000050412855,0.000038797985,0.000049836905,0.000033890497],"category_scores_gemma":[0.00005194663,0.000117527125,0.0000146689845,0.00016821809,0.00024737229,0.00007070495,0.0000705209,0.00023287453,0.0000027811395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045747166,0.00013754788,0.98452324,0.000051940024,0.00068867294,0.000094301,0.002619504,0.00007611879,0.002892162,9.37907e-7,0.000019535291,0.004321329],"study_design_scores_gemma":[0.013383574,0.003102227,0.9809304,0.00008386103,0.00048405194,0.000134744,0.0004197615,0.00032034054,0.00090845616,0.000005746102,0.0001145333,0.00011229453],"about_ca_topic_score_codex":0.0002270433,"about_ca_topic_score_gemma":0.00044250573,"teacher_disagreement_score":0.008808857,"about_ca_system_score_codex":0.000037908663,"about_ca_system_score_gemma":0.000047256963,"threshold_uncertainty_score":0.4792617},"labels":[],"label_agreement":null},{"id":"W2989830802","doi":"10.1016/j.euo.2019.11.001","title":"Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; CancerCare Manitoba; Health Sciences Centre; University of Manitoba; Princess Margaret Cancer Centre; University of Calgary","funders":"Instituto de Salud Carlos III; Genentech; Eisai; American Psychosocial Oncology Society; Exelixis; North Carolina GlaxoSmithKline Foundation; EMD Serono; Novartis; Merck; F. Hoffmann-La Roche; Roche; Astellas Pharma US; Health Research Fund of Central Denmark Region; Dana-Farber Cancer Institute; Pfizer; Ipsen Biopharmaceuticals; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Nivolumab; Immunotherapy; Cancer","score_opus":0.010604879800889895,"score_gpt":0.23012148977798388,"score_spread":0.219516609977094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989830802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97915393,0.00062338053,0.000014257805,0.0004547319,0.00018361246,0.001648675,0.000028148466,0.00007353591,0.0178197],"genre_scores_gemma":[0.9960174,0.000022508588,0.00132798,0.0011503407,0.000050507802,0.00007695792,0.00020437161,0.00014050568,0.0010094456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961026,0.0012709472,0.0008434643,0.00076139695,0.0003456868,0.000675907],"domain_scores_gemma":[0.9976688,0.00029059188,0.0006441572,0.0008064384,0.0003525552,0.0002374786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041701118,0.0005655463,0.0014822468,0.0003725008,0.00005108959,0.0000062814465,0.00022465535,0.00017872418,0.00081803324],"category_scores_gemma":[0.000026582931,0.00034345288,0.00021636249,0.00030620545,0.0005252566,0.00007769604,0.0001140849,0.00047280698,0.00030327786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020972913,0.002595141,0.96029216,0.000046985795,0.0007667315,0.0022783228,0.00090083614,0.00003079675,0.010016086,0.0000050589124,0.00016064872,0.0019342913],"study_design_scores_gemma":[0.02529319,0.055461474,0.89867646,0.000010324009,0.000607483,0.00017767743,0.000106396845,0.000007658946,0.012213531,0.0000029650862,0.0071540955,0.00028875904],"about_ca_topic_score_codex":0.00007021336,"about_ca_topic_score_gemma":0.000027316853,"teacher_disagreement_score":0.06161574,"about_ca_system_score_codex":0.0003431885,"about_ca_system_score_gemma":0.00038179694,"threshold_uncertainty_score":0.9999018},"labels":[],"label_agreement":null},{"id":"W2995340453","doi":"10.1016/j.euo.2019.11.005","title":"The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Lymphadenectomy; MEDLINE; Meta-analysis; Cochrane Library; Systematic review; Cancer; Surgery; Urology; Internal medicine","score_opus":0.04368535579554485,"score_gpt":0.3663460669193838,"score_spread":0.322660711123839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995340453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01682308,0.9739299,0.000012303867,0.0026116043,0.00029518147,0.0048158877,0.0013510254,0.000011692759,0.00014934877],"genre_scores_gemma":[0.022322513,0.9752252,0.00005144758,0.001225039,0.00008490836,0.00059458293,0.00009980226,0.00008101876,0.00031549545],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929905,0.0037756627,0.0020139783,0.0006434628,0.000193792,0.0003825914],"domain_scores_gemma":[0.9941818,0.002047781,0.0027562894,0.00053706934,0.00034526337,0.00013179544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032400687,0.00047171055,0.0034291719,0.00008784517,0.00011893269,0.000011001249,0.00021265606,0.00019630643,0.000057022036],"category_scores_gemma":[0.0012443963,0.00028247313,0.00023692207,0.00014374765,0.00077029405,0.000053882348,0.00022548453,0.0003888257,0.000002385525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058264256,0.0009756031,0.08212426,0.62584096,0.01808178,0.00026725707,0.0015477494,4.6952226e-7,0.000021222417,0.00005212037,0.02323277,0.24727316],"study_design_scores_gemma":[0.012398765,0.0118328,0.05917075,0.03460593,0.20262839,0.0014825121,0.00030451812,0.00007635125,0.0000075141775,0.00014983233,0.67598933,0.0013533151],"about_ca_topic_score_codex":0.00030136527,"about_ca_topic_score_gemma":0.00071533566,"teacher_disagreement_score":0.6527566,"about_ca_system_score_codex":0.00010362176,"about_ca_system_score_gemma":0.000465561,"threshold_uncertainty_score":0.99996275},"labels":[],"label_agreement":null},{"id":"W3004436801","doi":"10.1016/j.euo.2020.01.001","title":"Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Ipsen Biopharmaceuticals; Sanofi; Health Research Fund of Central Denmark Region; AstraZeneca; National Health and Medical Research Council; Amgen; Pfizer; Health Research Foundation; Roche","keywords":"Medicine; Renal cell carcinoma; Metastasis; Oncology; Disease; Internal medicine; Outcome (game theory); Cancer","score_opus":0.05860378922905161,"score_gpt":0.3120376677610792,"score_spread":0.2534338785320276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004436801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717702,0.000738097,0.000256253,0.009265092,0.00040289946,0.001278509,0.003902281,0.00007235596,0.012314291],"genre_scores_gemma":[0.990572,0.000019008556,0.0023288773,0.005037199,0.00022358287,0.0000371443,0.0015558496,0.000087856046,0.00013850884],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9948356,0.0018273696,0.0012313135,0.0009873477,0.00055824436,0.000560124],"domain_scores_gemma":[0.9950344,0.0022868558,0.0006397001,0.0010174109,0.00019228124,0.000829339],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006090228,0.0005352141,0.0011172578,0.00018710976,0.00010664105,0.000021456093,0.00063428434,0.000040340106,0.0019391752],"category_scores_gemma":[0.0013184214,0.0003546763,0.0005601142,0.00027587844,0.0003084538,0.00007104636,0.00038354474,0.0005194759,0.0029311928],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42420775,0.017336937,0.02916245,0.00031968975,0.030115945,0.10159153,0.013812636,0.04852098,0.08714687,0.00021035252,0.19108856,0.056486316],"study_design_scores_gemma":[0.10752284,0.19142902,0.44787118,0.000086501124,0.036858056,0.0008323486,0.0009645729,0.010978061,0.018073944,0.000030755466,0.18284753,0.0025051956],"about_ca_topic_score_codex":0.00029711548,"about_ca_topic_score_gemma":0.000022759043,"teacher_disagreement_score":0.4187087,"about_ca_system_score_codex":0.0005104627,"about_ca_system_score_gemma":0.00069977075,"threshold_uncertainty_score":0.9998905},"labels":[],"label_agreement":null},{"id":"W3012125381","doi":"10.1016/j.euo.2020.02.006","title":"Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non–muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University Health Centre","funders":"Ferring Pharmaceuticals","keywords":"Medicine; Bladder cancer; Meta-analysis; Cystectomy; Randomized controlled trial; Subgroup analysis; Cochrane Library; Internal medicine; Systematic review; Population; Oncology; MEDLINE; Clinical trial; Confidence interval; Carcinoma in situ; Cancer","score_opus":0.18456111749564127,"score_gpt":0.42578762561179667,"score_spread":0.2412265081161554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012125381","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028254715,0.989483,0.00064369675,0.0023767927,0.00015224509,0.006849411,0.00028595026,0.000041612326,0.00013904955],"genre_scores_gemma":[0.002484578,0.98742247,0.00046247864,0.0047833878,0.00014737462,0.0044144806,0.00006588517,0.00014116715,0.000078180965],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993543,0.0027077992,0.0017288232,0.0012167866,0.00029881232,0.000504751],"domain_scores_gemma":[0.99575263,0.0015571103,0.0014156688,0.00074399356,0.00026371513,0.00026687307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012654145,0.0009406302,0.01090293,0.00044768405,0.00010465191,0.000025248939,0.00029414348,0.00023359303,0.000497808],"category_scores_gemma":[0.0002453757,0.00060646725,0.0021306076,0.000561973,0.00033209333,0.00007397224,0.00019023898,0.00061714783,0.000008016145],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014347023,0.0002871074,0.00009291586,0.5668133,0.28585622,0.00026217973,0.00047592976,0.0000036267204,0.000004702031,0.000011065674,0.00023233856,0.14581712],"study_design_scores_gemma":[0.0013140998,0.0021371755,0.0002165356,0.013896058,0.81214976,0.0000618821,0.000021478712,0.000029799774,0.0000010334978,0.000003150863,0.16974196,0.00042708367],"about_ca_topic_score_codex":0.000031599822,"about_ca_topic_score_gemma":0.000058828176,"teacher_disagreement_score":0.55291724,"about_ca_system_score_codex":0.00019619706,"about_ca_system_score_gemma":0.001043522,"threshold_uncertainty_score":0.9996387},"labels":[],"label_agreement":null},{"id":"W3012478583","doi":"10.1016/j.euo.2020.02.010","title":"Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada); University of British Columbia","funders":"BC Cancer Agency; Decipher Biosciences","keywords":"Bladder cancer; Basal (medicine); Medicine; Cancer; Transcriptome; Subtyping; Internal medicine; Hormone; Androgen; Oncology; Physiology; Biology; Gene; Gene expression","score_opus":0.024928849280036216,"score_gpt":0.2774925359515167,"score_spread":0.2525636866714805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012478583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793713,0.002737539,0.00022468831,0.010646821,0.00016009912,0.0003340172,0.00022110832,0.00004216529,0.006262259],"genre_scores_gemma":[0.9921063,0.0010494444,0.00004234651,0.006367239,0.00013470065,0.000023165183,0.00012563434,0.00003163352,0.00011953845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983593,0.00040318412,0.00035178615,0.00045319326,0.00013163745,0.00030085136],"domain_scores_gemma":[0.99936736,0.000092260976,0.00013495948,0.00018880084,0.00006705622,0.00014959369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008701873,0.00019481388,0.0005066833,0.000048576625,0.00003167249,0.0000039035767,0.00015778164,0.00012837353,0.00060952205],"category_scores_gemma":[0.000046835557,0.00017178907,0.00008818599,0.00019137244,0.0002637308,0.00003026248,0.000075930904,0.0002821617,0.00009084202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020427334,0.001518356,0.7065058,0.00012628858,0.0008414913,0.002929078,0.007988781,0.000057752157,0.16023679,0.00029011158,0.052553933,0.06490892],"study_design_scores_gemma":[0.007971469,0.0071056387,0.81794995,0.000027542606,0.0003466593,0.00004777831,0.00024646442,0.00007998455,0.02138368,0.00010747318,0.1444137,0.00031967644],"about_ca_topic_score_codex":0.000056887875,"about_ca_topic_score_gemma":0.000029323664,"teacher_disagreement_score":0.13885312,"about_ca_system_score_codex":0.000089520836,"about_ca_system_score_gemma":0.0001718397,"threshold_uncertainty_score":0.7005355},"labels":[],"label_agreement":null},{"id":"W3017283363","doi":"10.1016/j.euo.2020.03.002","title":"Intermediate-risk Prostate Cancer: Stratification and Management","year":2020,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Université de Montréal; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Radiation therapy; Cohort; Androgen deprivation therapy; Cancer; Intensive care medicine; Oncology; Internal medicine","score_opus":0.035243128424543364,"score_gpt":0.3445443246397805,"score_spread":0.30930119621523716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017283363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000055020595,0.9837517,0.000008774813,0.0015338763,0.000527513,0.002231764,0.00015552697,0.00010390795,0.011631913],"genre_scores_gemma":[0.00020238844,0.9967157,0.00021643219,0.0009115413,0.000383384,0.00068917294,0.00039360023,0.000101287165,0.00038644607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970951,0.0008561218,0.00074160245,0.0008528778,0.000101276244,0.00035299236],"domain_scores_gemma":[0.9985058,0.00017914611,0.0006448848,0.00037330185,0.00004173508,0.00025513594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003208771,0.00044546562,0.0016365926,0.00016566663,0.000081692204,0.000019124778,0.00015775919,0.00018450878,0.0000898515],"category_scores_gemma":[0.000048437756,0.0003438453,0.0001949706,0.00016562147,0.00025522136,0.000028715822,0.00022277638,0.0006239238,0.00039396083],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008899584,0.00016906945,0.0002972268,0.0044059493,0.00096073875,0.0023741075,0.00019739427,3.148575e-7,1.437241e-7,0.00017429503,0.0041491333,0.9871826],"study_design_scores_gemma":[0.0012981938,0.0024566466,0.0014009224,0.00091659336,0.005359683,0.0002471579,0.000018310708,0.000003950177,3.122349e-7,0.000022846345,0.988058,0.00021738952],"about_ca_topic_score_codex":0.000010105753,"about_ca_topic_score_gemma":0.000016641512,"teacher_disagreement_score":0.98696524,"about_ca_system_score_codex":0.0003368167,"about_ca_system_score_gemma":0.0002906969,"threshold_uncertainty_score":0.99990135},"labels":[],"label_agreement":null},{"id":"W3025062498","doi":"10.1016/j.euo.2020.04.005","title":"Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Associazione Italiana per la Ricerca sul Cancro; Merck","keywords":"Fibroblast growth factor receptor 3; Bladder cancer; Medicine; Fibroblast growth factor receptor 4; Cancer research; Oncology; Pathological; Fibroblast growth factor receptor 2; Fibroblast growth factor receptor; Cancer; Internal medicine; Biology; Receptor; Fibroblast growth factor","score_opus":0.03695168064423887,"score_gpt":0.29507588222711273,"score_spread":0.25812420158287386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025062498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9533364,0.00010501488,0.000028336137,0.038211897,0.00019554705,0.0031743958,0.004372414,0.000039482373,0.0005364989],"genre_scores_gemma":[0.98515195,0.00003090885,0.00021488685,0.013817621,0.00017730624,0.00012363443,0.00037998913,0.00005547243,0.000048259455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752414,0.00087145745,0.00049019186,0.0005968894,0.00020394246,0.00031338795],"domain_scores_gemma":[0.9979825,0.0006172824,0.00038026104,0.0003789835,0.00046798875,0.00017299246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000741803,0.0003052803,0.00060239225,0.000036064506,0.0002189547,0.000017158147,0.00021687245,0.00008527469,0.00014608206],"category_scores_gemma":[0.00018297024,0.00017072086,0.00007949324,0.00015420122,0.00044815388,0.00004292472,0.00018006613,0.00035489892,0.0000035396404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034184013,0.0064868922,0.71942264,0.00015831825,0.012538741,0.00029802864,0.08951134,0.00040128746,0.017636152,0.00025416695,0.11366856,0.0054398435],"study_design_scores_gemma":[0.030293806,0.012968501,0.94285923,0.000018800194,0.0013690669,0.00000793562,0.0012594102,0.000039697577,0.00024403658,0.000021599368,0.010736593,0.00018130637],"about_ca_topic_score_codex":0.00061865797,"about_ca_topic_score_gemma":0.0018855832,"teacher_disagreement_score":0.2234366,"about_ca_system_score_codex":0.000100095174,"about_ca_system_score_gemma":0.0006110321,"threshold_uncertainty_score":0.69617945},"labels":[],"label_agreement":null},{"id":"W3034070398","doi":"10.1016/j.euo.2020.05.008","title":"Pearls to Pivoting a Multidisciplinary Prostate Cancer Survivorship Program During the COVID-19 Pandemic","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of British Columbia","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Multidisciplinary approach; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Survivorship curve; Prostate cancer; Betacoronavirus; Cancer; Intensive care medicine; Medical physics; Oncology; Internal medicine; Virology; Disease; Infectious disease (medical specialty)","score_opus":0.1582575525331245,"score_gpt":0.44981029469922473,"score_spread":0.2915527421661002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034070398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73687565,0.00047250337,0.00006226395,0.25823376,0.0002946985,0.0016837415,0.000017092243,0.0005067935,0.0018534824],"genre_scores_gemma":[0.88340724,0.00015341521,0.00025204688,0.114410974,0.0010009189,0.00014395158,0.000013634465,0.00007701046,0.00054081867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958446,0.0017705612,0.00054709555,0.00071688934,0.00020784349,0.0009129963],"domain_scores_gemma":[0.99711627,0.0007971435,0.00020903166,0.0003860389,0.0001112252,0.0013802748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015289066,0.0002870548,0.0005433818,0.00012919128,0.00044451508,0.000021245509,0.00033926702,0.00015293193,0.00020905788],"category_scores_gemma":[0.002953208,0.00021035539,0.00011701668,0.00047270374,0.00028524353,0.000048283306,0.00048826984,0.0010292294,0.00039802652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045639905,0.0002815191,0.9176537,0.00057259685,0.000117732015,0.0029775621,0.03465463,0.0006040315,0.004517934,0.00004278776,0.004115391,0.029898157],"study_design_scores_gemma":[0.0031302322,0.005500653,0.58142763,0.000019063407,0.00010990242,0.00069343677,0.00055798196,0.00023851279,0.000016607553,0.000014160245,0.4080564,0.00023539056],"about_ca_topic_score_codex":0.00066524756,"about_ca_topic_score_gemma":0.001924443,"teacher_disagreement_score":0.403941,"about_ca_system_score_codex":0.00047814398,"about_ca_system_score_gemma":0.0012420999,"threshold_uncertainty_score":0.85780436},"labels":[],"label_agreement":null},{"id":"W3034688971","doi":"10.1016/j.euo.2020.05.006","title":"Key Perspectives on Managing Older Patients with Prostate Cancer: What We Know About the Fit and What We Need to Know About the Frail","year":2020,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Need to know; Key (lock); Prostate cancer; Cancer; Intensive care medicine; Internal medicine; Computer science; Computer security","score_opus":0.019628359395526648,"score_gpt":0.294576433477559,"score_spread":0.27494807408203237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034688971","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014001108,0.12629712,0.0000038412745,0.85261345,0.0010219883,0.002836516,0.000046491532,0.000103815444,0.0030756537],"genre_scores_gemma":[0.013412016,0.3269674,0.00004110865,0.64244044,0.0030732667,0.00043126006,0.00019276084,0.00027436976,0.013167371],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947867,0.0017156544,0.00044880775,0.0013692867,0.00054080534,0.0011387673],"domain_scores_gemma":[0.9975269,0.00070619246,0.0003236597,0.00084949116,0.00032595513,0.00026781516],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00040762173,0.00074584375,0.0009673091,0.0003109578,0.00055760954,0.0003694346,0.00066265755,0.000361267,0.00029504317],"category_scores_gemma":[0.00008511376,0.00038437085,0.00015298095,0.00040794557,0.0013742398,0.00029945673,0.000517805,0.0036198576,0.00037502407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045263534,0.00023016012,0.002301344,0.00022095715,0.0010510605,0.003678467,0.042702734,0.000023453313,0.0000096922395,0.00002511407,0.7295607,0.21567],"study_design_scores_gemma":[0.004907951,0.00594899,0.01141818,0.0010302789,0.000514451,0.00006772141,0.006812035,0.000018391245,0.000006327931,0.000029777453,0.96886224,0.0003836337],"about_ca_topic_score_codex":0.00004030781,"about_ca_topic_score_gemma":0.00006188131,"teacher_disagreement_score":0.2393016,"about_ca_system_score_codex":0.00045041158,"about_ca_system_score_gemma":0.00042310316,"threshold_uncertainty_score":0.9998608},"labels":[],"label_agreement":null},{"id":"W3035162230","doi":"10.1016/j.euo.2020.05.001","title":"Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation","keywords":"Medicine; Prostatectomy; Prostate cancer; Oncology; Internal medicine; Somatic cell; Prostate; Cancer; Urology; Gene","score_opus":0.01715925271617926,"score_gpt":0.29760320811789287,"score_spread":0.28044395540171363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035162230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757668,0.002877583,0.00025763063,0.013715579,0.000094945324,0.002925477,0.0000121726525,0.00019932464,0.004150518],"genre_scores_gemma":[0.9919168,0.0003525086,0.0038887113,0.0027742684,0.00007074036,0.0007294938,0.000072935894,0.00010905512,0.00008550823],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969761,0.00079212134,0.00053122133,0.0007627798,0.000297995,0.00063978595],"domain_scores_gemma":[0.99880296,0.00020053753,0.0002821544,0.00026077442,0.00006133986,0.0003922122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034494433,0.0003931178,0.0009145578,0.0001319439,0.000104352206,0.000020173655,0.00014422803,0.000087178094,0.00012249935],"category_scores_gemma":[0.00008005089,0.00023778132,0.00008130015,0.00039060216,0.00033501707,0.00012204714,0.000110981164,0.0005605305,0.00006710238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029371493,0.002629715,0.85066915,0.0006153936,0.0011736448,0.04678069,0.011630466,0.0014159628,0.009555811,0.000055145516,0.002393451,0.043709103],"study_design_scores_gemma":[0.3031219,0.1676494,0.29603472,0.0062177675,0.006660084,0.0033333863,0.0040811333,0.016020227,0.034601774,0.00032816536,0.15864874,0.0033026705],"about_ca_topic_score_codex":0.000019270703,"about_ca_topic_score_gemma":0.000022474,"teacher_disagreement_score":0.5546344,"about_ca_system_score_codex":0.00023871647,"about_ca_system_score_gemma":0.0004621538,"threshold_uncertainty_score":0.96964407},"labels":[],"label_agreement":null},{"id":"W3037625979","doi":"10.1016/j.euo.2020.06.005","title":"Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Movember Foundation","keywords":"Prostate cancer; Prostatectomy; Medicine; Biochemical recurrence; Biomarker; Oncology; Precision medicine; Prostate; Disease; Internal medicine; Prospective cohort study; Radiation therapy; Localized disease; Spatial heterogeneity; Cancer; Pathology; Biology; Genetics","score_opus":0.04332919131118951,"score_gpt":0.34275509482311817,"score_spread":0.29942590351192866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037625979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898416,0.0004649651,0.00012922788,0.0067281523,0.00018263132,0.0017310256,0.00014794721,0.00004011263,0.0007343392],"genre_scores_gemma":[0.99557513,0.00018456552,0.00016538546,0.0035124482,0.00023522487,0.0002106111,0.00005837772,0.000050379633,0.000007899398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984501,0.00036934685,0.00036093922,0.00039202487,0.00007540538,0.00035215472],"domain_scores_gemma":[0.9988839,0.00038654255,0.00025141114,0.0002116534,0.00009840558,0.00016807258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002431485,0.00021066201,0.00047326976,0.000046842273,0.00007905424,0.000006018751,0.00014023697,0.00006477483,0.000060207472],"category_scores_gemma":[0.00022934545,0.0001291949,0.00023486298,0.000079476355,0.00026502693,0.000016266013,0.000076379234,0.00015549551,0.000029316845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0085736625,0.0006396657,0.8761859,0.00006954797,0.001261795,0.00020337713,0.0009440353,0.0007906037,0.0047056437,0.000012602056,0.0023169834,0.10429616],"study_design_scores_gemma":[0.009790371,0.032117654,0.9413342,0.000020465564,0.0005050971,0.000027909982,0.000017772041,0.0017269391,0.001727383,0.000013272812,0.0125765,0.00014247057],"about_ca_topic_score_codex":0.00007287909,"about_ca_topic_score_gemma":0.000032462158,"teacher_disagreement_score":0.10415369,"about_ca_system_score_codex":0.00019758358,"about_ca_system_score_gemma":0.00036996862,"threshold_uncertainty_score":0.5268415},"labels":[],"label_agreement":null},{"id":"W3041182614","doi":"10.1016/j.euo.2020.06.002","title":"Learning from Our Past Mistakes: A Call for Randomized Controlled Trials in Localized Renal Cell Carcinoma","year":2020,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Renal cell carcinoma; Randomized controlled trial; Carcinoma; MEDLINE; Oncology; Internal medicine","score_opus":0.05152276207536935,"score_gpt":0.29299089704263576,"score_spread":0.2414681349672664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041182614","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023273926,0.0059618154,0.002004722,0.90446925,0.0020698532,0.018334867,0.00016550468,0.00031152696,0.043408543],"genre_scores_gemma":[0.29633296,0.0001527333,0.0028843891,0.66462547,0.016453737,0.002193343,0.004870639,0.00055848743,0.011928232],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9511484,0.04073476,0.004614996,0.0018043172,0.00046674715,0.0012307891],"domain_scores_gemma":[0.9744815,0.021087589,0.0030981214,0.0007182749,0.00026310558,0.00035137284],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00871186,0.0012745599,0.019006569,0.0007177896,0.00012670623,0.000045137764,0.00052975584,0.0015483078,0.00027270507],"category_scores_gemma":[0.011485071,0.0009227068,0.0038548457,0.000197579,0.000377369,0.000030971918,0.0001400435,0.0048947106,0.00047566133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4284807,0.00025162514,0.00031526329,0.0001729468,0.0016893077,0.044615883,0.00079488906,0.00005599034,0.0011174042,0.0000020776947,0.5220521,0.00045178024],"study_design_scores_gemma":[0.49619585,0.0049026273,0.00010366448,0.00004080073,0.006148657,0.0001718777,0.000093124625,0.00049048313,0.0000785662,0.000035385885,0.49133286,0.00040610507],"about_ca_topic_score_codex":0.00017263235,"about_ca_topic_score_gemma":0.000024668238,"teacher_disagreement_score":0.27305904,"about_ca_system_score_codex":0.0006127363,"about_ca_system_score_gemma":0.00086536456,"threshold_uncertainty_score":0.9997479},"labels":[],"label_agreement":null},{"id":"W3047382221","doi":"10.1016/j.euo.2020.07.002","title":"Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Enzalutamide; Taxane; Urology; Docetaxel; Adverse effect; Prostate-specific antigen; Internal medicine; Oncology; Cancer; Surgery; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.0444505241222058,"score_gpt":0.33219623933308134,"score_spread":0.28774571521087555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047382221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809606,0.0010049045,0.000009816006,0.0114659425,0.000106831525,0.0024068195,0.00014459844,0.000018873858,0.0038816102],"genre_scores_gemma":[0.9973072,0.0012060363,0.00013446002,0.0002828502,0.000058715366,0.00007155004,0.00007216692,0.000036962007,0.0008300645],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99752295,0.00083347305,0.00060982775,0.0004175416,0.00027039915,0.00034580514],"domain_scores_gemma":[0.9989318,0.0001313944,0.00039745073,0.0002510443,0.00015754942,0.00013073142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006386561,0.00021048884,0.00062280794,0.00013913072,0.00009579471,0.000007879085,0.00015832996,0.00005551069,0.00013050511],"category_scores_gemma":[0.00006756331,0.00013625761,0.000058899914,0.0003761979,0.00076371327,0.00008460262,0.00012534876,0.00034158933,0.000003659396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48474398,0.008677803,0.0122312885,0.00091093074,0.0010765103,0.0022717635,0.03270534,0.00032597568,0.43275768,0.0011041483,0.0016022094,0.02159237],"study_design_scores_gemma":[0.65199655,0.14380883,0.07066877,0.00017426036,0.0007130052,0.00012970866,0.002490404,0.0011750985,0.07255579,0.00010843341,0.055631936,0.00054720964],"about_ca_topic_score_codex":0.00009753203,"about_ca_topic_score_gemma":0.00012310321,"teacher_disagreement_score":0.3602019,"about_ca_system_score_codex":0.000093014736,"about_ca_system_score_gemma":0.00059533236,"threshold_uncertainty_score":0.5556424},"labels":[],"label_agreement":null},{"id":"W3083033920","doi":"10.1016/j.euo.2020.08.007","title":"Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Germ cell tumors; Cumulative incidence; Testicular cancer; Regimen; Cancer; Chemotherapy regimen; Retrospective cohort study; Surgery; Cohort","score_opus":0.020159717392734144,"score_gpt":0.2737333821340344,"score_spread":0.2535736647413003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083033920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960121,0.00044470845,0.000880289,0.0011436999,0.000085792206,0.0009189861,0.00010756284,0.000060942286,0.00034591393],"genre_scores_gemma":[0.9932344,0.000004343605,0.0022135554,0.0042262934,0.00004044399,0.00002253461,0.00014555544,0.00006918343,0.000043699678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982569,0.0005811496,0.00034777157,0.00038312087,0.00012551484,0.00030554092],"domain_scores_gemma":[0.9984784,0.0006168844,0.00032439936,0.00026166387,0.00009932985,0.00021928329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002526676,0.00021139908,0.0006160969,0.000059115533,0.000055475,0.0000044685225,0.00012943699,0.0000309098,0.000055872584],"category_scores_gemma":[0.00028851087,0.00016641112,0.00017290056,0.00010994535,0.00014053764,0.00002264848,0.00004392614,0.00010382375,0.000044554505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022889573,0.0012775786,0.96853685,0.00015047092,0.0004907532,0.0024268804,0.00029708788,0.000011574242,0.0017044449,0.000004185955,0.0003122883,0.0018983049],"study_design_scores_gemma":[0.017674312,0.011063942,0.96766686,0.000010696304,0.00043228496,0.000051894855,0.000010524555,0.00006994659,0.00011169189,0.0000025526183,0.0027712926,0.00013397582],"about_ca_topic_score_codex":0.0000018097867,"about_ca_topic_score_gemma":0.0000021990213,"teacher_disagreement_score":0.009786364,"about_ca_system_score_codex":0.000040088187,"about_ca_system_score_gemma":0.00017725497,"threshold_uncertainty_score":0.67860484},"labels":[],"label_agreement":null},{"id":"W3084968377","doi":"10.1016/j.euo.2020.08.010","title":"Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Health Sciences Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Benchmarking; Medicine; Case mix index; Prostate cancer; Standardization; Quality (philosophy); Cancer; Health care; Emergency medicine; Intensive care medicine; Internal medicine; Nursing","score_opus":0.07394108093913258,"score_gpt":0.3823975231627333,"score_spread":0.3084564422236007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084968377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9501571,0.0011762662,0.0009165052,0.03689931,0.000354843,0.00089592824,0.00010018804,0.000053618318,0.009446224],"genre_scores_gemma":[0.98096687,0.00004660845,0.0008703412,0.017817553,0.00016902048,0.000038390852,0.000026277961,0.000018166671,0.000046755587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981342,0.00063303247,0.00044079413,0.00034259132,0.00013424814,0.0003151561],"domain_scores_gemma":[0.9990084,0.00021921881,0.00016214013,0.00017804808,0.00022030965,0.00021188357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042166875,0.00012860747,0.0005432272,0.00007364741,0.000033951837,0.0000031308834,0.00015101061,0.00007188685,0.000053129974],"category_scores_gemma":[0.0011903939,0.00012309387,0.00006623242,0.0003101275,0.00008936084,0.000037155947,0.00012781504,0.00028531926,0.00008730117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005234073,0.00031619065,0.8960663,0.00045292408,0.00021231279,0.0021200976,0.030133242,0.00091422215,0.014761756,0.0024205784,0.008613394,0.038754907],"study_design_scores_gemma":[0.003779504,0.0062293154,0.9572284,0.000036391044,0.00008073154,0.000010916062,0.00034750838,0.000039796592,0.0004170947,0.000027494953,0.03166954,0.00013330544],"about_ca_topic_score_codex":0.00034887713,"about_ca_topic_score_gemma":0.0004147898,"teacher_disagreement_score":0.0611621,"about_ca_system_score_codex":0.00015177725,"about_ca_system_score_gemma":0.0002692841,"threshold_uncertainty_score":0.50196224},"labels":[],"label_agreement":null},{"id":"W3088737306","doi":"10.1016/j.euo.2020.08.013","title":"Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment","year":2020,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University","funders":"Ontario Ministry of Research, Innovation and Science; Queen's University","keywords":"Medicine; Bladder cancer; Immunotherapy; Context (archaeology); Immune system; Oncology; Cancer; Incidence (geometry); Clinical trial; Internal medicine; Bioinformatics; Immunology; Biology","score_opus":0.07633012349854808,"score_gpt":0.4030424398314802,"score_spread":0.32671231633293213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088737306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032923377,0.9818243,0.000018140658,0.0090742335,0.00012926708,0.0049772025,0.00059706223,0.00005104414,0.0032958197],"genre_scores_gemma":[0.00014218829,0.99008846,0.00024047698,0.004606605,0.00015335408,0.0037102292,0.0003171725,0.00009695914,0.00064452586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968187,0.0010754552,0.00073395844,0.0008905302,0.000051079835,0.0004302783],"domain_scores_gemma":[0.9982252,0.0006690486,0.00044041104,0.00039151718,0.000100286175,0.00017355016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018251248,0.0006400063,0.0042902795,0.00016150749,0.00008669738,0.000007861738,0.00018006843,0.00026720934,0.00008853738],"category_scores_gemma":[0.00007881868,0.00037697356,0.0002291192,0.0003319835,0.00035560914,0.000023561339,0.0000772582,0.00028268687,0.000036576694],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023920069,0.00040527363,0.0042380993,0.0038323025,0.0029450431,0.00021592167,0.00033721773,4.194803e-8,7.719175e-7,0.00009065733,0.0011119371,0.98658353],"study_design_scores_gemma":[0.0035655636,0.008782671,0.004539275,0.0015837181,0.0077869734,0.0004424021,0.000022925007,3.1093012e-7,1.1733861e-7,0.000013692556,0.97298443,0.00027794196],"about_ca_topic_score_codex":0.000048273876,"about_ca_topic_score_gemma":0.00023026057,"teacher_disagreement_score":0.9863056,"about_ca_system_score_codex":0.00041185442,"about_ca_system_score_gemma":0.0017000792,"threshold_uncertainty_score":0.9998682},"labels":[],"label_agreement":null},{"id":"W3090235171","doi":"10.1016/j.euo.2020.09.001","title":"Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group","funders":"","keywords":"Medicine; Cystoscopy; Cytology; Bladder cancer; Urology; Urine cytology; Urine; Prostate cancer; Confidence interval; Internal medicine; Cancer; Urinary system; Pathology","score_opus":0.01914884813810823,"score_gpt":0.27980414680220383,"score_spread":0.2606552986640956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090235171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487025,0.00011695121,0.00077229284,0.0024088197,0.00012959319,0.000888238,0.00006359059,0.000020462585,0.0007298062],"genre_scores_gemma":[0.99801004,0.00000787145,0.00022390456,0.0015253137,0.000113801274,0.000043118227,0.000033359014,0.000027332326,0.000015230761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991332,0.00018020989,0.00025974604,0.0002017723,0.000088665234,0.0001363536],"domain_scores_gemma":[0.9992573,0.00020392562,0.00018726982,0.00015927348,0.00013822757,0.000053983298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014752679,0.000103765415,0.00027808972,0.00005782802,0.000027853026,0.0000014254413,0.00008467736,0.00005608432,0.00009932445],"category_scores_gemma":[0.00011508158,0.00006742625,0.000038570794,0.00013945774,0.00013087246,0.000030710788,0.000016541802,0.00012188643,0.0000042638817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034134563,0.0040800674,0.82895446,0.00027107887,0.0006382941,0.00007139347,0.0020185143,0.0036806844,0.035461333,0.000021183947,0.0003180583,0.090350345],"study_design_scores_gemma":[0.0152819585,0.02394934,0.9295498,0.000011856142,0.0004530471,0.000004659336,0.000029923449,0.00092945556,0.02598764,0.000008218101,0.0037117947,0.00008231222],"about_ca_topic_score_codex":0.000048631013,"about_ca_topic_score_gemma":0.00008454056,"teacher_disagreement_score":0.10059531,"about_ca_system_score_codex":0.000037544156,"about_ca_system_score_gemma":0.00013100119,"threshold_uncertainty_score":0.2749563},"labels":[],"label_agreement":null},{"id":"W3111044160","doi":"10.1016/j.euo.2020.11.005","title":"Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Incidence (geometry); Proportional hazards model; Urology; Stage (stratigraphy); Epidemiology; Internal medicine; Cancer; Oncology; Biology","score_opus":0.032265003367357104,"score_gpt":0.2766939002745177,"score_spread":0.24442889690716058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111044160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702504,0.0004116637,0.00002798948,0.0028416682,0.00012913583,0.00047258465,0.000045394077,0.00003349135,0.025787639],"genre_scores_gemma":[0.99364877,0.000031591117,0.00016229604,0.005840631,0.00016424523,0.0000081267035,0.000046348046,0.00004210263,0.000055877073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984822,0.0004760432,0.0003049844,0.00038206877,0.00013890599,0.00021578523],"domain_scores_gemma":[0.99909884,0.00022100403,0.0001680371,0.00016628757,0.000131364,0.00021446693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013644084,0.00019575155,0.00052394555,0.000059205093,0.000046649606,0.0000042308684,0.00010911918,0.000082803344,0.0001137462],"category_scores_gemma":[0.00016209272,0.00014738434,0.00004989094,0.00010162433,0.00040640836,0.00006845949,0.00008693947,0.00024299478,0.00004482872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037908412,0.00034742674,0.9907129,0.000040892308,0.00012120898,0.0006541039,0.0014001426,0.0000011545575,0.00095527025,0.000040609295,0.0005533967,0.0013820548],"study_design_scores_gemma":[0.009585277,0.015075069,0.9667438,0.00001030851,0.0001582745,0.000074015246,0.00010680758,0.000006039655,0.00071027037,0.000010919271,0.0073962985,0.00012288992],"about_ca_topic_score_codex":0.00005048845,"about_ca_topic_score_gemma":0.000011431282,"teacher_disagreement_score":0.025731761,"about_ca_system_score_codex":0.000025975472,"about_ca_system_score_gemma":0.00041195942,"threshold_uncertainty_score":0.6010159},"labels":[],"label_agreement":null},{"id":"W3111713883","doi":"10.1016/j.euo.2020.11.004","title":"Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fundação para a Ciência e a Tecnologia; Canadian Urological Oncology Group","keywords":"Medicine; Testicular cancer; Seminoma; Odds ratio; Confidence interval; Internal medicine; Oncology; Human chorionic gonadotropin; Stage (stratigraphy); Biomarker; Orchiectomy; Logistic regression; Cohort; Cancer; Chemotherapy","score_opus":0.02854266477537129,"score_gpt":0.3100855794733484,"score_spread":0.2815429146979771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111713883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427086,0.00033733342,0.0000074038676,0.0009606004,0.00013714598,0.0005637004,0.00012303548,0.000043324868,0.0035565791],"genre_scores_gemma":[0.99763685,0.000031769225,0.00015137717,0.001990261,0.00006485717,0.000008195252,0.000043470805,0.000038146456,0.000035085926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707294,0.0011879228,0.00066165545,0.0005657173,0.0001680782,0.0003437122],"domain_scores_gemma":[0.9985622,0.00046710312,0.0003416721,0.00031151672,0.00008472541,0.00023277989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046171484,0.00020286467,0.00063988956,0.000075741315,0.000023098206,0.0000022956076,0.00012348183,0.00012387543,0.00013878124],"category_scores_gemma":[0.00089268945,0.0001623463,0.00007770532,0.0002312236,0.00022354627,0.00002532027,0.00009646963,0.000514553,0.00003632953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002938447,0.0024397657,0.9884994,0.00006827966,0.00006358558,0.0017473723,0.00015885929,0.0001886254,0.0000080354175,0.0000043028795,0.00008602078,0.0037973218],"study_design_scores_gemma":[0.0123129655,0.007151059,0.9783824,0.000032722302,0.00008891833,0.0000036229983,0.000019715557,0.0007223341,0.000009135375,0.0000018218401,0.0011687535,0.00010652647],"about_ca_topic_score_codex":0.00007385937,"about_ca_topic_score_gemma":0.0001730046,"teacher_disagreement_score":0.010116959,"about_ca_system_score_codex":0.000055354678,"about_ca_system_score_gemma":0.0002481454,"threshold_uncertainty_score":0.662029},"labels":[],"label_agreement":null},{"id":"W3119966384","doi":"10.1016/j.euo.2020.12.008","title":"A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Takeda Canada; Roche Products; Pfizer UK; Shionogi; Astellas Pharma; European Association of Urology; Sir John Fisher Foundation; Ipsen Fund; Cancer Australia; Cancer Research UK; Novartis; Janssen Biotech; Les Laboratories Pierre Fabre; Medical Research Council; Bayer; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Prostatectomy; Prostate cancer; Retrospective cohort study; Randomized controlled trial; Radiation therapy; Systematic review; Adverse effect; Surgery; MEDLINE; Internal medicine; Cancer","score_opus":0.3987709870444513,"score_gpt":0.553696313638174,"score_spread":0.15492532659372266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119966384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015492931,0.9728581,0.00013168584,0.011679596,0.00010743534,0.014647854,0.00024121851,0.00000568987,0.00031296263],"genre_scores_gemma":[0.000044513792,0.98741263,0.00674852,0.0010735821,0.000040751507,0.0044247573,0.00006639898,0.00004245921,0.00014640689],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907099,0.0061749057,0.0021113115,0.00056328817,0.00019302181,0.00024757866],"domain_scores_gemma":[0.9760013,0.020919848,0.0014751854,0.00046252145,0.0010649518,0.00007615947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008870599,0.00022473613,0.0027320194,0.00013127271,0.00008828748,0.000010693787,0.00015879977,0.00013000412,0.000015215842],"category_scores_gemma":[0.005250478,0.00013146248,0.0002193064,0.0003688579,0.0006172083,0.000056286808,0.00013896172,0.00048045805,0.0000014899044],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001931831,0.0016429215,0.0005064059,0.50311315,0.0034228358,0.000038607774,0.0012496642,0.0000026316914,7.119875e-8,0.0006881826,0.008953718,0.47845],"study_design_scores_gemma":[0.002767045,0.008600471,0.0001221735,0.3107227,0.0052100914,0.000035708163,0.0005143214,0.000013523502,1.6999488e-7,0.000020719328,0.6718963,0.00009678951],"about_ca_topic_score_codex":0.000008635282,"about_ca_topic_score_gemma":0.00004392357,"teacher_disagreement_score":0.6629426,"about_ca_system_score_codex":0.00022761188,"about_ca_system_score_gemma":0.0010629884,"threshold_uncertainty_score":0.6285692},"labels":[],"label_agreement":null},{"id":"W3120001159","doi":"10.1016/j.euo.2020.12.002","title":"Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non–muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non–muscle-invasive Bladder Cancer Guidelines Panel Study","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Internal medicine; Urology; Concomitant; Stage (stratigraphy); Oncology; Concordance; Cancer; Univariate analysis; Clinical endpoint; Multivariate analysis; Clinical trial","score_opus":0.05179884433526188,"score_gpt":0.32581378281523016,"score_spread":0.2740149384799683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120001159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782098,0.0043367757,0.00019430311,0.008465821,0.0017000027,0.004242368,0.00029747383,0.000047789108,0.0025056985],"genre_scores_gemma":[0.99125934,0.0026656066,0.00017449187,0.003573445,0.0006575031,0.00053636415,0.000089160385,0.00013214022,0.00091196457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936076,0.0028476112,0.0015029791,0.0009987258,0.00036989828,0.0006732249],"domain_scores_gemma":[0.9954612,0.0012347129,0.0012928984,0.0006687204,0.0011834098,0.00015905486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00133601,0.00047035105,0.0012081271,0.00023928814,0.00014988631,0.000018171253,0.0003584456,0.0002873543,0.00004531097],"category_scores_gemma":[0.0014135544,0.00037158592,0.00022048835,0.00040069636,0.0004099954,0.000102436556,0.00029060268,0.00051414856,0.000014248972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014824998,0.0043782922,0.893594,0.00071015384,0.0027600299,0.0005060805,0.008964149,0.0011247871,0.06545783,0.00005737571,0.007999739,0.01296501],"study_design_scores_gemma":[0.013674346,0.003312716,0.9700308,0.00020099508,0.0023580545,0.0000618876,0.0014885865,0.0006521419,0.00044375786,0.000019707011,0.0074640913,0.00029292834],"about_ca_topic_score_codex":0.0006012972,"about_ca_topic_score_gemma":0.0015958502,"teacher_disagreement_score":0.076436736,"about_ca_system_score_codex":0.0005363574,"about_ca_system_score_gemma":0.001633073,"threshold_uncertainty_score":0.99987364},"labels":[],"label_agreement":null},{"id":"W3120377060","doi":"10.1016/j.euo.2020.12.011","title":"Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Yakuhin; Astellas Pharma; Roche Italia; GlaxoSmithKline; Novartis; Pfizer","keywords":"Medicine; Kidney cancer; Medical physics; Cancer; Intensive care medicine; Pathology; Engineering ethics; Internal medicine; Engineering","score_opus":0.04897353009965996,"score_gpt":0.38862529324275014,"score_spread":0.3396517631430902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120377060","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023784898,0.96050704,0.0000051792344,0.03125313,0.0005425589,0.006903836,0.00037844354,0.000015902195,0.00037011958],"genre_scores_gemma":[0.00007482097,0.967964,0.00030488413,0.027500652,0.00013181691,0.003317476,0.00052009773,0.00010578281,0.00008050535],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924161,0.0043315096,0.0017879168,0.00078353856,0.00021192511,0.00046901748],"domain_scores_gemma":[0.9947625,0.001446742,0.0020433539,0.00076002756,0.0008240731,0.0001633428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024490962,0.00059825537,0.00403394,0.00034852573,0.000066454166,0.000030729523,0.00033153032,0.0002188338,0.000021561696],"category_scores_gemma":[0.0063579553,0.00037211782,0.00043465424,0.0012505936,0.00014565107,0.000117917996,0.00040162206,0.0007778262,0.0000021348487],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019988636,0.00043614852,0.000058999005,0.95794433,0.0026457885,0.0013065578,0.0009298056,4.683312e-8,0.000016520431,0.00006525346,0.01194862,0.024448067],"study_design_scores_gemma":[0.001360817,0.00065220706,0.000018339932,0.48385146,0.008322134,0.0026365004,0.00041990832,5.5627214e-7,0.000005393482,3.6219743e-7,0.5025484,0.00018392014],"about_ca_topic_score_codex":0.00004350646,"about_ca_topic_score_gemma":0.000042041313,"teacher_disagreement_score":0.49059978,"about_ca_system_score_codex":0.0006542131,"about_ca_system_score_gemma":0.0019571204,"threshold_uncertainty_score":0.9998731},"labels":[],"label_agreement":null},{"id":"W3126442745","doi":"10.1016/j.euo.2021.01.003","title":"Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Magnetic resonance imaging; Radiation therapy; Prostate; Radiology; Medical physics; Cancer; Internal medicine","score_opus":0.06560416963650754,"score_gpt":0.3869610336598013,"score_spread":0.3213568640232937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126442745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00084684516,0.98156244,0.00029467573,0.005780275,0.0018176319,0.00833032,0.0011151175,0.0001205927,0.0001320942],"genre_scores_gemma":[0.0014642464,0.9757147,0.008450145,0.003632233,0.000683464,0.008634807,0.00089677464,0.00024331007,0.00028034134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921703,0.0010057514,0.0030408863,0.0022837792,0.0003895398,0.0011097483],"domain_scores_gemma":[0.99346143,0.002002161,0.0024088437,0.0006902719,0.001123045,0.0003142257],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002208089,0.0009964447,0.0024516594,0.00062134984,0.00024258667,0.000102952356,0.0003191284,0.0002495735,0.00005802279],"category_scores_gemma":[0.003860576,0.000847425,0.0004970044,0.00058847904,0.0009244954,0.00008095971,0.00015828574,0.0008676331,0.0000120910345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002533766,0.00041093506,0.005751689,0.0015483161,0.00006873051,0.0017192318,0.00016106536,0.000023642393,0.000002131277,0.00002363624,0.00509802,0.98265886],"study_design_scores_gemma":[0.0094043175,0.003537523,0.0041296086,0.0062575676,0.00070779794,0.0008667376,0.000021766635,0.004956408,0.000014191542,0.00003670045,0.96937394,0.00069341646],"about_ca_topic_score_codex":0.00004378589,"about_ca_topic_score_gemma":0.000016772763,"teacher_disagreement_score":0.9819654,"about_ca_system_score_codex":0.0009652587,"about_ca_system_score_gemma":0.0021184818,"threshold_uncertainty_score":0.99939764},"labels":[],"label_agreement":null},{"id":"W3139733574","doi":"10.1016/j.euo.2021.02.007","title":"Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Systematic review; Cancer; Kidney cancer; Bladder cancer; CINAHL; MEDLINE; Internal medicine; Oncology; Psychological intervention","score_opus":0.030855555202399024,"score_gpt":0.27920069884354676,"score_spread":0.24834514364114774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139733574","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007304719,0.9910514,0.000055856173,0.00046071433,0.00052051066,0.0026846444,0.00063348445,0.000035917292,0.003827032],"genre_scores_gemma":[0.00014105192,0.9911239,0.000088691726,0.006985724,0.00017500258,0.00037083833,0.0001064546,0.00009989343,0.0009084415],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965198,0.00040631014,0.0014690155,0.0010441601,0.000033433316,0.00052727194],"domain_scores_gemma":[0.99743104,0.00013758817,0.0015211157,0.0004587694,0.00009878625,0.00035269625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008833437,0.0005425016,0.0046305247,0.00026448132,0.00014270493,0.000057764693,0.0002801515,0.00035367665,0.000117794014],"category_scores_gemma":[0.0010014737,0.00049911515,0.00016789444,0.000258565,0.00024315163,0.00018477454,0.00027126132,0.0005847948,0.00014490807],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011691351,0.00046640047,0.005942582,0.73143804,0.0015532252,0.00022631607,0.0005914871,0.0000034176703,4.653105e-8,0.003696046,0.047372974,0.20859252],"study_design_scores_gemma":[0.0006083387,0.0007761696,0.0027146114,0.022370666,0.0012650309,0.000048487695,0.0000024001429,0.0000014380231,1.9667176e-8,0.00003279502,0.9716097,0.00057031715],"about_ca_topic_score_codex":0.000098326534,"about_ca_topic_score_gemma":0.00019433208,"teacher_disagreement_score":0.9242368,"about_ca_system_score_codex":0.00032374918,"about_ca_system_score_gemma":0.00036751557,"threshold_uncertainty_score":0.999746},"labels":[],"label_agreement":null},{"id":"W3151619115","doi":"10.1016/j.euo.2021.03.005","title":"Incidental Prostate Cancer (cT1a–cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Prostate; Oncology; Medical physics; Internal medicine","score_opus":0.22262775962300127,"score_gpt":0.5128784833823907,"score_spread":0.29025072375938943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151619115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73472214,0.0064190994,0.0000010658314,0.2549922,0.00043279718,0.0006443565,0.000087689004,0.000019368814,0.0026813329],"genre_scores_gemma":[0.92340386,0.047370896,0.00016868551,0.019943122,0.0007052882,0.00023223028,0.00009406652,0.00004821213,0.008033623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537134,0.002009118,0.0006951691,0.0007936264,0.0005224035,0.0006083534],"domain_scores_gemma":[0.9981907,0.0005226124,0.000118745746,0.00033328167,0.00063787,0.00019680092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041120723,0.00020614544,0.0004523365,0.0002089255,0.0002040303,0.00006821364,0.0002687766,0.00015946773,0.00033563218],"category_scores_gemma":[0.0009052583,0.00013004389,0.00007268752,0.00033590602,0.0013456774,0.00010530355,0.00068375235,0.0013140312,0.000020763939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003348087,0.00059023034,0.8758079,0.00006796259,0.00027994782,0.006063924,0.006692898,0.0000032725593,0.0019062487,0.00014762366,0.059144415,0.045947522],"study_design_scores_gemma":[0.0075260876,0.0014928824,0.54511774,0.000063575026,0.00009919855,0.0005418675,0.0014298408,0.0002117171,0.00021056776,0.00031572694,0.44283614,0.00015466053],"about_ca_topic_score_codex":0.0006366826,"about_ca_topic_score_gemma":0.0031439436,"teacher_disagreement_score":0.38369173,"about_ca_system_score_codex":0.00020087739,"about_ca_system_score_gemma":0.0010548003,"threshold_uncertainty_score":0.57088846},"labels":[],"label_agreement":null},{"id":"W3163731137","doi":"10.1016/j.euo.2021.04.008","title":"Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Clinical endpoint; Prostate cancer; Hazard ratio; Androgen deprivation therapy; Population; Prostatectomy; Internal medicine; Urology; Testosterone (patch); Prostate-specific antigen; Biochemical recurrence; Randomized controlled trial; Confidence interval; Oncology; Cancer","score_opus":0.0251811069725022,"score_gpt":0.33797486306754854,"score_spread":0.31279375609504634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163731137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858949,0.006431571,0.000035460354,0.0024447846,0.00035128978,0.004177641,0.000029367337,0.00003239826,0.00060255284],"genre_scores_gemma":[0.98145974,0.015296676,0.00028093092,0.0005595883,0.00021776384,0.0013250695,0.0001195005,0.000047010504,0.00069371465],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99486387,0.003074733,0.00090342865,0.0005058524,0.00023416468,0.00041794553],"domain_scores_gemma":[0.9975389,0.0011811941,0.00049569336,0.00031151375,0.00034070018,0.00013196513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019881134,0.0002596819,0.0022539515,0.00025654887,0.000038720817,0.000009110639,0.00008575858,0.00013457733,0.00034360314],"category_scores_gemma":[0.0007834952,0.00014575738,0.00023629719,0.00034311856,0.0005057172,0.0000454684,0.000055439607,0.00040744382,0.000010377303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94459987,0.0034917945,0.019980276,0.000032511478,0.0010013985,0.0016863062,0.0004721218,0.0000036614892,0.0021602456,0.000005629076,0.00018555485,0.026380658],"study_design_scores_gemma":[0.9832635,0.0073901583,0.0013232719,0.000055146655,0.00046869664,0.00007895456,0.000026399019,0.00007135153,0.004539859,0.000032125434,0.0026029306,0.00014762039],"about_ca_topic_score_codex":0.000055273933,"about_ca_topic_score_gemma":0.00010481519,"teacher_disagreement_score":0.038663644,"about_ca_system_score_codex":0.00012300866,"about_ca_system_score_gemma":0.0015398298,"threshold_uncertainty_score":0.59438133},"labels":[],"label_agreement":null},{"id":"W3165599343","doi":"10.1016/j.euo.2021.05.004","title":"Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press","year":2021,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Gynecology; Cancer; Internal medicine","score_opus":0.055677404488332166,"score_gpt":0.37010723138857665,"score_spread":0.31442982690024446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165599343","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.281043,0.014450487,0.00002663966,0.68252647,0.0014986244,0.008256503,0.00034564806,0.000124236,0.011728416],"genre_scores_gemma":[0.019383712,0.013474413,0.0012650845,0.92680407,0.005029409,0.0028484745,0.0015650619,0.0005348559,0.029094934],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928191,0.0021608898,0.0014118683,0.0017309987,0.00041642995,0.0014607633],"domain_scores_gemma":[0.9973344,0.0006329838,0.00040024397,0.0007957805,0.0005014157,0.00033518404],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016523061,0.0007256585,0.0017222232,0.0008248482,0.00011985714,0.00004837437,0.00042698812,0.00084650447,0.00014651811],"category_scores_gemma":[0.0007234652,0.0006301448,0.00019518357,0.0004662867,0.00033800007,0.00010854666,0.0007198784,0.0026968475,0.000044357716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007039647,0.00048590582,0.018721338,0.0004417373,0.0003429623,0.030641567,0.0024003359,0.00010603375,0.0009802481,0.000007047047,0.88896084,0.049872313],"study_design_scores_gemma":[0.013058012,0.004627392,0.022301678,0.00032605944,0.0003066045,0.00071201584,0.00016086872,0.00017979079,0.00009567005,0.000059408114,0.95765555,0.00051692885],"about_ca_topic_score_codex":0.0017544685,"about_ca_topic_score_gemma":0.001688801,"teacher_disagreement_score":0.26165926,"about_ca_system_score_codex":0.0010422993,"about_ca_system_score_gemma":0.0014297097,"threshold_uncertainty_score":0.999615},"labels":[],"label_agreement":null},{"id":"W3176723026","doi":"10.1016/j.euo.2021.06.003","title":"Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Androgen deprivation therapy; Interquartile range; Prostate-specific antigen; Hazard ratio; Lymph node; Proportional hazards model; Oncology; Dissection (medical); Multimodal therapy; Urology; Internal medicine; Cancer; Surgery","score_opus":0.058550550389696844,"score_gpt":0.3746373579487231,"score_spread":0.31608680755902624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176723026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790614,0.004662209,0.00015548524,0.010270199,0.00055696134,0.0035403227,0.0014924172,0.00007837999,0.00018258301],"genre_scores_gemma":[0.9811456,0.009399681,0.0024670998,0.0028674507,0.00019730444,0.0029677323,0.0008060475,0.00009309031,0.00005598138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670666,0.00062430685,0.00094371894,0.0009869535,0.00012792367,0.0006104499],"domain_scores_gemma":[0.99755746,0.00084944407,0.00041664226,0.0004258241,0.00049478334,0.00025583516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006408387,0.00042312167,0.0010079105,0.00016002497,0.00015310376,0.00002551535,0.00009448581,0.00025047924,0.00007493055],"category_scores_gemma":[0.00019408167,0.0003097939,0.00047135164,0.00018634743,0.0004710921,0.00007569217,0.00006853338,0.0002996538,0.000011074672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035449676,0.0037315555,0.884604,0.00011077905,0.0007982467,0.00018474505,0.0005726029,0.000017889475,0.0026601185,0.00013393965,0.0005415428,0.07119491],"study_design_scores_gemma":[0.016647179,0.013180556,0.95654035,0.000061799,0.00032924573,0.000121997,0.000056908735,0.00006209779,0.00043411955,0.0002767831,0.012024145,0.00026483263],"about_ca_topic_score_codex":0.000012847446,"about_ca_topic_score_gemma":0.000025271078,"teacher_disagreement_score":0.07193634,"about_ca_system_score_codex":0.00048030206,"about_ca_system_score_gemma":0.0006605903,"threshold_uncertainty_score":0.9999354},"labels":[],"label_agreement":null},{"id":"W3178692749","doi":"10.1016/j.euo.2021.05.007","title":"Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Discontinuation; Sunitinib; Adverse effect; Internal medicine; Renal cell carcinoma; Gastroenterology; Incidence (geometry); Cancer; Immunotherapy","score_opus":0.020506700954942267,"score_gpt":0.24325640937435572,"score_spread":0.22274970841941344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178692749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938879,0.00022949254,0.00008211104,0.0011524471,0.00025134807,0.0014465193,0.00011190698,0.000024513343,0.0028137832],"genre_scores_gemma":[0.9967519,0.0005329733,0.0005030308,0.00030266657,0.00013019728,0.000052272342,0.0013473426,0.00004539231,0.00033419236],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970555,0.00095523044,0.0007662267,0.0006766949,0.00019363749,0.0003527438],"domain_scores_gemma":[0.9984312,0.0003370168,0.000432976,0.00056333555,0.00011793731,0.00011753047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026745992,0.0003021545,0.00065384776,0.00009137984,0.00009409739,0.000007799013,0.00011791466,0.00009843406,0.000059647755],"category_scores_gemma":[0.00008073526,0.00020995777,0.00008277511,0.00021510616,0.00015052661,0.000049170034,0.00015712774,0.00020279043,0.000012397199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5587467,0.0072649023,0.3207658,0.00024019937,0.0009964532,0.0068478803,0.006231367,0.0010285197,0.011076924,0.000038952574,0.00011055978,0.086651795],"study_design_scores_gemma":[0.14936985,0.016985795,0.8283333,0.0000491817,0.00047620037,0.000023208091,0.00008422914,0.0001477248,0.0023083529,0.0000033971612,0.0020726342,0.00014610101],"about_ca_topic_score_codex":0.00008985626,"about_ca_topic_score_gemma":0.00031710655,"teacher_disagreement_score":0.5075675,"about_ca_system_score_codex":0.00046161102,"about_ca_system_score_gemma":0.00016282816,"threshold_uncertainty_score":0.85618293},"labels":[],"label_agreement":null},{"id":"W3185280489","doi":"10.1016/j.euo.2021.07.002","title":"The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Meta-analysis; Prostate cancer; Subgroup analysis; Relative risk; Adverse effect; Randomized controlled trial; Systematic review; Internal medicine; Confidence interval; Urology; Oncology; Gynecology; MEDLINE; Cancer","score_opus":0.13708938105967342,"score_gpt":0.43064019404415815,"score_spread":0.2935508129844847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185280489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076172623,0.9919368,0.0000065021054,0.00046861605,0.00013009715,0.005268185,0.00015586746,0.000012490106,0.0012597297],"genre_scores_gemma":[0.0013360541,0.99660933,0.00016509792,0.0001086955,0.00005678302,0.0006164743,0.0005287709,0.000062870466,0.00051592634],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9771429,0.018449936,0.002932846,0.00066940405,0.00029495347,0.0005099645],"domain_scores_gemma":[0.9828336,0.01344098,0.0025173172,0.00059801026,0.00048371506,0.00012633052],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008118912,0.00048200903,0.01940493,0.00045759353,0.000089643494,0.000008924931,0.00025365502,0.00020722243,0.00013116407],"category_scores_gemma":[0.0022624421,0.00022053212,0.0020971769,0.0014180344,0.0011746117,0.00002360069,0.00021171325,0.00066946703,0.0000021011251],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21856539,0.0007932737,0.0004016386,0.0018297952,0.4752109,0.0003521524,0.0005757757,0.0007372262,4.415478e-7,0.000116641306,0.0005157973,0.30090097],"study_design_scores_gemma":[0.107167706,0.0014286146,0.00035214674,0.00045709294,0.44592538,0.000011590511,0.000018492174,0.000014204441,3.1927487e-7,0.000004585976,0.44446874,0.0001511189],"about_ca_topic_score_codex":0.000051839474,"about_ca_topic_score_gemma":0.00022054664,"teacher_disagreement_score":0.44395295,"about_ca_system_score_codex":0.00015744618,"about_ca_system_score_gemma":0.0009352212,"threshold_uncertainty_score":0.995153},"labels":[],"label_agreement":null},{"id":"W3201577472","doi":"10.1016/j.euo.2021.08.001","title":"Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Lymph node; Meta-analysis; Confidence interval; Receiver operating characteristic; Glutamate carboxypeptidase II; Prostate-specific antigen; Radiology; Subgroup analysis; Dissection (medical); Nuclear medicine; Internal medicine; Cancer","score_opus":0.033752146628727,"score_gpt":0.3139504814814593,"score_spread":0.2801983348527323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201577472","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015762035,0.9803843,0.000022578562,0.0032121926,0.00016421625,0.013447746,0.000921569,0.0000718335,0.00019936314],"genre_scores_gemma":[0.0040606298,0.9845358,0.00028962607,0.0021535635,0.000045417884,0.0065071057,0.0020745874,0.00015550581,0.00017776195],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9899832,0.005079285,0.001978045,0.0017576235,0.0003649244,0.00083690207],"domain_scores_gemma":[0.9944025,0.0015618127,0.0019876782,0.0009938726,0.00073553406,0.00031860045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012223765,0.0011467474,0.009882887,0.00095207733,0.00029778396,0.000058496164,0.00037077715,0.0003539312,0.00012316811],"category_scores_gemma":[0.00023255816,0.00064611074,0.0015184031,0.0023340054,0.0005058879,0.00008118986,0.00017914486,0.0008074312,0.000005935027],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039072405,0.0034835415,0.013107702,0.6095688,0.3246978,0.0038829304,0.0043505533,0.0000725738,0.0000075460216,0.00017235716,0.002659594,0.034089413],"study_design_scores_gemma":[0.00792055,0.007453617,0.0040180827,0.023810126,0.82909656,0.0004633134,0.00019221258,0.000008081166,0.000007593417,0.000020180632,0.12588242,0.0011272967],"about_ca_topic_score_codex":0.00026625665,"about_ca_topic_score_gemma":0.0006691507,"teacher_disagreement_score":0.5857586,"about_ca_system_score_codex":0.0008308631,"about_ca_system_score_gemma":0.00086424313,"threshold_uncertainty_score":0.99959904},"labels":[],"label_agreement":null},{"id":"W3211281229","doi":"10.1016/j.euo.2021.09.006","title":"Epidemiology and Prevention of Prostate Cancer","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":609,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"World Health Organization","keywords":"Medicine; Incidence (geometry); Epidemiology; Prostate cancer; Family history; Disease; Demography; Mortality rate; Cancer; Diabetes mellitus; Cumulative incidence; Internal medicine","score_opus":0.10638041372015321,"score_gpt":0.43002780410647046,"score_spread":0.32364739038631724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211281229","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015021597,0.99250954,0.000008965218,0.0009951608,0.00047248806,0.0010886507,0.000071800285,0.00003087672,0.004672314],"genre_scores_gemma":[0.000069431386,0.9965804,0.0005004987,0.0007740673,0.0002541736,0.00027963048,0.00033322812,0.00007493428,0.0011336162],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99488366,0.0028901065,0.0010617519,0.00070201117,0.000059496888,0.00040295822],"domain_scores_gemma":[0.9976431,0.0007992389,0.0008844693,0.000393351,0.000109690205,0.00017011314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010016157,0.00036927764,0.0036625008,0.00017932805,0.000041481875,0.0000015962794,0.000099467245,0.00034291678,0.00023283449],"category_scores_gemma":[0.00033506073,0.000281465,0.00040563225,0.00016087783,0.00041794608,0.000020140757,0.00021102987,0.00050427736,0.000042468455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047805086,0.00025236892,0.001737317,0.004398396,0.00088889943,0.00068493054,0.00007414733,6.099503e-7,3.8393375e-7,0.00035901915,0.0021113497,0.9894448],"study_design_scores_gemma":[0.0011131979,0.002947703,0.0012835293,0.0026716085,0.0039579123,0.0009723344,0.000007999259,7.3361014e-7,9.523523e-7,0.000066362765,0.9868181,0.00015958259],"about_ca_topic_score_codex":0.000017738335,"about_ca_topic_score_gemma":0.000014921555,"teacher_disagreement_score":0.9892852,"about_ca_system_score_codex":0.00019944432,"about_ca_system_score_gemma":0.0008644027,"threshold_uncertainty_score":0.99996376},"labels":[],"label_agreement":null},{"id":"W3212268582","doi":"10.1016/j.euo.2021.10.005","title":"Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Janssen Pharmaceuticals; National Cancer Institute; National Institutes of Health; RefleXion Medical; Ipsen; Stand Up To Cancer; Ferring Pharmaceuticals; Prostate Cancer Foundation; AstraZeneca; Movember Foundation; Merck; Bayer; Kom op tegen Kanker; Astellas Pharma US; Pfizer","keywords":"Medicine; Disease; Biomarker; Prostate cancer; Oncology; Clinical trial; Internal medicine; Cancer; Bioinformatics; Biology; Genetics","score_opus":0.06133329220559403,"score_gpt":0.3943840527493043,"score_spread":0.3330507605437103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212268582","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004780631,0.9843089,0.000017759765,0.0012656293,0.00025048712,0.012823142,0.0003420266,0.00007400984,0.00087022176],"genre_scores_gemma":[0.000012765135,0.9920997,0.0004947902,0.0014585354,0.00016508262,0.0023045465,0.00092984526,0.00020698558,0.0023277407],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99295294,0.0036435353,0.0013349333,0.0010969181,0.00018622827,0.00078546203],"domain_scores_gemma":[0.9967057,0.0011400771,0.0008733209,0.0006321851,0.00030445805,0.00034422099],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016372079,0.00072731177,0.0066991826,0.00032319382,0.00016252248,0.000025788277,0.00023184398,0.00022962627,0.000051465187],"category_scores_gemma":[0.0006198614,0.00051339326,0.00054141885,0.00034979658,0.00051507895,0.000037178765,0.00028753394,0.00061366067,0.000109741],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023358285,0.00022247365,0.0000010315583,0.8031119,0.008713188,0.006384126,0.0002163371,5.6632143e-8,0.0000886227,0.000021809157,0.0033174474,0.1776894],"study_design_scores_gemma":[0.0036181991,0.00352535,0.000007728571,0.13957682,0.06298455,0.005358751,0.000058273712,0.0000025297975,0.000007439041,0.0000048960674,0.7843922,0.00046329648],"about_ca_topic_score_codex":0.000014063784,"about_ca_topic_score_gemma":0.000009500768,"teacher_disagreement_score":0.7810747,"about_ca_system_score_codex":0.00035492197,"about_ca_system_score_gemma":0.0015462212,"threshold_uncertainty_score":0.9997318},"labels":[],"label_agreement":null},{"id":"W4200305543","doi":"10.1016/j.euo.2021.11.002","title":"Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research; Krebsliga Schweiz","keywords":"Medicine; Bladder cancer; Immunotherapy; Somatic cell; Bacillus (shape); Oncology; Cancer immunotherapy; Complete response; Internal medicine; Urology; Cancer; Chemotherapy; Microbiology","score_opus":0.013395024961628378,"score_gpt":0.28206992650191864,"score_spread":0.2686749015402903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200305543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828192,0.003949593,0.000014701091,0.0039801444,0.00010862476,0.0004064797,0.00002836803,0.00003423827,0.008658668],"genre_scores_gemma":[0.99301064,0.00096616865,0.00042552323,0.0031970798,0.0000705566,0.000048585167,0.000020958887,0.000065457854,0.0021950344],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974249,0.0012403673,0.00037621328,0.0004749029,0.00012832775,0.00035527188],"domain_scores_gemma":[0.9987676,0.00043943257,0.00015605811,0.0003893746,0.00013027966,0.000117254465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003365349,0.00025707204,0.00068344123,0.00019861729,0.000052825897,0.0000059969775,0.00009394844,0.0001592718,0.0003330309],"category_scores_gemma":[0.000137925,0.00019986457,0.00006723195,0.0003021955,0.00036709302,0.000041167932,0.00006221053,0.00036936515,0.000020801943],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054411013,0.0027742293,0.37253568,0.00023637546,0.0027005146,0.03690494,0.009998826,0.000113538736,0.40732747,0.00005705101,0.0026299541,0.110310405],"study_design_scores_gemma":[0.015616876,0.0064880927,0.96211773,0.000072029776,0.0003032978,0.0012195054,0.00026817745,0.000007780517,0.00782085,0.000018013034,0.0058853226,0.00018233365],"about_ca_topic_score_codex":0.00031547042,"about_ca_topic_score_gemma":0.0010547399,"teacher_disagreement_score":0.589582,"about_ca_system_score_codex":0.0001407367,"about_ca_system_score_gemma":0.0006042148,"threshold_uncertainty_score":0.8150241},"labels":[],"label_agreement":null},{"id":"W4206710181","doi":"10.1016/j.euo.2021.12.007","title":"Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy","year":2022,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Pazopanib; Internal medicine; Renal cell carcinoma; Hazard ratio; Kidney cancer; Adverse effect; Oncology; Placebo; Nephrectomy; Adjuvant; Confidence interval; Cancer; Kidney; Sunitinib; Immunotherapy; Pathology","score_opus":0.006648434148015535,"score_gpt":0.20948290704344646,"score_spread":0.20283447289543094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206710181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98611635,0.0008470181,0.0000029177927,0.00060178206,0.0004607175,0.0014420745,0.00007228114,0.00008803587,0.010368824],"genre_scores_gemma":[0.99579155,0.00002626404,0.00031003277,0.0013102056,0.00023315698,0.00038891184,0.00037349097,0.00014464904,0.0014217469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99555355,0.0014942357,0.00067678205,0.000989831,0.00042805605,0.00085755193],"domain_scores_gemma":[0.9983273,0.00013182666,0.00034636218,0.000748499,0.00009513024,0.0003508912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036978247,0.0005703206,0.000910072,0.0005274318,0.00023079148,0.000011550796,0.00021607675,0.00012483314,0.0010951789],"category_scores_gemma":[0.000030363746,0.00042002072,0.00017940515,0.00037488714,0.0002594513,0.000071190036,0.00034396115,0.00083943014,0.0004036636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027381396,0.004583236,0.93792367,0.000018608927,0.00012992401,0.01576284,0.0012640211,0.00030762202,0.00026158543,0.000012175623,0.0005633095,0.011791638],"study_design_scores_gemma":[0.033843573,0.073071554,0.8602087,0.000005627336,0.0005124826,0.0003837405,0.00009538292,0.000018914327,0.00089638436,0.000012240588,0.03061852,0.00033287422],"about_ca_topic_score_codex":0.0007110327,"about_ca_topic_score_gemma":0.00016633014,"teacher_disagreement_score":0.07771494,"about_ca_system_score_codex":0.0018878897,"about_ca_system_score_gemma":0.00045824234,"threshold_uncertainty_score":0.9998252},"labels":[],"label_agreement":null},{"id":"W4214711830","doi":"10.1016/j.euo.2021.11.005","title":"TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells","year":2022,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Council for Science, Technology and Innovation; A.P. Giannini Foundation; Svenska Läkaresällskapet; National Cancer Institute; National Institutes of Health; Vetenskapsrådet; National Institute of General Medical Sciences; Giannini Foundation of Agricultural Economics","keywords":"Medicine; Gene knockdown; Bladder cancer; Cancer research; Cancer; Oncology; Internal medicine; Gene; Biology; Genetics","score_opus":0.01368146384953848,"score_gpt":0.27848123575721934,"score_spread":0.26479977190768084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214711830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97423637,0.0009596302,0.00006344692,0.00052966457,0.0003436585,0.0003994229,0.000119480705,0.00004148643,0.023306845],"genre_scores_gemma":[0.9964673,0.000031974483,0.00035014906,0.0025514518,0.00012034418,0.000035919627,0.00004042573,0.000049559934,0.00035285516],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764395,0.00093768944,0.00036657488,0.00042950493,0.0002360656,0.00038621295],"domain_scores_gemma":[0.9991979,0.00009790442,0.00017363094,0.0003599483,0.00004682337,0.0001237682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045381134,0.00020200205,0.00046372367,0.0000962686,0.00018859147,0.000005601736,0.00020312793,0.00007175251,0.00039652834],"category_scores_gemma":[0.000030709612,0.0001830444,0.000108762426,0.00011360764,0.00025859562,0.000026277981,0.00026412492,0.00035439385,0.000026017882],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008504,0.0014236409,0.016890401,0.000090825735,0.00017004783,0.0080073085,0.005852395,0.000043708995,0.947861,0.0004228427,0.0024930816,0.0082407575],"study_design_scores_gemma":[0.032346405,0.05975579,0.253912,0.000020090332,0.0009809519,0.0034730653,0.0028430363,0.00006328474,0.14024854,0.00028557892,0.5053294,0.0007418783],"about_ca_topic_score_codex":0.000053567677,"about_ca_topic_score_gemma":0.0000052123314,"teacher_disagreement_score":0.8076125,"about_ca_system_score_codex":0.000075147276,"about_ca_system_score_gemma":0.00019715185,"threshold_uncertainty_score":0.7464334},"labels":[],"label_agreement":null},{"id":"W4220776275","doi":"10.1016/j.euo.2022.03.001","title":"Establishing a Foundation for Studying the Immune Contexture Across the Spectrum of Bladder Cancer","year":2022,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bladder cancer; Immune system; Cancer; Medicine; Broad spectrum; Cancer therapy; Foundation (evidence); Bioinformatics; Immunology; Cancer research; Internal medicine; Biology","score_opus":0.04373693572779449,"score_gpt":0.3407628625726476,"score_spread":0.2970259268448531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220776275","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004840879,0.0057735606,0.0002296929,0.96925217,0.0043301373,0.0029899734,0.00044120802,0.00007744478,0.012064953],"genre_scores_gemma":[0.12836191,0.00046275262,0.000054202617,0.8508889,0.009427024,0.00093201286,0.00092311815,0.0002503283,0.008699746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962678,0.001504105,0.00064994954,0.000595071,0.00030204677,0.0006810582],"domain_scores_gemma":[0.996849,0.0014677069,0.0006955462,0.0008049572,0.00014459048,0.000038171886],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013265118,0.00038895427,0.0008473383,0.000083235005,0.00068306964,0.00003932054,0.0007262847,0.0003451623,0.0017586922],"category_scores_gemma":[0.00020640592,0.00022812284,0.00034773423,0.00020507889,0.00060848094,0.000055538363,0.00038637928,0.0027052555,0.000035832218],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018534975,0.0002269143,0.00097648526,0.00012968102,0.0024851211,0.00072749023,0.006575521,0.00004895555,0.00018680777,0.00007988213,0.9652629,0.021446776],"study_design_scores_gemma":[0.003573671,0.0031520217,0.004419438,0.000015924039,0.001296779,0.00029910041,0.00061669975,0.000020175954,0.000034683417,0.000115721,0.9862805,0.0001752819],"about_ca_topic_score_codex":0.00041515048,"about_ca_topic_score_gemma":0.00023005587,"teacher_disagreement_score":0.12352103,"about_ca_system_score_codex":0.00032504855,"about_ca_system_score_gemma":0.00053088507,"threshold_uncertainty_score":0.9995955},"labels":[],"label_agreement":null},{"id":"W4229059608","doi":"10.1016/j.euo.2021.07.001","title":"Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non–muscle-invasive Bladder Cancer","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"FP7 Health; University of Sheffield; University of Birmingham; Instituto de Salud Carlos III; National Institute for Health and Care Research; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Cancer Research UK","keywords":"Single-nucleotide polymorphism; Hazard ratio; Genome-wide association study; Bladder cancer; Oncology; SNP; Medicine; Candidate gene; Locus (genetics); Proportional hazards model; Expression quantitative trait loci; 1000 Genomes Project; Genetic association; Genetics; Gene; Internal medicine; Confidence interval; Genotype; Biology; Cancer","score_opus":0.1060085893577181,"score_gpt":0.38479782066120766,"score_spread":0.27878923130348954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229059608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009461503,0.99453855,0.000045568522,0.00045852773,0.00021475219,0.0013702858,0.00020801628,0.000047251146,0.0021709125],"genre_scores_gemma":[0.0022533142,0.9938131,0.00019788127,0.0008793281,0.0001583635,0.00057351287,0.000717875,0.00012814815,0.0012784812],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949155,0.001829503,0.0009740668,0.0013735318,0.0002860922,0.0006213155],"domain_scores_gemma":[0.9972097,0.0008333475,0.0008662758,0.0006089965,0.00026240686,0.00021926941],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007727946,0.0007583497,0.005835886,0.00069814286,0.000117901334,0.000034978715,0.00027713482,0.0004776163,0.000629527],"category_scores_gemma":[0.00029339993,0.0005075913,0.0010376959,0.0012346496,0.00043962343,0.00006538921,0.00027962145,0.00089198165,0.00003590008],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022132962,0.0020555342,0.006292281,0.0026875355,0.47178835,0.0099679865,0.0011019423,0.00003644426,0.000026100006,0.0000074854056,0.00047554992,0.50533944],"study_design_scores_gemma":[0.0018867922,0.001407294,0.020870287,0.0005955002,0.51521766,0.00022229037,0.000040239247,0.0000024665421,0.0000023593411,0.0000022686913,0.45925504,0.0004977941],"about_ca_topic_score_codex":0.00008462114,"about_ca_topic_score_gemma":0.0020151678,"teacher_disagreement_score":0.5048417,"about_ca_system_score_codex":0.00032359618,"about_ca_system_score_gemma":0.0012537434,"threshold_uncertainty_score":0.99973756},"labels":[],"label_agreement":null},{"id":"W4281725891","doi":"10.1016/j.euo.2022.04.009","title":"First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Androgen deprivation therapy; Docetaxel; Oncology; Systematic review; Prostate-specific antigen; Systemic therapy; Internal medicine; Radiation therapy; Quality of life (healthcare); Cancer; Watchful waiting; MEDLINE; Intensive care medicine; Breast cancer","score_opus":0.05646314654128041,"score_gpt":0.37166315697840985,"score_spread":0.3152000104371294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281725891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043351276,0.9862927,0.000001607631,0.0006098026,0.0006953058,0.011041378,0.0005383989,0.000033202516,0.0007442592],"genre_scores_gemma":[0.00014725201,0.99055135,0.000009891873,0.00082309375,0.00018605533,0.0041576237,0.00038649712,0.00013306474,0.0036051683],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99132836,0.0051886886,0.0018699609,0.00068906485,0.0004285436,0.00049535406],"domain_scores_gemma":[0.9962205,0.00065283454,0.001578889,0.0012172292,0.00019483855,0.00013567052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010188078,0.0006798993,0.0054783165,0.0002633571,0.00009294492,0.000006417647,0.0005031404,0.00025735595,0.0006413739],"category_scores_gemma":[0.00013755643,0.00029767203,0.0011159175,0.00079396134,0.0004851679,0.00002561219,0.0002976525,0.00076986605,0.000027103311],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014156362,0.00076258136,0.000016494709,0.7304627,0.0015308959,0.0014232039,0.0007099323,6.358942e-7,4.5840642e-7,0.00000234276,0.00038058122,0.26329458],"study_design_scores_gemma":[0.0018892861,0.00679535,0.000018450919,0.3899044,0.004933693,0.0014295769,0.000012294395,9.453704e-7,6.701146e-7,9.221637e-7,0.59485954,0.00015486509],"about_ca_topic_score_codex":0.00001032289,"about_ca_topic_score_gemma":0.000013109811,"teacher_disagreement_score":0.59447896,"about_ca_system_score_codex":0.0017355201,"about_ca_system_score_gemma":0.0022385765,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W4282915663","doi":"10.1016/j.euo.2022.04.006","title":"Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography–targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Meta-analysis; Glutamate carboxypeptidase II; Confidence interval; Magnetic resonance imaging; Prostate; Biopsy; Prospective cohort study; Nuclear medicine; Radiology; Internal medicine; Cancer","score_opus":0.08277012584212112,"score_gpt":0.37797085764769944,"score_spread":0.2952007318055783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282915663","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014827152,0.9857621,0.000014055866,0.00024883225,0.00011674664,0.011592328,0.0006416597,0.000042848547,0.000098694945],"genre_scores_gemma":[0.0045613553,0.99099964,0.00014218873,0.00012203811,0.000037485825,0.002895753,0.00068060536,0.000105116174,0.00045583787],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9916142,0.0034384055,0.0030439873,0.0009932548,0.00036593564,0.0005442032],"domain_scores_gemma":[0.99324685,0.0025762664,0.0028001876,0.0007952969,0.00035932675,0.00022205093],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003687986,0.0006167403,0.009989658,0.0009147084,0.00016113573,0.000008509488,0.00036311627,0.0002534717,0.00026292136],"category_scores_gemma":[0.0006937215,0.00039352817,0.002272378,0.001500093,0.000492957,0.000046664805,0.00021113093,0.0007138575,0.0000047893227],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013332492,0.00062112784,0.0003008573,0.86315906,0.10933684,0.00020734442,0.00022503892,0.0000068276486,0.0002744326,0.0000023229027,0.00009272441,0.024440158],"study_design_scores_gemma":[0.0016859653,0.010639239,0.00011414992,0.0076415576,0.865097,0.00020773655,0.000028656697,0.000023926481,0.000098912424,0.0000018849302,0.11405068,0.00041028112],"about_ca_topic_score_codex":0.000020169098,"about_ca_topic_score_gemma":0.0000020927212,"teacher_disagreement_score":0.8555175,"about_ca_system_score_codex":0.00018042773,"about_ca_system_score_gemma":0.0005307327,"threshold_uncertainty_score":0.99985164},"labels":[],"label_agreement":null},{"id":"W4282926990","doi":"10.1016/j.euo.2022.04.001","title":"Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer","year":2022,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Propensity score matching; Lymph node; Cisplatin; Oncology; Internal medicine; Proportional hazards model; Cohort; Urology; Clinical endpoint; Lymph; Stage (stratigraphy); Cancer; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.009836005636316718,"score_gpt":0.266905499013577,"score_spread":0.2570694933772603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282926990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98971826,0.0005325039,0.00020607625,0.004131153,0.00041927976,0.0016205666,0.00015959659,0.000073410614,0.00313918],"genre_scores_gemma":[0.98171026,0.000010440114,0.00025113975,0.01560349,0.00032746315,0.001061495,0.00010317146,0.00010881011,0.0008237475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978357,0.0005750705,0.00031305358,0.0005068217,0.00023560994,0.0005337466],"domain_scores_gemma":[0.9989451,0.00030079586,0.00019246199,0.0003139121,0.00011403127,0.00013366253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003451814,0.000270952,0.00043649628,0.00010048171,0.00043079117,0.0000115292305,0.00020501555,0.00007208888,0.0012249108],"category_scores_gemma":[0.00003820418,0.00017662247,0.000108789245,0.0002073314,0.00036343923,0.000029944194,0.000074838434,0.00052127184,0.000022744602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01330209,0.0011845515,0.95548004,0.000029949639,0.0007564371,0.00032156034,0.0013375625,0.00034019956,0.00013741686,0.0000066278894,0.005662627,0.02144093],"study_design_scores_gemma":[0.035618905,0.019596893,0.6588288,0.000020596624,0.0011775994,0.00012972116,0.0001852426,0.0008506353,0.00025577526,0.000017897419,0.2829104,0.00040755162],"about_ca_topic_score_codex":0.0002169903,"about_ca_topic_score_gemma":0.00030408258,"teacher_disagreement_score":0.29665127,"about_ca_system_score_codex":0.00028081104,"about_ca_system_score_gemma":0.00044085857,"threshold_uncertainty_score":0.9996881},"labels":[],"label_agreement":null},{"id":"W4284887428","doi":"10.1016/j.euo.2022.06.003","title":"Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Ottawa Hospital; University of Ottawa; University Health Network; University of Toronto; Université de Montréal","funders":"","keywords":"Docetaxel; Androgen deprivation therapy; Medicine; Prostate cancer; Oncology; Internal medicine; Hazard ratio; Clinical endpoint; Randomized controlled trial; Confidence interval; Androgen receptor; Meta-analysis; Cancer","score_opus":0.1584241569403467,"score_gpt":0.38862274295798793,"score_spread":0.23019858601764123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284887428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060179033,0.987935,0.000013016047,0.00079847185,0.00010339341,0.0038691205,0.0007392258,0.000040440696,0.00048340132],"genre_scores_gemma":[0.0013984231,0.99281394,0.00049044465,0.00086494826,0.00012214149,0.0013136326,0.0025748725,0.00010891315,0.00031269641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99218875,0.004775339,0.001104584,0.0009808472,0.000325426,0.00062508],"domain_scores_gemma":[0.99762434,0.0007249833,0.0007687077,0.00049707486,0.00016671424,0.00021818912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018687181,0.0005736153,0.0048194383,0.0010704094,0.00013213462,0.000013677743,0.00022485238,0.0001873094,0.0013306689],"category_scores_gemma":[0.00009926983,0.00040717475,0.0009900404,0.002133791,0.00025692667,0.00006058438,0.00019166167,0.0007364786,0.000026098109],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039171963,0.00055799517,0.00033889932,0.00040357516,0.1419544,0.00079882145,0.0013630355,0.0001302551,0.000034200682,0.000024237856,0.0019854319,0.84849197],"study_design_scores_gemma":[0.0032149425,0.005452052,0.0006254693,0.000038068018,0.058302294,0.00012747532,0.000054461714,0.00001564876,0.000012399491,0.000025122501,0.931822,0.00031007137],"about_ca_topic_score_codex":0.00011639602,"about_ca_topic_score_gemma":0.00009006445,"teacher_disagreement_score":0.9298366,"about_ca_system_score_codex":0.00035810235,"about_ca_system_score_gemma":0.00065132184,"threshold_uncertainty_score":0.999838},"labels":[],"label_agreement":null},{"id":"W4292178027","doi":"10.1016/j.euo.2022.08.001","title":"Erratum to “Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)” [Eur Urol Oncol 2021;4:543–52]","year":2022,"lang":"en","type":"erratum","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Oncology; Randomized controlled trial; Internal medicine; Urology; Cancer","score_opus":0.022105357981230114,"score_gpt":0.3328123005631535,"score_spread":0.3107069425819234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292178027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9087501,0.019350806,0.000034425393,0.0076468796,0.017392505,0.037219178,0.0006520715,0.00013012718,0.00882388],"genre_scores_gemma":[0.6770219,0.10904907,0.000611489,0.005700888,0.007161261,0.049072802,0.005695826,0.0010006137,0.14468612],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98605114,0.0079844715,0.002390039,0.0015546888,0.0008805771,0.001139091],"domain_scores_gemma":[0.9943751,0.0017609304,0.0019062604,0.0009352424,0.0005647586,0.00045772383],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005000034,0.0009859753,0.0067406157,0.0014107145,0.0001423368,0.000031582505,0.00046615972,0.00066339166,0.0019357023],"category_scores_gemma":[0.001626587,0.00061761256,0.00065223855,0.0009856608,0.00078340835,0.00007846536,0.00031760568,0.0028909214,0.00003917447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8449372,0.0037185643,0.0015606135,0.00012624901,0.0023572217,0.0027120933,0.0008510058,0.000013812709,0.00023730737,0.0000019249937,0.123105615,0.020378394],"study_design_scores_gemma":[0.75616384,0.02296897,0.0003005877,0.00015864757,0.0013187546,0.000077030534,0.000036325346,0.000052398893,0.0001182369,0.000019156345,0.21831313,0.0004729033],"about_ca_topic_score_codex":0.0002995085,"about_ca_topic_score_gemma":0.00040485864,"teacher_disagreement_score":0.23172818,"about_ca_system_score_codex":0.0008036435,"about_ca_system_score_gemma":0.0063666226,"threshold_uncertainty_score":0.99962753},"labels":[],"label_agreement":null},{"id":"W4307153601","doi":"10.1016/j.euo.2022.09.007","title":"Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Genitourinary system; Prospective cohort study; Clinical trial; Oncology; Radiosurgery; Radiation therapy; Cancer; Prostate; Internal medicine","score_opus":0.14529858941571672,"score_gpt":0.46872939060602287,"score_spread":0.32343080119030615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307153601","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003087839,0.986945,0.000002004107,0.0002629799,0.00026215683,0.009468956,0.00020161254,0.000026467078,0.002522042],"genre_scores_gemma":[0.00041084483,0.995847,0.000110941626,0.00021905928,0.00016762047,0.0024639962,0.0005445067,0.00009087639,0.00014518185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863117,0.010809801,0.0017067255,0.0005416731,0.00021889377,0.00041122857],"domain_scores_gemma":[0.99285895,0.00447858,0.0019309528,0.0005139434,0.00014058525,0.000077009136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004624735,0.00043054656,0.0044495733,0.0005305312,0.000098024124,0.000006699253,0.0002757292,0.000117379095,0.0003530034],"category_scores_gemma":[0.0010283702,0.0002452837,0.00084343634,0.00070348824,0.00025324515,0.000048956976,0.00008391723,0.0004859468,0.000004768966],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090928044,0.000777887,0.00018532657,0.012816619,0.0031277759,0.00014927358,0.00031301455,8.4371254e-7,0.000013413816,0.00001512104,0.0001832728,0.9815082],"study_design_scores_gemma":[0.0050787274,0.00943073,0.0005775709,0.002809126,0.0055729835,0.00018416095,0.00007545735,0.0000066827556,0.000019492407,0.000031528052,0.9760621,0.00015139971],"about_ca_topic_score_codex":0.00009760906,"about_ca_topic_score_gemma":0.00000988131,"teacher_disagreement_score":0.9813568,"about_ca_system_score_codex":0.001740414,"about_ca_system_score_gemma":0.0032169477,"threshold_uncertainty_score":0.99999994},"labels":[],"label_agreement":null},{"id":"W4308034719","doi":"10.1016/j.euo.2022.10.004","title":"Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2022,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cabozantinib; Medicine; Radiation therapy; Discontinuation; Renal cell carcinoma; Oncology; Adverse effect; Internal medicine","score_opus":0.035861587331712935,"score_gpt":0.3030438251672152,"score_spread":0.2671822378355022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308034719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756663,0.0029769493,0.00012053867,0.0065366863,0.00049634324,0.0009687612,0.0016218822,0.000022829765,0.011589736],"genre_scores_gemma":[0.99334246,0.00071203004,0.0018694474,0.0023143413,0.00015687075,0.000051161827,0.0010412945,0.000062704596,0.00044966544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926592,0.00430451,0.0012225851,0.0009139613,0.00043755583,0.00046215474],"domain_scores_gemma":[0.99432606,0.0037902182,0.0008990599,0.00065214257,0.00012691919,0.00020558553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024002846,0.00038017827,0.0008450652,0.00031819366,0.00017180385,0.00001794629,0.00037723422,0.0000423974,0.00034970624],"category_scores_gemma":[0.00030575474,0.00030396413,0.00010447399,0.0002436301,0.00050199183,0.00010509545,0.0005858215,0.0009765049,0.000008200655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07308392,0.009006482,0.67569387,0.00038812545,0.0021087292,0.0630053,0.028125046,0.0009281563,0.10787737,0.0011732657,0.022354132,0.016255599],"study_design_scores_gemma":[0.041591298,0.007472772,0.8105172,0.000024634945,0.0017801388,0.0022476376,0.0024655685,0.0013024542,0.0035213102,0.000019069867,0.12860273,0.00045519642],"about_ca_topic_score_codex":0.0032964314,"about_ca_topic_score_gemma":0.0008378551,"teacher_disagreement_score":0.13482332,"about_ca_system_score_codex":0.00031901395,"about_ca_system_score_gemma":0.00043337015,"threshold_uncertainty_score":0.99994123},"labels":[],"label_agreement":null},{"id":"W4317690982","doi":"10.1016/j.euo.2023.01.004","title":"Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sorbonne Université; Universitat Autònoma de Barcelona; Karl-Franzens-Universität Graz; European Association of Urology; Radboud Universiteit; Radboud Universitair Medisch Centrum; Royal Free London NHS Foundation Trust; Medizinische Universität Graz; Univerzita Karlova v Praze","keywords":"Medicine; Bladder cancer; Confidence interval; Concomitant; Internal medicine; Risk stratification; Urology; Incidence (geometry); Proportional hazards model; Cumulative incidence; Oncology; Gastroenterology; Cancer; Cohort","score_opus":0.03348403002527243,"score_gpt":0.3052974684279435,"score_spread":0.271813438402671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317690982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8857755,0.0011704931,0.0000065151066,0.030344892,0.0006042261,0.001069266,0.000052328218,0.00010803932,0.08086872],"genre_scores_gemma":[0.9874499,0.0018933117,0.00004694756,0.009377706,0.00043981653,0.00013228605,0.000054205128,0.000057354355,0.0005484822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976915,0.0007471928,0.00041930718,0.00042882818,0.00020420305,0.00050897175],"domain_scores_gemma":[0.9989475,0.0003683296,0.0001586428,0.00039708443,0.000043721277,0.00008472061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005849018,0.00022099643,0.0005325611,0.00024556526,0.000068968395,0.0000047524277,0.00029724944,0.00013421016,0.00030706762],"category_scores_gemma":[0.00007300004,0.0001554891,0.0001312226,0.00060124265,0.00034809846,0.00003724402,0.00013804216,0.00042677895,0.0002913291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023187199,0.004059039,0.70627034,0.0004914896,0.0017887001,0.019182308,0.018204972,0.00022375917,0.035957817,0.00046646057,0.114099346,0.09693703],"study_design_scores_gemma":[0.003523059,0.003106088,0.9458527,0.000025309848,0.00031064218,0.00017935372,0.00027632678,0.000016726037,0.00058961223,0.00017143437,0.04581217,0.0001365649],"about_ca_topic_score_codex":0.00016123509,"about_ca_topic_score_gemma":0.00033333167,"teacher_disagreement_score":0.23958236,"about_ca_system_score_codex":0.00012397236,"about_ca_system_score_gemma":0.00046056416,"threshold_uncertainty_score":0.63406616},"labels":[],"label_agreement":null},{"id":"W4318293174","doi":"10.1016/j.euo.2023.01.003","title":"Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada; Occupational Cancer Research Centre; Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute for Health and Care Research; Movember Foundation","keywords":"Medicine; Prostate cancer; Rectal examination; Likert scale; Best practice; Medical physics; Family medicine; Prostate-specific antigen; Cancer; Internal medicine; Psychology","score_opus":0.08208314405228695,"score_gpt":0.4447289611247385,"score_spread":0.3626458170724515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318293174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95129514,0.003131181,0.0000019700628,0.031171653,0.00069110846,0.0010077987,0.00011456089,0.000030375491,0.012556205],"genre_scores_gemma":[0.99154836,0.006685176,0.00034136497,0.0002813294,0.00020674618,0.00032910448,0.00007167449,0.000030023491,0.0005062082],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812406,0.0006024669,0.0003991951,0.00038449815,0.00016324941,0.00032650394],"domain_scores_gemma":[0.9968416,0.002158167,0.00023342468,0.00014916444,0.00055082515,0.00006680613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022059833,0.00010465957,0.00032320851,0.000240529,0.00005575283,0.000006371139,0.00006507028,0.000050498387,0.000009440358],"category_scores_gemma":[0.002516194,0.0000960212,0.000033470238,0.00022036771,0.00035172366,0.00003415592,0.00014182393,0.00029059287,0.000009687298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008957514,0.0013966691,0.6663384,0.00038121443,0.00060535455,0.01105641,0.009318357,0.00016186053,0.0018648914,0.0007050507,0.017334683,0.28187963],"study_design_scores_gemma":[0.005303253,0.0028770813,0.27871615,0.0001291445,0.0000651125,0.0007014594,0.0011933976,0.00023947287,0.00042967394,0.00021374637,0.71001273,0.00011877832],"about_ca_topic_score_codex":0.00026482966,"about_ca_topic_score_gemma":0.00032054549,"teacher_disagreement_score":0.69267803,"about_ca_system_score_codex":0.0002240803,"about_ca_system_score_gemma":0.00040562756,"threshold_uncertainty_score":0.3915631},"labels":[],"label_agreement":null},{"id":"W4318754961","doi":"10.1016/j.euo.2023.01.010","title":"Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; Eisai Incorporated; Genentech; Ipsen; Astellas Pharma; EUSA Pharma; Seagen; Sanofi; Exelixis; Memorial Sloan-Kettering Cancer Center; Merck Sharp and Dohme; Ono Pharmaceutical; Eisai; Merck KGaA; Handok; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Lenvatinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Everolimus; Subgroup analysis; Kidney cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Cancer; Phases of clinical research; Meta-analysis; Immunotherapy","score_opus":0.03463152331413209,"score_gpt":0.3178959216777795,"score_spread":0.2832643983636474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940331,0.00039735416,0.000050212817,0.00038482336,0.00021517539,0.001725693,0.0004216084,0.00003590065,0.0027361487],"genre_scores_gemma":[0.9982636,0.000036710302,0.00017579897,0.000100909616,0.000026931402,0.000064260224,0.00084652664,0.00006951039,0.00041575573],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98924387,0.0076268655,0.0012633252,0.0008183619,0.0005333136,0.00051429064],"domain_scores_gemma":[0.9931972,0.0047113462,0.00087920827,0.00079429854,0.00021763514,0.00020033776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031442859,0.00042991134,0.0019092908,0.0008441316,0.00008818533,0.000009467412,0.00043145873,0.000087425724,0.00010517746],"category_scores_gemma":[0.000775705,0.0003090879,0.00027466804,0.0012363855,0.0010229537,0.00007267524,0.0003514107,0.00054988015,0.000010609484],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88086575,0.0041044867,0.046024382,0.000052948395,0.0017897071,0.0028989043,0.0027735343,0.0006412493,0.059857637,0.000012071269,0.00059630483,0.00038299788],"study_design_scores_gemma":[0.65175587,0.020013914,0.3069261,0.0000118279395,0.0072571053,0.000078595425,0.0020595437,0.0016212527,0.009411206,9.911256e-7,0.0005664837,0.00029713416],"about_ca_topic_score_codex":0.00031796106,"about_ca_topic_score_gemma":0.0003542022,"teacher_disagreement_score":0.26090172,"about_ca_system_score_codex":0.00020597946,"about_ca_system_score_gemma":0.0004295357,"threshold_uncertainty_score":0.9999361},"labels":[],"label_agreement":null},{"id":"W4319226694","doi":"10.1016/j.euo.2023.01.008","title":"A Matched Analysis of Active Surveillance Versus Nephrectomy for T1a Small Renal Masses","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Nephrectomy; Hazard ratio; Confidence interval; Internal medicine; Proportional hazards model; Cohort; Renal cell carcinoma; Urology; Surgery; Kidney","score_opus":0.06771732435127352,"score_gpt":0.32778051386068147,"score_spread":0.26006318950940793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319226694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732677,0.00012972389,0.00029517023,0.0017484449,0.0003537819,0.0005099072,0.000066331704,0.00015129767,0.02347766],"genre_scores_gemma":[0.9960449,0.00006983855,0.0018563259,0.0003890107,0.0001684188,0.000059062764,0.00040746122,0.00005080293,0.0009542098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978261,0.0006681668,0.0004334147,0.000500249,0.0001216712,0.00045039956],"domain_scores_gemma":[0.99739575,0.0015782656,0.000272504,0.0004397695,0.00017782248,0.00013590141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068493065,0.00021470984,0.0009456819,0.00065925665,0.00005564489,0.0000038961107,0.00017522222,0.0001318325,0.000142273],"category_scores_gemma":[0.00038502697,0.0001887314,0.00037118082,0.0010920916,0.00022001208,0.000019495712,0.00011699005,0.00019352595,0.00016419463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14967108,0.0032814688,0.43847552,0.00044791316,0.06455434,0.013274796,0.0072286064,0.0051599257,0.14917205,0.0015241379,0.02441675,0.1427934],"study_design_scores_gemma":[0.0096760085,0.008278928,0.8660054,0.000004161643,0.0039755236,0.00006163366,0.00020956821,0.0011168591,0.0017911908,0.000037372247,0.10864443,0.00019888218],"about_ca_topic_score_codex":0.000036392878,"about_ca_topic_score_gemma":0.0002778745,"teacher_disagreement_score":0.4275299,"about_ca_system_score_codex":0.00015128966,"about_ca_system_score_gemma":0.00016301824,"threshold_uncertainty_score":0.7696243},"labels":[],"label_agreement":null},{"id":"W4323032055","doi":"10.1016/j.euo.2023.02.003","title":"Where To Draw the Line: Stratifying Risk for High-grade Ta Bladder Cancer","year":2023,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Oncology; Line (geometry); Internal medicine; Cancer","score_opus":0.04740955244551244,"score_gpt":0.3424454065617327,"score_spread":0.2950358541162203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323032055","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026095072,0.0022771829,0.00040359984,0.97724587,0.005130665,0.002836157,0.0010204915,0.00036326353,0.008113245],"genre_scores_gemma":[0.008676494,0.0018111508,0.00056064076,0.93040156,0.025693845,0.0010390326,0.00063824275,0.0005368259,0.030642191],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955832,0.0012132998,0.0006774944,0.0011505631,0.00029603756,0.001079457],"domain_scores_gemma":[0.9971489,0.0010786374,0.00040665705,0.0009822283,0.00019163678,0.00019199275],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062246807,0.00065853057,0.0010963285,0.00024489392,0.00038567706,0.000039141698,0.00063098903,0.00091844564,0.0007000056],"category_scores_gemma":[0.00023005264,0.00045931566,0.00033046716,0.00029582385,0.00035018483,0.00003260347,0.00024077242,0.0029463812,0.0014402323],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046320911,0.00010127424,0.0005152615,0.00012228805,0.0013861562,0.0022022976,0.0005353581,0.000060125956,0.000100696445,0.000027748707,0.98211825,0.012367337],"study_design_scores_gemma":[0.003592436,0.004822737,0.0042752433,0.000049444654,0.002372648,0.0001633172,0.000046813628,0.000016030672,0.000036099937,0.00021154902,0.98403525,0.00037841892],"about_ca_topic_score_codex":0.0006793138,"about_ca_topic_score_gemma":0.001286078,"teacher_disagreement_score":0.04684431,"about_ca_system_score_codex":0.00029196026,"about_ca_system_score_gemma":0.00074045843,"threshold_uncertainty_score":0.99978584},"labels":[],"label_agreement":null},{"id":"W4362469300","doi":"10.1016/j.euo.2023.03.004","title":"Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Université de Sherbrooke; University of Toronto; Western University; University of Calgary; McGill University Health Centre; University of Ottawa; McGill University; Queen's University; McMaster University; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Confidence interval; Internal medicine; Odds ratio; Urology; Stage (stratigraphy); Hazard ratio; Radiation therapy; Chemotherapy; Retrospective cohort study; Neoadjuvant therapy; Oncology; Cancer; Gastroenterology; Breast cancer","score_opus":0.04950774386209853,"score_gpt":0.3620813512570833,"score_spread":0.31257360739498474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362469300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9399649,0.0019289256,0.00022468498,0.04446716,0.0023887928,0.0022013069,0.0005139844,0.0005971069,0.007713142],"genre_scores_gemma":[0.95182943,0.0004853466,0.00008746092,0.045083363,0.00045563705,0.00035411434,0.0003854067,0.00010560644,0.0012136283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979099,0.0004093061,0.00040599843,0.00054556906,0.00013445919,0.00059473905],"domain_scores_gemma":[0.99847007,0.0006968027,0.00017657601,0.00036350667,0.000104216764,0.00018881257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039185796,0.00028811407,0.0005476838,0.0001537584,0.00019730511,0.000011922618,0.00019447805,0.00015422166,0.00018476378],"category_scores_gemma":[0.00012953467,0.00023614826,0.00025710685,0.0001943228,0.00025280597,0.000055283068,0.000051830313,0.00021754432,0.0002908691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028906818,0.00079226855,0.7739477,0.000056134726,0.0013351727,0.0011674204,0.0021222578,0.00013622889,0.0030388646,0.000025761232,0.09720256,0.117284924],"study_design_scores_gemma":[0.01610052,0.002733334,0.7184606,0.000008956192,0.00010636304,0.000015889167,0.00013877638,0.00011462653,0.00058268505,0.000029772247,0.26152152,0.0001869491],"about_ca_topic_score_codex":0.00013397122,"about_ca_topic_score_gemma":0.00006637701,"teacher_disagreement_score":0.16431896,"about_ca_system_score_codex":0.00014382809,"about_ca_system_score_gemma":0.00068376696,"threshold_uncertainty_score":0.9629847},"labels":[],"label_agreement":null},{"id":"W4365812973","doi":"10.1016/j.euo.2023.03.002","title":"Adaptive Immunity in Genitourinary Cancers","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; Queen's University","funders":"Cancer Research Institute","keywords":"Immune system; Medicine; Prostate cancer; Cancer; Tumor microenvironment; Immunotherapy; Acquired immune system; Immune checkpoint; Genitourinary system; Immunology; Cancer research; Immunity; Oncology; Internal medicine","score_opus":0.12046106995638806,"score_gpt":0.3908199258552533,"score_spread":0.27035885589886527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365812973","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011096371,0.9491794,0.0000036053245,0.00024392501,0.0012633627,0.0010137942,0.000039575647,0.00017128413,0.04797407],"genre_scores_gemma":[0.000095213865,0.99486566,0.000076771896,0.0010530328,0.00063706364,0.000111204165,0.00016168298,0.0001890724,0.0028103024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947162,0.002836072,0.0010315186,0.0006490734,0.00013092585,0.00063617754],"domain_scores_gemma":[0.9981256,0.00057597837,0.000470018,0.00064942834,0.00004609448,0.00013286629],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013793467,0.00050397706,0.0023928117,0.0007280672,0.00008301107,0.0000060867737,0.00043888355,0.000570214,0.0003152867],"category_scores_gemma":[0.000118158096,0.00043310627,0.0005989506,0.00075996906,0.00049471733,0.000028843097,0.0002891041,0.0018011604,0.0015123265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013869896,0.00015333245,0.000018755249,0.0016378427,0.00075617334,0.007862902,0.00019357924,0.0000013870706,0.0000022028019,0.000015448035,0.00390694,0.98406446],"study_design_scores_gemma":[0.0019809005,0.0031530024,0.0008568377,0.00138029,0.00080174906,0.0016952094,0.00006656478,0.0000029910825,9.047687e-8,0.000008399611,0.98973846,0.0003155191],"about_ca_topic_score_codex":0.00032876496,"about_ca_topic_score_gemma":0.00030931726,"teacher_disagreement_score":0.9858315,"about_ca_system_score_codex":0.0014314229,"about_ca_system_score_gemma":0.0019145126,"threshold_uncertainty_score":0.99981207},"labels":[],"label_agreement":null},{"id":"W4383874542","doi":"10.1016/j.euo.2023.05.013","title":"Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Cystectomy; Internal medicine; Oncology; Clinical endpoint; Radiation therapy; Trastuzumab; Bladder cancer; Toxicity; Paclitaxel; Chemotherapy; Urology; Randomized controlled trial; Cancer; Breast cancer","score_opus":0.050891716655193604,"score_gpt":0.3631017691669565,"score_spread":0.3122100525117629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383874542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916383,0.00028880205,0.00020195691,0.0020691017,0.00043320368,0.0030136472,0.00096615404,0.00005983203,0.0013290016],"genre_scores_gemma":[0.9969083,0.00049789733,0.00038597683,0.00035377164,0.00027458867,0.0003762353,0.0007182014,0.00008876191,0.00039625147],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9962798,0.0007243338,0.0013937888,0.0006979902,0.0003434104,0.0005607216],"domain_scores_gemma":[0.9963521,0.0012166589,0.0014127996,0.00047915376,0.0003784903,0.00016081562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009785995,0.00040329434,0.001596182,0.0006674956,0.00006564219,0.00000511995,0.00021110685,0.00029954244,0.00008061225],"category_scores_gemma":[0.0005584615,0.00029747986,0.00015662068,0.00076395186,0.000462352,0.00014349836,0.00004495868,0.00030523265,0.000010035122],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7193693,0.006444022,0.12657061,0.0006078171,0.002373277,0.0010661436,0.009036885,0.00083054166,0.007953371,0.000031601106,0.0016300832,0.124086365],"study_design_scores_gemma":[0.35801053,0.06741992,0.56956124,0.000089571055,0.0011457899,0.00007152083,0.00028991693,0.00019477923,0.0019138309,0.000013386697,0.0010370674,0.00025242154],"about_ca_topic_score_codex":0.0006076083,"about_ca_topic_score_gemma":0.004362128,"teacher_disagreement_score":0.44299063,"about_ca_system_score_codex":0.00050468085,"about_ca_system_score_gemma":0.002279754,"threshold_uncertainty_score":0.9999477},"labels":[],"label_agreement":null},{"id":"W4384701084","doi":"10.1016/j.euo.2023.06.006","title":"Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Shanghai Education Development Foundation; Changhai Hospital of Shanghai; Shanghai Municipal Health Bureau; Shanghai Municipal Education Commission; National Natural Science Foundation of China","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Hazard ratio; Clear cell renal cell carcinoma; Oncology; Nephrectomy; Proportional hazards model; Adjuvant therapy; Cancer; Urology; Confidence interval; Kidney","score_opus":0.038756231525032145,"score_gpt":0.2903480757409217,"score_spread":0.25159184421588954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384701084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943155,0.0013272368,0.000052935007,0.0015508501,0.000032049706,0.0011713672,0.00010151394,0.000018740457,0.0014298199],"genre_scores_gemma":[0.99854565,0.00018385786,0.0006820646,0.0001804168,0.000033700704,0.000060553175,0.00010383636,0.000036057547,0.00017386963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980006,0.00058357255,0.00055894157,0.00045551753,0.000102322694,0.00029902227],"domain_scores_gemma":[0.99799097,0.00092909054,0.00042148452,0.0005057305,0.00006791378,0.000084801984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005544457,0.00018120716,0.00081631227,0.00026300637,0.00006532062,0.0000032987755,0.00016073648,0.00006389054,0.000005688259],"category_scores_gemma":[0.0000962498,0.00012094272,0.00014173109,0.00066678243,0.0005162988,0.00002058465,0.00012108183,0.00020795754,0.0000022095865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046696095,0.0006621343,0.9338214,0.00021800137,0.00034751242,0.00013674698,0.00096773717,0.000050555238,0.060768567,0.000030107445,0.00016616346,0.0023641593],"study_design_scores_gemma":[0.0024696633,0.0035071764,0.98890775,0.000009190818,0.0018652946,0.00004517302,0.00008545998,0.00007283833,0.0023171343,0.00011279026,0.0005154293,0.000092110684],"about_ca_topic_score_codex":0.000053604646,"about_ca_topic_score_gemma":0.000039297505,"teacher_disagreement_score":0.058451433,"about_ca_system_score_codex":0.00006448237,"about_ca_system_score_gemma":0.00016556468,"threshold_uncertainty_score":0.4931901},"labels":[],"label_agreement":null},{"id":"W4384937683","doi":"10.1016/j.euo.2023.06.010","title":"Efficacy and Effectiveness: Bridging the Gap Between Clinical Trials and Real-world Practice","year":2023,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Clinical trial; Oncology; Androgen deprivation therapy; Internal medicine; Cancer","score_opus":0.19224935275203967,"score_gpt":0.5299734068866627,"score_spread":0.33772405413462303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384937683","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024830129,0.0069979215,0.000035530502,0.025897512,0.90784585,0.004291468,0.0002509561,0.00042561468,0.029424986],"genre_scores_gemma":[0.010380692,0.029715378,0.00007609835,0.0006465978,0.9545496,0.000101315454,0.0007087715,0.0002441458,0.0035774042],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96824926,0.02840342,0.0011945078,0.0010753581,0.00041330032,0.00066417654],"domain_scores_gemma":[0.8520632,0.14617372,0.0006840653,0.0005128006,0.0002559544,0.00031026878],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.036889236,0.00042637312,0.0022603602,0.00030734396,0.00029491156,0.000054991793,0.0002741795,0.00077732536,0.000020840573],"category_scores_gemma":[0.058877543,0.00026770632,0.00019845822,0.00028617177,0.0014073728,0.00005993176,0.00064296706,0.0032816592,0.00022707619],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009693817,0.00019669335,0.0042139622,0.00017853506,0.0018831317,0.0029022114,0.00018804267,3.6994788e-7,0.000024967609,0.000035042518,0.9223797,0.058303554],"study_design_scores_gemma":[0.012138231,0.0051400964,0.086153544,0.00009724364,0.0027611814,0.000051815332,0.000027587976,0.000003926952,0.0000030242657,0.00004317794,0.8933939,0.00018628628],"about_ca_topic_score_codex":0.00014322554,"about_ca_topic_score_gemma":0.000042150015,"teacher_disagreement_score":0.11777029,"about_ca_system_score_codex":0.00017975639,"about_ca_system_score_gemma":0.0008965401,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W4385552827","doi":"10.1016/j.euo.2023.07.001","title":"Navigating Nomograms To Identify Prostate Cancer Patients for Lymph Node Dissection","year":2023,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nomogram; Prostate cancer; Medicine; Lymph node; Positron emission tomography; Dissection (medical); Prostate-specific antigen; Cancer; Prostate; Radiology; Nuclear medicine; Oncology; Internal medicine","score_opus":0.018976499963864062,"score_gpt":0.3726251895906243,"score_spread":0.3536486896267602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385552827","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.075199485,0.0005045793,0.000036305155,0.002946018,0.9158342,0.002715026,0.0014896715,0.0003434164,0.0009313284],"genre_scores_gemma":[0.034032594,0.0024919997,0.0005551587,0.003050023,0.9378792,0.005477797,0.013279274,0.0008174664,0.002416507],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640656,0.00037015663,0.0007754647,0.0011942337,0.00036356755,0.00089001044],"domain_scores_gemma":[0.9967792,0.0012415834,0.00050543906,0.00044170633,0.0006744138,0.00035766527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006503426,0.0005290114,0.0010132664,0.000132649,0.00022814084,0.000040371127,0.0002534281,0.0006018605,0.00003776697],"category_scores_gemma":[0.0015070892,0.00048659372,0.00027125995,0.00029174375,0.00013517251,0.00005099359,0.00026226495,0.0009267835,0.00054300594],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013843145,0.0006399399,0.013552925,0.00026699487,0.00047876005,0.0002918658,0.0007121409,0.00004819102,0.000066368484,0.0000019748554,0.91227955,0.07027695],"study_design_scores_gemma":[0.0064021093,0.0055393493,0.029367374,0.0003170207,0.0008140761,0.0000066231396,0.000033319262,0.000014399557,0.000042852094,0.000017428325,0.9570764,0.00036908677],"about_ca_topic_score_codex":0.00021901344,"about_ca_topic_score_gemma":0.00015743187,"teacher_disagreement_score":0.06990787,"about_ca_system_score_codex":0.0012370289,"about_ca_system_score_gemma":0.0005256778,"threshold_uncertainty_score":0.9997586},"labels":[],"label_agreement":null},{"id":"W4385649872","doi":"10.1016/j.euo.2023.07.011","title":"Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Else Kröner-Fresenius-Stiftung","keywords":"Medicine; Bladder cancer; Oncology; Cystectomy; Grading (engineering); Immune checkpoint; Immune system; Internal medicine; Adjuvant; Extracellular matrix; Pathology; Cancer; Immunotherapy; Immunology; Biology","score_opus":0.029991755215776218,"score_gpt":0.2978869095146267,"score_spread":0.26789515429885047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385649872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644121,0.00095133187,0.021378111,0.0038914953,0.0013669818,0.00545979,0.00033848837,0.0004800553,0.001721662],"genre_scores_gemma":[0.9913984,0.000031830874,0.0050852634,0.0012356616,0.00036335518,0.0014465502,0.00010714302,0.00011258376,0.00021919247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977894,0.00022364354,0.00039500534,0.0007925134,0.00017828982,0.0006211751],"domain_scores_gemma":[0.99866617,0.00035611365,0.0002920165,0.00022594305,0.00015855009,0.00030120095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024567568,0.0003429976,0.0006657629,0.00017335465,0.0003647636,0.0000197168,0.00012238177,0.00013296245,0.000010245081],"category_scores_gemma":[0.00027366896,0.00024704234,0.00015717301,0.0001432132,0.00030742362,0.000057224504,0.00012097403,0.00023002992,0.000010291455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10803791,0.008040509,0.46518284,0.0063997125,0.010945468,0.022130672,0.02003805,0.016670922,0.033147644,0.018870492,0.0051234453,0.2854123],"study_design_scores_gemma":[0.13249843,0.06460638,0.69471335,0.001092802,0.013616744,0.005620019,0.007802762,0.047011144,0.00064728764,0.00062486465,0.028596684,0.0031695038],"about_ca_topic_score_codex":0.000041168554,"about_ca_topic_score_gemma":0.000014265742,"teacher_disagreement_score":0.28224283,"about_ca_system_score_codex":0.0002258424,"about_ca_system_score_gemma":0.00074410404,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W4386052342","doi":"10.1016/j.euo.2023.07.015","title":"Re: Francesco Giganti, Louise Dickinson, Clement Orczyk, et al. Prostate Imaging After Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023;6:629–634","year":2023,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate; Multiparametric MRI; Magnetic resonance imaging; Ablation Therapy; Ablation; Prostate cancer; Radiology; Nuclear medicine; Medical physics; Internal medicine","score_opus":0.020006935837552156,"score_gpt":0.29612002832099477,"score_spread":0.2761130924834426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052342","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04577123,0.008846904,0.0031286872,0.88999486,0.008721798,0.03898259,0.0029949686,0.0006292318,0.0009297394],"genre_scores_gemma":[0.4333599,0.0025864877,0.004311117,0.5236037,0.004655221,0.026845206,0.0014410131,0.001131174,0.002066234],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99194443,0.0017276926,0.0019515216,0.0020352993,0.0006996814,0.0016413825],"domain_scores_gemma":[0.9948971,0.0013612481,0.0015487242,0.0012297529,0.0007374566,0.00022571564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024613221,0.0011100103,0.0019394042,0.00071609643,0.00026761234,0.000085796295,0.00057054445,0.0005546985,0.000035871122],"category_scores_gemma":[0.00035487363,0.00080715615,0.0008484728,0.00076781184,0.0006552079,0.00017532114,0.00042580292,0.0019191654,0.00008929747],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021512352,0.0013430822,0.05091929,0.0030789366,0.0020215926,0.0058429386,0.0026105023,0.00026699662,0.0003063,0.000029683548,0.8673039,0.04476443],"study_design_scores_gemma":[0.017155798,0.0098722605,0.026924651,0.0008783624,0.001187627,0.00016320586,0.00013597411,0.0014272041,0.00041313109,0.00007051238,0.9410255,0.0007457544],"about_ca_topic_score_codex":0.00008043136,"about_ca_topic_score_gemma":0.00013373316,"teacher_disagreement_score":0.38758865,"about_ca_system_score_codex":0.00095062546,"about_ca_system_score_gemma":0.0012700745,"threshold_uncertainty_score":0.9994379},"labels":[],"label_agreement":null},{"id":"W4386753000","doi":"10.1016/j.euo.2023.08.004","title":"Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Medicine; Prostate cancer; Genetic testing; Guideline; Molecular diagnostics; Disease; Clinical trial; Cancer; Bioinformatics; Homologous recombination; Intensive care medicine; Internal medicine; Pathology; Gene; Genetics","score_opus":0.19306534459357183,"score_gpt":0.4938495154396637,"score_spread":0.3007841708460919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386753000","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063461936,0.95080614,0.00085148186,0.0073869806,0.001727427,0.029234434,0.0006097556,0.00039994722,0.002637645],"genre_scores_gemma":[0.0004118356,0.9177436,0.06592834,0.0016853542,0.00042003425,0.010427659,0.0020624674,0.00044569618,0.00087497203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927727,0.0035524755,0.0015812595,0.0011140098,0.00024195411,0.0007375792],"domain_scores_gemma":[0.9849632,0.01286286,0.0009528783,0.00040796268,0.00066680554,0.00014628822],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045681032,0.0004312775,0.0017586964,0.0006208121,0.00012107682,0.000034503995,0.00017896859,0.00028313967,0.000004126388],"category_scores_gemma":[0.021012582,0.00032522425,0.00025515386,0.00076544273,0.00021108385,0.00018392438,0.000114300004,0.0011561803,0.000023896957],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046436195,0.004406313,0.0026375703,0.0059135742,0.00084094127,0.005360933,0.00023179506,0.00009593396,8.5343623e-7,0.00037202868,0.0015773621,0.9739191],"study_design_scores_gemma":[0.013147508,0.026046833,0.0016538035,0.0036797188,0.0019058434,0.00017948747,0.00005828356,0.00049504737,0.0000012178645,0.0001290058,0.9522715,0.00043173984],"about_ca_topic_score_codex":0.000039366554,"about_ca_topic_score_gemma":0.00016939439,"teacher_disagreement_score":0.9734873,"about_ca_system_score_codex":0.0007471921,"about_ca_system_score_gemma":0.0025763134,"threshold_uncertainty_score":0.99992},"labels":[],"label_agreement":null},{"id":"W4387422001","doi":"10.1016/j.euo.2023.09.023","title":"Corrigendum to “Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes” [European Urology Oncology (2023)]","year":2023,"lang":"en","type":"erratum","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Grading (engineering); Bladder cancer; Urothelial cancer; Stromal cell; Disease; Regret; Pathology; Cancer; Oncology; Urology; Internal medicine","score_opus":0.03803041929556203,"score_gpt":0.30375274419700765,"score_spread":0.26572232490144565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387422001","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08645685,0.026587155,0.18577217,0.055795815,0.37441233,0.08569699,0.017685136,0.00595312,0.16164045],"genre_scores_gemma":[0.7937412,0.0012379733,0.029516779,0.043740854,0.020513477,0.017889714,0.007925936,0.004339965,0.081094086],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912873,0.0016751314,0.001511804,0.0030022848,0.00051706046,0.0020064344],"domain_scores_gemma":[0.9949668,0.0007697271,0.0014923111,0.00089527824,0.00061701506,0.0012588657],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009408831,0.00147206,0.0029447633,0.00078230916,0.0008394801,0.00006341149,0.0006774177,0.001031228,0.000059126207],"category_scores_gemma":[0.0011615169,0.001199903,0.00060828833,0.00037599716,0.0008658514,0.000088906905,0.0007429834,0.0018876883,0.000112270274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09732677,0.008437669,0.010364444,0.0062484746,0.016030034,0.060578242,0.010323409,0.0041937334,0.003150689,0.0035561505,0.63461775,0.14517264],"study_design_scores_gemma":[0.040254157,0.068627566,0.034873094,0.0008444,0.014618781,0.00545551,0.0020123234,0.0041574147,0.0000170799,0.00011124304,0.8260009,0.0030275036],"about_ca_topic_score_codex":0.00020077467,"about_ca_topic_score_gemma":0.00021746007,"teacher_disagreement_score":0.7072844,"about_ca_system_score_codex":0.0014695164,"about_ca_system_score_gemma":0.0044885143,"threshold_uncertainty_score":0.9998029},"labels":[],"label_agreement":null},{"id":"W4387581643","doi":"10.1016/j.euo.2023.09.013","title":"Magnetic Resonance Imaging–Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE)","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University; London Health Sciences Centre; University of British Columbia; Health Sciences Centre; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Magnetic resonance imaging; Prostate cancer; Biopsy; Prospective cohort study; Randomized controlled trial; Cohort; Prostate; Clinical trial; Radiology; Cancer; Internal medicine","score_opus":0.01715593541524281,"score_gpt":0.28339348363802047,"score_spread":0.2662375482227777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387581643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93602127,0.015305166,0.000015587933,0.003301525,0.004564958,0.013276364,0.0001005977,0.0004939674,0.026920594],"genre_scores_gemma":[0.9941636,0.0013550059,0.00023087529,0.00035025008,0.00023262626,0.0014013645,0.00008385631,0.00009235444,0.0020901198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99552554,0.0019179651,0.0010572383,0.0006553993,0.0002639441,0.0005799267],"domain_scores_gemma":[0.996797,0.0017391886,0.00047391167,0.000557713,0.00026809212,0.000164066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019137842,0.00033401925,0.0019157103,0.00033012978,0.00008825254,0.00001237156,0.00020323927,0.0001025998,0.00016733464],"category_scores_gemma":[0.0021693667,0.0002561095,0.00036698696,0.0005323257,0.0006673242,0.000052304964,0.0001586303,0.00028284776,0.00069378264],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98642987,0.0005058861,0.0023216507,0.0008830221,0.00041138905,0.0013315023,0.0022188786,0.000006591852,0.00028959752,0.00044339825,0.0030259197,0.0021322968],"study_design_scores_gemma":[0.97620434,0.011449612,0.005645358,0.0003663085,0.0013136907,0.0000683734,0.00031104998,0.0002078915,0.00025060851,0.00019593388,0.0037753896,0.00021142495],"about_ca_topic_score_codex":0.000026277985,"about_ca_topic_score_gemma":0.000011640106,"teacher_disagreement_score":0.05814231,"about_ca_system_score_codex":0.00024053136,"about_ca_system_score_gemma":0.0002889796,"threshold_uncertainty_score":0.9999891},"labels":[],"label_agreement":null},{"id":"W4388039327","doi":"10.1016/j.euo.2023.10.002","title":"Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Western University; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; University of Calgary","funders":"Genentech; Yasuda Memorial Medical Foundation; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Subgroup analysis; Systemic therapy; Internal medicine; Nephrectomy; Oncology; Proportional hazards model; Immunotherapy; Urology; Cancer; Surgery; Kidney; Breast cancer; Confidence interval","score_opus":0.027935149860748514,"score_gpt":0.25839536693978665,"score_spread":0.23046021707903813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388039327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937299,0.00008902247,0.00019651132,0.0012087176,0.00032541607,0.001251654,0.0007647934,0.000027008002,0.0024070009],"genre_scores_gemma":[0.9929944,0.000048187285,0.0008015054,0.0006487526,0.000091053036,0.000054187873,0.005112125,0.000059391547,0.0001903481],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99526054,0.0023319349,0.0010027967,0.000556311,0.00048849534,0.00035994212],"domain_scores_gemma":[0.99597806,0.0019271725,0.0009971942,0.00065498287,0.00037574538,0.00006684155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011506993,0.00032396978,0.0006178692,0.00026759057,0.00009699947,0.000015901087,0.0004890702,0.00006334846,0.0001072517],"category_scores_gemma":[0.000305889,0.00019104512,0.000109619556,0.0005003499,0.00040318212,0.00014559926,0.00015098172,0.0005182077,0.00005466647],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09608049,0.008462087,0.4147387,0.00027710173,0.0016072931,0.0042875106,0.031208009,0.0004992989,0.43449497,0.00018290218,0.0035522475,0.004609352],"study_design_scores_gemma":[0.020613883,0.0069749705,0.9575561,0.000036621244,0.000565598,0.000055392837,0.00079391396,0.00043806952,0.011541892,0.000024416495,0.0012184861,0.00018063093],"about_ca_topic_score_codex":0.00030586863,"about_ca_topic_score_gemma":0.00018804203,"teacher_disagreement_score":0.5428174,"about_ca_system_score_codex":0.00021363822,"about_ca_system_score_gemma":0.0005231887,"threshold_uncertainty_score":0.7790594},"labels":[],"label_agreement":null},{"id":"W4388182309","doi":"10.1016/j.euo.2023.10.004","title":"Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Abiraterone; Medicine; Prostate cancer; Pharmacokinetics; Pharmacology; Oncology; Internal medicine; Drug; Abiraterone acetate; Urology; Cancer; Androgen deprivation therapy; Androgen receptor; Chemistry","score_opus":0.20734976340744182,"score_gpt":0.4296062803691044,"score_spread":0.2222565169616626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388182309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8697729,0.0028321312,0.0013743595,0.098947406,0.0063879197,0.009078934,0.005593343,0.00066864985,0.005344326],"genre_scores_gemma":[0.9565493,0.0018495056,0.0023624508,0.022927867,0.0050740195,0.0013200316,0.005420948,0.00024533083,0.0042505693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967939,0.0010618784,0.0006845297,0.000709271,0.00022011876,0.00053029746],"domain_scores_gemma":[0.99752593,0.0009330596,0.00033006817,0.00091388734,0.00016187543,0.0001351562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015201336,0.00025499397,0.00053417135,0.000091039066,0.0002303807,0.000030887313,0.0005911305,0.000075236334,0.00041404815],"category_scores_gemma":[0.00028490354,0.00018291558,0.00007838289,0.00030035785,0.00042115425,0.00008724944,0.00023376667,0.00041482027,0.00046340155],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20404355,0.0006622451,0.00035566694,0.00010170111,0.0015023531,0.0012164997,0.003034857,0.0011895174,0.11249442,0.00027987745,0.6476668,0.027452487],"study_design_scores_gemma":[0.11975656,0.004453168,0.0030104306,0.000020974307,0.00084558775,0.000060550177,0.00017336273,0.004487287,0.0007644435,0.00024668098,0.8659479,0.00023304047],"about_ca_topic_score_codex":0.000105664236,"about_ca_topic_score_gemma":0.00024166483,"teacher_disagreement_score":0.21828109,"about_ca_system_score_codex":0.00016740867,"about_ca_system_score_gemma":0.0008119801,"threshold_uncertainty_score":0.7459081},"labels":[],"label_agreement":null},{"id":"W4388448664","doi":"10.1016/j.euo.2023.10.008","title":"Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Western University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Pembrolizumab; Internal medicine; Oncology; Cohort; Interquartile range; Adverse effect; Clinical endpoint; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Immunotherapy","score_opus":0.024215989961962586,"score_gpt":0.33157935936329525,"score_spread":0.3073633694013327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388448664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513274,0.0002629322,7.524714e-7,0.0009293513,0.00012565886,0.002562611,0.000074227835,0.00005155272,0.000860154],"genre_scores_gemma":[0.99850744,0.00015617223,0.000020516021,0.00015182735,0.000019860092,0.00014299163,0.000092112045,0.00004766659,0.0008613929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721557,0.0010866895,0.00047289615,0.0004718606,0.00028617727,0.00046678004],"domain_scores_gemma":[0.99900854,0.00014214622,0.00020519897,0.0003510615,0.00017519938,0.00011783647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006129117,0.00023303131,0.0005674788,0.0002609937,0.000113650785,0.000010666247,0.00014618733,0.000048903315,0.000038093945],"category_scores_gemma":[0.00007804168,0.00013953012,0.000037922116,0.0006435946,0.00050336757,0.000061444465,0.00013760464,0.00034188572,0.000020510835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017591145,0.0029230725,0.96669424,0.00007056316,0.000524418,0.0012305382,0.0029928207,0.00010972551,0.0023332636,0.0000073925476,0.0001887573,0.0053340537],"study_design_scores_gemma":[0.05103817,0.013207689,0.9340544,0.000027856191,0.0003930281,0.000020459402,0.00031884018,0.00008317509,0.00031840755,0.000011630325,0.00041363615,0.00011276115],"about_ca_topic_score_codex":0.00020915338,"about_ca_topic_score_gemma":0.0005889733,"teacher_disagreement_score":0.033447027,"about_ca_system_score_codex":0.00017090199,"about_ca_system_score_gemma":0.00034949015,"threshold_uncertainty_score":0.5689873},"labels":[],"label_agreement":null},{"id":"W4388573879","doi":"10.1016/j.euo.2023.10.014","title":"Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphovascular invasion; Proportional hazards model; Seminoma; Oncology; Testicular cancer; Hazard ratio; Internal medicine; Stage (stratigraphy); Cohort; Nomogram; Cancer; Confidence interval; Chemotherapy; Metastasis","score_opus":0.2090117117722878,"score_gpt":0.43286572740200224,"score_spread":0.22385401562971444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388573879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98351115,0.005682773,0.00080785714,0.0036524779,0.00036057745,0.0009624312,0.004741248,0.00014907407,0.00013241787],"genre_scores_gemma":[0.989747,0.0016060694,0.0013091464,0.0025012665,0.00047585956,0.000043947282,0.004066628,0.00007449299,0.000175599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99371403,0.0032922777,0.001311741,0.0009230506,0.000280762,0.0004781226],"domain_scores_gemma":[0.9944131,0.0025662356,0.0011746745,0.0009372722,0.0006592213,0.0002495154],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0034968976,0.00029931168,0.00078404124,0.00019012118,0.00018953894,0.000020196805,0.00047111072,0.00017481692,0.000040766332],"category_scores_gemma":[0.013028345,0.00021056239,0.00019581847,0.0004596777,0.0002852521,0.00007245129,0.00057134085,0.00032011335,0.000032800825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029974338,0.00069278025,0.88539046,0.00002620515,0.003323532,0.00025599188,0.0002043795,0.00030083494,0.00006801083,0.000009234702,0.024116697,0.085312136],"study_design_scores_gemma":[0.0028140158,0.003380565,0.9195763,0.000006640854,0.011540699,0.000029850275,0.000117579664,0.0069637583,0.0000018413247,0.000014307762,0.055387843,0.00016662585],"about_ca_topic_score_codex":0.00014492043,"about_ca_topic_score_gemma":0.00018424577,"teacher_disagreement_score":0.08514551,"about_ca_system_score_codex":0.000048888876,"about_ca_system_score_gemma":0.00018623161,"threshold_uncertainty_score":0.99528533},"labels":[],"label_agreement":null},{"id":"W4388783891","doi":"10.1016/j.euo.2023.11.001","title":"Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Oncology; Internal medicine; Hazard ratio; Metastasectomy; Durvalumab; Metastasis; Atezolizumab; Meta-analysis; Clinical endpoint; Randomized controlled trial; Confidence interval; Cancer; Pembrolizumab; Immunotherapy; Bladder cancer","score_opus":0.1729184333299326,"score_gpt":0.41188422629875726,"score_spread":0.23896579296882467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388783891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004543596,0.97291744,0.00004959958,0.0004975046,0.00026491773,0.025547897,0.0003011981,0.00006280595,0.00031318478],"genre_scores_gemma":[0.00090527174,0.99033403,0.00007848225,0.0006902461,0.00015581724,0.005988038,0.00024310875,0.00017515525,0.0014298691],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.8923974,0.098014385,0.007678519,0.0009848144,0.00032941168,0.00059548725],"domain_scores_gemma":[0.96526545,0.028521148,0.004807602,0.0010291339,0.00014965388,0.00022699797],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.021012165,0.0012111551,0.118075386,0.0015713566,0.0000649427,0.00001731786,0.00029972903,0.00033361453,0.00090274675],"category_scores_gemma":[0.010370947,0.0006030532,0.015454683,0.0013185353,0.00042096368,0.000022810225,0.00015094772,0.0004834431,0.00010442475],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09123528,0.0005086458,0.0000016812857,0.17349477,0.73197055,0.0015811416,0.00015265492,0.0000038536273,5.011965e-7,0.000055792098,0.00007361652,0.0009215263],"study_design_scores_gemma":[0.15384074,0.0023588298,0.0000088173265,0.004352789,0.83459496,0.00019658572,0.000005304753,0.0000189536,6.0601955e-8,0.000012939484,0.0043564355,0.00025359998],"about_ca_topic_score_codex":0.000074811294,"about_ca_topic_score_gemma":0.00005140292,"teacher_disagreement_score":0.16914198,"about_ca_system_score_codex":0.00034216556,"about_ca_system_score_gemma":0.00095089705,"threshold_uncertainty_score":0.9996421},"labels":[],"label_agreement":null},{"id":"W4388784547","doi":"10.1016/j.euo.2023.10.024","title":"Liquid Biopsies Will Drive Treatment Decisions in the Future","year":2023,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Positron emission tomography; Biopsy; Cancer; Radiology; Molecular imaging; Prostate cancer; Fluorodeoxyglucose; Cancer treatment; Medical physics; Internal medicine","score_opus":0.01006620525191059,"score_gpt":0.2800884320993827,"score_spread":0.2700222268474721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388784547","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019343328,0.0050700605,0.000038480794,0.004045349,0.9614441,0.00054888515,0.00095129595,0.000047082016,0.008511411],"genre_scores_gemma":[0.0084388135,0.04841009,0.0001109836,0.0017236876,0.9365849,0.0001343275,0.0031003873,0.00019319981,0.0013035918],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666405,0.001111734,0.00051523244,0.00089665496,0.00019937751,0.00061297935],"domain_scores_gemma":[0.9966591,0.001888374,0.00026146395,0.00095502665,0.00013278288,0.000103229264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077981217,0.00047345282,0.00053875643,0.00017704903,0.0001543733,0.000033958044,0.00096998835,0.0011588858,0.000023349367],"category_scores_gemma":[0.0016380282,0.00035471027,0.00024215494,0.00019161569,0.0003261331,0.0000024995438,0.00046601208,0.00071329484,0.00032226116],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005679693,0.00020128126,0.000025299922,0.0000035037922,0.00012510411,0.0007466769,0.00033075063,0.00012765406,0.0007891478,0.000061448234,0.99006,0.0069611846],"study_design_scores_gemma":[0.0013464482,0.007849134,0.00034527067,0.000006474117,0.00011895953,0.000025852218,0.00019199417,0.00000292295,0.000043171596,0.000047191723,0.989705,0.00031753985],"about_ca_topic_score_codex":0.000043349657,"about_ca_topic_score_gemma":0.002961931,"teacher_disagreement_score":0.04334003,"about_ca_system_score_codex":0.00015190251,"about_ca_system_score_gemma":0.00074283534,"threshold_uncertainty_score":0.9998905},"labels":[],"label_agreement":null},{"id":"W4388792763","doi":"10.1016/j.euo.2023.10.029","title":"Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Meta-analysis; Prostate cancer; Prostate; Diagnostic accuracy; Cancer detection; Clinical Practice; Oncology; Medical physics; Cancer; Radiology; Pathology; Internal medicine","score_opus":0.146282979589173,"score_gpt":0.4195829427805316,"score_spread":0.27329996319135863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388792763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009980072,0.9833812,0.00004666771,0.00076971564,0.0002427904,0.013666596,0.0016672007,0.00006447313,0.00006152514],"genre_scores_gemma":[0.0018983074,0.986247,0.00012372149,0.00083925674,0.00006892038,0.0102072265,0.00037772107,0.00015520821,0.00008263031],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99147373,0.0026280025,0.0040326305,0.0011085361,0.00024033802,0.00051674445],"domain_scores_gemma":[0.94698584,0.04741855,0.0038831963,0.001004847,0.00045684172,0.00025071856],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.003180097,0.0007402104,0.014691134,0.0007078861,0.00007516361,0.000008851872,0.00035024216,0.00034182615,0.000097393844],"category_scores_gemma":[0.024153933,0.00048885023,0.0035274494,0.0012328047,0.0005371129,0.000039364684,0.00023806824,0.0003999631,0.000026172072],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026338073,0.000519413,0.00022046397,0.66698956,0.31657776,0.000362784,0.000085297834,0.000009046412,0.0000017138274,0.000009494542,0.00037433498,0.014586755],"study_design_scores_gemma":[0.0011744733,0.0069258236,0.00021318567,0.02970787,0.9201468,0.00006688227,0.000012911149,0.000012490733,0.0000032119815,0.000004358245,0.04141232,0.00031965287],"about_ca_topic_score_codex":0.00005957474,"about_ca_topic_score_gemma":0.00011090218,"teacher_disagreement_score":0.6372817,"about_ca_system_score_codex":0.00019744599,"about_ca_system_score_gemma":0.0006415783,"threshold_uncertainty_score":0.9999368},"labels":[],"label_agreement":null},{"id":"W4389506762","doi":"10.1016/j.euo.2023.11.015","title":"Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Titan (rocket family); Post-hoc analysis; Hazard ratio; Androgen deprivation therapy; Prostate-specific antigen; Oncology; Internal medicine; Proportional hazards model; Urology; Cancer; Confidence interval","score_opus":0.03240159015732779,"score_gpt":0.33411530116144855,"score_spread":0.30171371100412075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389506762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867171,0.009502734,0.0000011089388,0.0023499464,0.000052142397,0.001033584,0.00012907168,0.000032792836,0.00018148513],"genre_scores_gemma":[0.98796314,0.0110872565,0.0001467888,0.00034116948,0.0000068332965,0.000025926161,0.00035927756,0.0000307443,0.000038889957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971903,0.0007004046,0.0009872739,0.00051504245,0.00020275453,0.00040422328],"domain_scores_gemma":[0.9984122,0.00021458586,0.0006171824,0.00023963925,0.0002831303,0.00023325616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006898709,0.00019366654,0.0010284588,0.0006290114,0.000066554705,0.0000049004525,0.000054052543,0.00008336643,0.000033422053],"category_scores_gemma":[0.00014443256,0.00014668643,0.00004016099,0.0010117317,0.000649762,0.00005907481,0.0001433558,0.00022797535,0.0000013568317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013583195,0.0003353205,0.9096872,0.00011019854,0.0008046687,0.0001862987,0.003682181,0.000055337157,0.00087954244,0.000009512298,0.000039295363,0.07062723],"study_design_scores_gemma":[0.010283051,0.010359888,0.9773641,0.000027619477,0.00016862573,0.000006547046,0.00042133074,0.00011126713,0.000025154357,0.000011843459,0.0011063386,0.00011423742],"about_ca_topic_score_codex":0.0003051976,"about_ca_topic_score_gemma":0.0009963745,"teacher_disagreement_score":0.07051299,"about_ca_system_score_codex":0.00006876656,"about_ca_system_score_gemma":0.00022284708,"threshold_uncertainty_score":0.5981699},"labels":[],"label_agreement":null},{"id":"W4389664194","doi":"10.1016/j.euo.2023.11.016","title":"Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; London Health Sciences Centre; Western University; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University of Calgary; Université Laval; Centre Hospitalier de l’Université de Montréal; McMaster University; Alberta Health Services; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; University Health Network; Dalhousie University; University of Manitoba; Juravinski Cancer Centre; McGill University Health Centre","funders":"McGill University","keywords":"Medicine; Renal cell carcinoma; Systemic therapy; Oncology; Internal medicine; Intensive care medicine; Pathology; Cancer","score_opus":0.04354414202864189,"score_gpt":0.3461018557140005,"score_spread":0.3025577136853586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389664194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898065,0.00008350356,0.000025411946,0.0005341718,0.000078969555,0.0017316545,0.000028733824,0.00015298625,0.0075581074],"genre_scores_gemma":[0.9944144,0.00010763544,0.0025789938,0.00029311137,0.000052194227,0.0000988255,0.00020701505,0.00014585911,0.0021019832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99498653,0.0018680571,0.0011758419,0.00083491096,0.00048573216,0.0006489036],"domain_scores_gemma":[0.99671006,0.0012245295,0.0007856464,0.00078494474,0.00025294707,0.00024189406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009550295,0.0005570758,0.0021462953,0.00066183455,0.00008480478,0.000010290867,0.00026163427,0.000119172604,0.00006411639],"category_scores_gemma":[0.0000592846,0.0002844078,0.00013627266,0.00080650183,0.0005787236,0.00007111042,0.00011097506,0.0006352663,0.000036758167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015924964,0.00192953,0.9736577,0.00021639613,0.00079686666,0.005949611,0.00048030843,0.00030226828,0.00006235211,0.000019727086,0.00016872789,0.0004915358],"study_design_scores_gemma":[0.027211092,0.04294834,0.9276683,0.0001492893,0.00085668464,0.00031147065,0.00018329911,0.00007396713,0.00006843972,0.0000017355319,0.0002621928,0.00026521317],"about_ca_topic_score_codex":0.00032662798,"about_ca_topic_score_gemma":0.0034358853,"teacher_disagreement_score":0.045989435,"about_ca_system_score_codex":0.00023787051,"about_ca_system_score_gemma":0.0006402128,"threshold_uncertainty_score":0.9999608},"labels":[],"label_agreement":null},{"id":"W4390147069","doi":"10.1016/j.euo.2023.11.024","title":"Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Testosterone (patch); Prostate cancer; Discontinuation; Urology; Internal medicine; Adverse effect; Androgen; Endocrinology; Hormone; Cancer","score_opus":0.06108210601142114,"score_gpt":0.3852625919943143,"score_spread":0.3241804859828932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390147069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679688,0.0007143315,0.0000057643056,0.01867681,0.00040890992,0.003505085,0.00028880226,0.00014566694,0.008285831],"genre_scores_gemma":[0.9912847,0.0011005632,0.00014575369,0.000834967,0.00034628875,0.0008005262,0.00047671972,0.000089554655,0.00492091],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99720234,0.0007618128,0.00045483804,0.00071350246,0.00018829397,0.00067920773],"domain_scores_gemma":[0.9974549,0.0015983746,0.00017671518,0.0005289568,0.00011340635,0.00012769383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011157464,0.00024224621,0.0005000899,0.00016469348,0.00015886495,0.000013936594,0.0002502802,0.00008096811,0.000024727882],"category_scores_gemma":[0.00043308118,0.00015015951,0.000053974465,0.0004771927,0.00027065567,0.00007431845,0.00015615547,0.00046797062,0.0001189997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6414617,0.0030798747,0.03398021,0.00003614926,0.0011682853,0.007755734,0.013786008,0.000975011,0.0035634371,0.000012447898,0.03630903,0.25787213],"study_design_scores_gemma":[0.42778233,0.12890343,0.20516062,0.00009378384,0.00066007266,0.000057118,0.006251406,0.00061618024,0.0005247519,0.00015682721,0.22928748,0.00050601194],"about_ca_topic_score_codex":0.00028090403,"about_ca_topic_score_gemma":0.0014047943,"teacher_disagreement_score":0.25736612,"about_ca_system_score_codex":0.0002911548,"about_ca_system_score_gemma":0.00041381747,"threshold_uncertainty_score":0.6123327},"labels":[],"label_agreement":null},{"id":"W4390238410","doi":"10.1016/j.euo.2023.11.018","title":"A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Cancer Research UK","keywords":"Medicine; Prostate cancer; External beam radiotherapy; Brachytherapy; Prostatectomy; Androgen deprivation therapy; Hazard ratio; Radiation therapy; Oncology; Internal medicine; Meta-analysis; Urology; Randomized controlled trial; Systematic review; Cancer; Surgery; Confidence interval; MEDLINE","score_opus":0.03625900258292838,"score_gpt":0.3562044579438824,"score_spread":0.31994545536095403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390238410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006665766,0.98577154,0.000029580255,0.0006368307,0.00020324659,0.012340434,0.00026254763,0.000026638167,0.000062590625],"genre_scores_gemma":[0.00007607889,0.995776,0.0002418976,0.0017193749,0.00007218737,0.0016777106,0.00004733439,0.00013773481,0.00025170567],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963192,0.0012944783,0.0013857054,0.0004909262,0.00018529057,0.00032442948],"domain_scores_gemma":[0.9957204,0.0014436865,0.0019450522,0.00063083146,0.00015839312,0.00010164487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010554616,0.0004546087,0.0046650763,0.00012501449,0.00005886693,0.0000050764816,0.00026467675,0.00011222414,0.00002585846],"category_scores_gemma":[0.00022276935,0.00023376396,0.00042048105,0.0002943979,0.00045828053,0.000019433232,0.00007568347,0.0002933242,0.0000041046214],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006915954,0.0005409507,0.00008785401,0.94502634,0.0034898857,0.00010421517,0.00022377368,0.0000016446943,0.000015159242,0.000038915638,0.0004141636,0.049365487],"study_design_scores_gemma":[0.009599537,0.020912774,0.00040128583,0.8177739,0.021611137,0.0006772675,0.000009607032,0.000006895587,0.00003008799,0.000012265056,0.12861744,0.0003477968],"about_ca_topic_score_codex":0.000008543341,"about_ca_topic_score_gemma":0.0000099040835,"teacher_disagreement_score":0.12820327,"about_ca_system_score_codex":0.00018901599,"about_ca_system_score_gemma":0.0006059302,"threshold_uncertainty_score":0.9532618},"labels":[],"label_agreement":null},{"id":"W4390589225","doi":"10.1016/j.euo.2023.12.005","title":"Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Rectal examination; Prostate cancer; Prostate-specific antigen; Confidence interval; Meta-analysis; Internal medicine; Prospective cohort study; Prostate cancer screening; Oncology; Prostate; Gynecology; Clinical endpoint; Cancer; Randomized controlled trial","score_opus":0.11174096733802175,"score_gpt":0.3616802524531709,"score_spread":0.24993928511514918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390589225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00091621757,0.990484,0.0000061359533,0.00069664407,0.00005100569,0.007063299,0.0003509614,0.00003665665,0.00039510487],"genre_scores_gemma":[0.018637024,0.9780797,0.000065209264,0.00026260767,0.000042874337,0.0021152066,0.00027287737,0.000075111755,0.00044940485],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969645,0.0006570808,0.0012106088,0.0007084333,0.00014623819,0.00031314875],"domain_scores_gemma":[0.99739605,0.0009720523,0.0009563079,0.00041310687,0.00016339401,0.00009908415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014817638,0.00048682824,0.0059790607,0.0002861981,0.000115408926,0.000053856347,0.00015692171,0.00010624158,0.000015806389],"category_scores_gemma":[0.00018994202,0.00026035425,0.00076455023,0.000498484,0.00030859862,0.00007474684,0.00019472426,0.000355736,0.000014316654],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071688366,0.00018627234,0.00083678117,0.81862366,0.10471107,0.00016965646,0.00058231986,0.0000030850713,5.566262e-7,0.000028913344,0.00036559987,0.07442038],"study_design_scores_gemma":[0.0005056119,0.0031592594,0.00037949425,0.014397487,0.8317461,0.0005051922,0.0000308367,0.00007747266,6.6868233e-7,0.0000022729746,0.1489587,0.00023690243],"about_ca_topic_score_codex":0.0000074543887,"about_ca_topic_score_gemma":0.000009344193,"teacher_disagreement_score":0.80422616,"about_ca_system_score_codex":0.00011486044,"about_ca_system_score_gemma":0.0001585536,"threshold_uncertainty_score":0.99998486},"labels":[],"label_agreement":null},{"id":"W4391235019","doi":"10.1016/j.euo.2024.01.006","title":"Propensity-matched Analysis of Open Versus Robotic Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Testicular Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Retroperitoneal lymph node dissection; Testicular cancer; Surgery; Perioperative; Interquartile range; Propensity score matching; Confidence interval; Internal medicine; Chemotherapy","score_opus":0.1065948100420579,"score_gpt":0.4281949242288868,"score_spread":0.3216001141868289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391235019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98467505,0.004116777,0.0012549304,0.0022382913,0.0015256136,0.0012260536,0.00011232038,0.00014238802,0.0047085863],"genre_scores_gemma":[0.99484295,0.00029859593,0.0018835061,0.00092522835,0.00026583424,0.00008513346,0.0004240478,0.00006584358,0.0012088452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976055,0.0005877241,0.00063699926,0.0007022683,0.0001408196,0.00032671294],"domain_scores_gemma":[0.998416,0.00053370104,0.00020641531,0.00046207578,0.00017053247,0.00021124959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068216753,0.00022278012,0.0011124227,0.00023897226,0.00012885802,0.000027618262,0.00024488269,0.00014784012,0.0002084199],"category_scores_gemma":[0.0004936548,0.0001758725,0.00041813997,0.0005421542,0.00028154353,0.00008005021,0.00038376084,0.00022300084,0.000036424277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024426024,0.007733509,0.8433337,0.0010171215,0.03804565,0.009693445,0.00051136187,0.005484477,0.00519337,0.0009341327,0.004077588,0.05954961],"study_design_scores_gemma":[0.0067124427,0.005516426,0.9370996,0.000048118607,0.02116632,0.000067295216,0.000027243768,0.008658471,0.000022315424,0.0000087735725,0.020484345,0.0001886847],"about_ca_topic_score_codex":0.00012951653,"about_ca_topic_score_gemma":0.000054110846,"teacher_disagreement_score":0.093765855,"about_ca_system_score_codex":0.00026126695,"about_ca_system_score_gemma":0.00059422915,"threshold_uncertainty_score":0.7171872},"labels":[],"label_agreement":null},{"id":"W4391426559","doi":"10.1016/j.euo.2024.01.004","title":"External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"AI in cancer detection","field":"Computer Science","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Foundation Medicine; University of California, San Francisco; EMD Serono; Astellas Pharma; Endocyte; Advanced Accelerator Applications; NRG Oncology; Varian Medical Systems; Sanofi; Invitae; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Hazard ratio; Confidence interval; Oncology; Internal medicine; Randomized controlled trial; Clinical trial; Proportional hazards model; Histopathology; Pathology","score_opus":0.041464742584998965,"score_gpt":0.33211571387983935,"score_spread":0.2906509712948404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391426559","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2912213,0.00013490119,0.70145273,0.0030659942,0.0019220554,0.00038649785,0.000010092256,0.0001270631,0.0016794016],"genre_scores_gemma":[0.9941841,0.000005265137,0.004577745,0.00061421137,0.000542003,0.000037440383,0.000008463935,0.000019801508,0.000010975729],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99648374,0.0017162883,0.00061799877,0.00061770144,0.00021892872,0.00034532175],"domain_scores_gemma":[0.99827826,0.00093601336,0.0001802376,0.00050872535,0.000050047445,0.00004671172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001710904,0.00019262049,0.00026319086,0.0003708314,0.00007143274,0.00010593995,0.00110685,0.00014525626,0.000034316916],"category_scores_gemma":[0.00026039695,0.00015113708,0.0001255285,0.00055925077,0.0003844156,0.00021234865,0.00018789695,0.0007100169,0.00016074904],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006097445,0.000848818,0.00005869967,0.000022552103,0.000023135268,0.0020390148,0.0041443426,0.009046307,0.005580504,0.0073151183,0.00014281107,0.96468127],"study_design_scores_gemma":[0.04531971,0.06485826,0.0020982008,0.00015226843,0.00025807004,0.0047532506,0.00044382134,0.62625873,0.030423997,0.15560235,0.06795437,0.0018769783],"about_ca_topic_score_codex":0.000005558568,"about_ca_topic_score_gemma":0.000015865593,"teacher_disagreement_score":0.96280426,"about_ca_system_score_codex":0.00008726622,"about_ca_system_score_gemma":0.00023299716,"threshold_uncertainty_score":0.6163191},"labels":[],"label_agreement":null},{"id":"W4391579712","doi":"10.1016/j.euo.2024.01.014","title":"Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Université de Sherbrooke; University of Toronto; Western University; Princess Margaret Cancer Centre; University of Calgary; Queen's University; McMaster University; University of British Columbia; McGill University Health Centre; University of Ottawa; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Lymphovascular invasion; Cystectomy; Cohort; Hazard ratio; Oncology; Internal medicine; Chemotherapy; Cisplatin; Gemcitabine; Radiation therapy; Neoadjuvant therapy; Cancer; Stage (stratigraphy); Subgroup analysis; Urology; Confidence interval; Breast cancer","score_opus":0.02563735697349227,"score_gpt":0.31314711485307073,"score_spread":0.28750975787957844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391579712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993529,0.00023323004,0.00009578495,0.0017668,0.0000966866,0.0024239,0.00028307736,0.00012154396,0.001449985],"genre_scores_gemma":[0.99472106,0.00017104628,0.0010880659,0.0021208643,0.000101722944,0.0005229266,0.0009760143,0.00009040286,0.00020789435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745494,0.0005084627,0.0006168754,0.00082066224,0.00017448825,0.0004245891],"domain_scores_gemma":[0.99835014,0.0005259378,0.00025708933,0.00044959062,0.00024304302,0.00017419197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029168132,0.00040178403,0.0009100796,0.0007824088,0.00006750856,0.000012775672,0.00012476831,0.00014310659,0.0003671332],"category_scores_gemma":[0.000024180823,0.00028591,0.00025147008,0.0011060371,0.00022718248,0.000060544782,0.000008967954,0.0001682758,0.000006343317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010330611,0.003636226,0.91004837,0.000066870365,0.0029013597,0.00015840877,0.0013334855,0.0028560334,0.0005592722,0.000028550387,0.00014358977,0.067937255],"study_design_scores_gemma":[0.03782251,0.036908112,0.8909825,0.000055274075,0.0031021596,0.0000029216046,0.000029652083,0.020276679,0.00560004,0.00006648969,0.004787575,0.00036609347],"about_ca_topic_score_codex":0.001904116,"about_ca_topic_score_gemma":0.012606982,"teacher_disagreement_score":0.067571156,"about_ca_system_score_codex":0.0007812171,"about_ca_system_score_gemma":0.001173696,"threshold_uncertainty_score":0.9999593},"labels":[],"label_agreement":null},{"id":"W4393902181","doi":"10.1016/j.euo.2024.03.010","title":"Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Movember Foundation","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Oncology; Castration; Metastasis; Internal medicine; Cancer therapy; Cancer; Hormone","score_opus":0.06196786233524793,"score_gpt":0.3735454185204336,"score_spread":0.3115775561851857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393902181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927148,0.0036718904,0.00042310086,0.0012533913,0.0000944632,0.0009546495,0.00009796708,0.00009253747,0.0006972077],"genre_scores_gemma":[0.99258053,0.0040730983,0.0019706443,0.00042328265,0.000044954668,0.00011278694,0.000293704,0.00003411292,0.00046690748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979469,0.00068073854,0.00039159297,0.0004647901,0.00020681476,0.00030916164],"domain_scores_gemma":[0.99915093,0.00022442073,0.00011173964,0.00018845935,0.0002365786,0.00008789204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054986187,0.00021744361,0.000680265,0.00094113214,0.000063887695,0.000014594246,0.00007679573,0.00006753418,0.00021781397],"category_scores_gemma":[0.000042050622,0.00012530843,0.00010119905,0.0017264198,0.0004218928,0.0000947801,0.000022697157,0.00027831222,0.00001465048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047085475,0.0030663714,0.54033315,0.00016980065,0.0293801,0.011304586,0.01556313,0.005873699,0.07939159,0.00019982406,0.00020436,0.2674279],"study_design_scores_gemma":[0.019313533,0.009566125,0.92149657,0.000089718145,0.0023114346,0.00041442752,0.00040132174,0.027052179,0.009547313,0.000014558054,0.009445913,0.0003469195],"about_ca_topic_score_codex":0.00025427135,"about_ca_topic_score_gemma":0.0016937559,"teacher_disagreement_score":0.3811634,"about_ca_system_score_codex":0.00020108942,"about_ca_system_score_gemma":0.000985954,"threshold_uncertainty_score":0.51099294},"labels":[],"label_agreement":null},{"id":"W4393947130","doi":"10.1016/j.euo.2024.03.007","title":"A Systematic Review and Meta-analysis of the Impact of Local Therapies on Local Event Suppression in Metastatic Hormone-sensitive Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Docetaxel; Systemic therapy; Randomized controlled trial; Incidence (geometry); Context (archaeology); Meta-analysis; Hormone therapy; Cancer; Breast cancer","score_opus":0.06297612795242534,"score_gpt":0.40676260869719383,"score_spread":0.3437864807447685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393947130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016021928,0.9940873,0.000013107192,0.00082818704,0.0000571507,0.0040935487,0.00059786806,0.000010299463,0.0001523199],"genre_scores_gemma":[0.035175666,0.96332896,0.000007766294,0.00056665397,0.0000089178775,0.00066722214,0.00006750818,0.000059010166,0.00011830417],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99284106,0.004449912,0.0016214027,0.000587686,0.00020955455,0.00029036577],"domain_scores_gemma":[0.99718153,0.000749184,0.0012204512,0.0006395998,0.000117751726,0.000091480935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012546416,0.0005584917,0.0102740005,0.00047990234,0.000024218742,0.0000043774453,0.00017724582,0.00012277979,0.000078206496],"category_scores_gemma":[0.00009421931,0.0002325263,0.002815235,0.0008567581,0.0005234705,0.000018491344,0.00018196992,0.00055307924,0.000013806913],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022144138,0.0007978981,0.000012941632,0.43791068,0.53578883,0.00090883876,0.00090260815,0.00017420699,0.000001406509,0.000054817836,0.0009643361,0.022261953],"study_design_scores_gemma":[0.00050410884,0.0029200092,0.00031409427,0.024528528,0.96705157,0.00014938603,0.0000562967,0.000039534567,0.0000020316731,0.00000821449,0.0042661894,0.00016004057],"about_ca_topic_score_codex":0.00017302626,"about_ca_topic_score_gemma":0.00007546644,"teacher_disagreement_score":0.4312627,"about_ca_system_score_codex":0.0005257442,"about_ca_system_score_gemma":0.0005175777,"threshold_uncertainty_score":0.9482147},"labels":[],"label_agreement":null},{"id":"W4394015334","doi":"10.1016/j.euo.2024.03.006","title":"Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Prostate cancer; Placebo; Adverse effect; Abiraterone; Internal medicine; Oncology; Enzalutamide; Prednisone; Common Terminology Criteria for Adverse Events; Cancer; Pathology","score_opus":0.03318067851103599,"score_gpt":0.32747253788979147,"score_spread":0.29429185937875546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394015334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778147,0.00056989485,0.000007302824,0.0069882176,0.00019621509,0.0027483774,0.0004288665,0.000041273935,0.0012384062],"genre_scores_gemma":[0.9985388,0.000046269048,0.00014476605,0.00024005599,0.000083577615,0.00013714332,0.000378443,0.000042170912,0.00038877584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972344,0.0010541063,0.0005805376,0.00052239356,0.0002585232,0.00035003875],"domain_scores_gemma":[0.99877316,0.00040173,0.0001679365,0.0003845967,0.00018063714,0.00009195842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007961994,0.00021461606,0.00052437105,0.000095745876,0.000057742105,0.000020467816,0.00014222167,0.000050469484,0.000097433105],"category_scores_gemma":[0.000086065855,0.000104266976,0.000042284635,0.0003133619,0.0006002117,0.00007331667,0.000048966336,0.00043539843,0.000021464128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9464095,0.0036593894,0.02584494,0.00008755164,0.00075615844,0.0012569522,0.006083884,0.00008744943,0.0010509368,0.00003480098,0.00068544026,0.014042992],"study_design_scores_gemma":[0.5570963,0.114523694,0.315161,0.00021765714,0.00083103403,0.000015213079,0.000383727,0.00026611006,0.0005587144,0.00008025492,0.010576377,0.00028990637],"about_ca_topic_score_codex":0.00043474408,"about_ca_topic_score_gemma":0.0011404149,"teacher_disagreement_score":0.38931316,"about_ca_system_score_codex":0.00017992093,"about_ca_system_score_gemma":0.0008148052,"threshold_uncertainty_score":0.42518836},"labels":[],"label_agreement":null},{"id":"W4394936185","doi":"10.1016/j.euo.2024.03.015","title":"Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; NRG Oncology","keywords":"Medicine; Bladder cancer; Oncology; Internal medicine; Infiltration (HVAC); Cancer","score_opus":0.0150333448679207,"score_gpt":0.2704961794348791,"score_spread":0.2554628345669584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394936185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97122514,0.005722759,0.00010087179,0.0005775732,0.00007900851,0.0006006814,0.00012478148,0.00003739449,0.021531802],"genre_scores_gemma":[0.9982484,0.0007549255,0.00017833547,0.00035938277,0.00005830945,0.00008003154,0.00011926597,0.000034934143,0.00016641342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983662,0.0003696407,0.0004991669,0.00042786723,0.00011346684,0.00022367106],"domain_scores_gemma":[0.99895626,0.00043304847,0.00021105072,0.00018861219,0.00013891635,0.00007209203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002260845,0.00020172971,0.000689023,0.00050920085,0.000026800995,0.000006036067,0.000066150074,0.000111925634,0.00031647817],"category_scores_gemma":[0.00005885391,0.00016610051,0.000092708295,0.00093388814,0.00034908231,0.00006902214,0.000028313745,0.00026719397,0.000008773225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005107662,0.0021320551,0.80369675,0.0010728647,0.009633397,0.003398081,0.015226828,0.0013761764,0.09616384,0.00028042795,0.00032822078,0.06158368],"study_design_scores_gemma":[0.0045571057,0.0052325474,0.97349125,0.0000849925,0.005387294,0.000054856493,0.00032172995,0.00046407487,0.009476611,0.000023389755,0.00073623826,0.00016990695],"about_ca_topic_score_codex":0.00045229928,"about_ca_topic_score_gemma":0.00074933714,"teacher_disagreement_score":0.16979448,"about_ca_system_score_codex":0.000101146135,"about_ca_system_score_gemma":0.00066638313,"threshold_uncertainty_score":0.6773382},"labels":[],"label_agreement":null},{"id":"W4395084982","doi":"10.1016/j.euo.2024.04.004","title":"The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology; Pfizer","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Prostate; Internal medicine; Intensive care medicine","score_opus":0.09682521397665769,"score_gpt":0.4804949331967629,"score_spread":0.3836697192201052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395084982","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046912227,0.9819792,4.1816702e-7,0.0011048304,0.0034142954,0.0029408482,0.00030498256,0.000030187688,0.005534005],"genre_scores_gemma":[0.0009243404,0.9825287,0.000010916838,0.00015075969,0.00036975555,0.00050381257,0.00014889071,0.00013642419,0.015226423],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99343866,0.0028334076,0.0018605262,0.0008295484,0.00019220308,0.0008456432],"domain_scores_gemma":[0.9960421,0.0027760381,0.0004625133,0.00043580588,0.00011807297,0.00016548156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043432293,0.0004655633,0.002569907,0.00049140817,0.00004131904,0.000018367564,0.00043483305,0.00025928422,0.00008561572],"category_scores_gemma":[0.0006649741,0.0002697998,0.0005496689,0.00037618878,0.0008824225,0.000032617823,0.00042345806,0.0018701797,0.00026846761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028165209,0.0003693432,0.0017558805,0.005712804,0.0007835982,0.0030165045,0.00038673953,0.000002428362,0.0000010426243,0.00008713832,0.0034108083,0.9816572],"study_design_scores_gemma":[0.0039485726,0.003420635,0.001845033,0.0023533457,0.0007784222,0.00007944408,0.000025379813,0.00002340189,8.411085e-7,0.0005050508,0.986823,0.00019688052],"about_ca_topic_score_codex":0.000077871126,"about_ca_topic_score_gemma":0.0013794267,"teacher_disagreement_score":0.9834122,"about_ca_system_score_codex":0.00045370896,"about_ca_system_score_gemma":0.002245208,"threshold_uncertainty_score":0.99997544},"labels":[],"label_agreement":null},{"id":"W4396580817","doi":"10.1016/j.euo.2024.04.006","title":"Association Between GLP1R Agonists and Prostate, Kidney, and Bladder Cancers","year":2024,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"American Urological Association; UroGen Pharma; Bladder Cancer Advocacy Network","keywords":"Medicine; Internal medicine; Prostate; Oncology; Urology; Endocrinology; Cancer","score_opus":0.012779636498212742,"score_gpt":0.2633122084156718,"score_spread":0.2505325719174591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396580817","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010473938,0.0018615553,0.0000026813896,0.86186117,0.0010465479,0.0008008478,0.00010531801,0.00018637405,0.12366156],"genre_scores_gemma":[0.008035988,0.0012474247,0.00015347695,0.87071204,0.004245444,0.000059550588,0.0014811741,0.00015687563,0.113908015],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771523,0.00047254915,0.0003495537,0.0007304688,0.00017198132,0.0005602253],"domain_scores_gemma":[0.999052,0.00024478862,0.00023222982,0.00024644367,0.000053997046,0.00017055597],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048176514,0.00036907307,0.0007521047,0.00026102707,0.00007839816,0.000046769535,0.00009275668,0.00060081005,0.000116727526],"category_scores_gemma":[0.00012542724,0.00032495908,0.00007835778,0.00009805884,0.00023726192,0.00003848671,0.00027676308,0.00136124,0.00040430148],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039289058,0.000022397984,0.016620958,0.0002471311,0.0024786603,0.003579268,0.00024420393,1.0717233e-7,0.000008630558,0.000015156083,0.9649486,0.011795587],"study_design_scores_gemma":[0.0018503538,0.0019712185,0.020319274,0.00003786798,0.003986035,0.00005889794,0.000009350635,0.000004096416,0.0000026971743,0.000114651884,0.97142106,0.00022448604],"about_ca_topic_score_codex":0.000029257406,"about_ca_topic_score_gemma":0.00001229559,"teacher_disagreement_score":0.011571101,"about_ca_system_score_codex":0.00055044965,"about_ca_system_score_gemma":0.00022218429,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W4396851239","doi":"10.1016/j.euo.2024.04.016","title":"Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Regret; Medicine; Prostate cancer; Cancer; Clinical decision making; Oncology; Prostate; Intensive care medicine; Gynecology; Internal medicine; Computer science","score_opus":0.019947117813326087,"score_gpt":0.3648454804820636,"score_spread":0.3448983626687375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396851239","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035689247,0.9867724,0.000014982893,0.000095365,0.0006524048,0.008490301,0.00019629434,0.00008704782,0.00012224194],"genre_scores_gemma":[0.00094850996,0.9960829,0.0007749273,0.0006111509,0.0000875987,0.00094725704,0.00027566895,0.00020773416,0.000064223095],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99476665,0.0010981514,0.0018120542,0.0013173635,0.00032853804,0.0006772496],"domain_scores_gemma":[0.99629945,0.0015046878,0.0010382413,0.0006853256,0.00019055075,0.00028176385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059181853,0.001098767,0.005366786,0.000575902,0.00009898433,0.000068376285,0.00020499436,0.000358632,0.000051096387],"category_scores_gemma":[0.0005798459,0.00053318875,0.00037878874,0.0008515897,0.00015778282,0.00011417637,0.00022463841,0.0008254221,0.00004579545],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020206298,0.00040037668,0.0014015476,0.19165461,0.0009123685,0.0061188093,0.0003710018,0.000005786739,1.5845124e-8,0.0000026323075,0.00024722284,0.796865],"study_design_scores_gemma":[0.005657016,0.009221919,0.0003906275,0.6903779,0.008948728,0.0007192366,0.000016542417,0.0000060054977,4.593797e-8,0.000008296955,0.28425214,0.00040154564],"about_ca_topic_score_codex":0.000007812691,"about_ca_topic_score_gemma":0.000100866106,"teacher_disagreement_score":0.79646343,"about_ca_system_score_codex":0.0018429309,"about_ca_system_score_gemma":0.00106845,"threshold_uncertainty_score":0.999712},"labels":[],"label_agreement":null},{"id":"W4399119977","doi":"10.1016/j.euo.2024.05.008","title":"Patient-reported Outcome Measures and Experience Measures After Active Surveillance Versus Radiation Therapy Versus Radical Prostatectomy for Prostate Cancer: A Systematic Review of Prospective Comparative Studies","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Prospective cohort study; Urology; Prostate; Cancer; Oncology; Internal medicine","score_opus":0.16056889472391286,"score_gpt":0.4397345203007834,"score_spread":0.2791656255768705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399119977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015380803,0.97904277,0.0000026933465,0.0003107402,0.0014464185,0.016981026,0.00038232794,0.00008516624,0.00021078267],"genre_scores_gemma":[0.015046882,0.96647215,0.000046351866,0.00025992014,0.00012979892,0.017782854,0.00012401861,0.00010326956,0.00003474794],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.994064,0.0019826107,0.0019497359,0.0011333871,0.00037423582,0.00049608643],"domain_scores_gemma":[0.9953128,0.0015468221,0.0017304589,0.00050485774,0.00073354115,0.00017150718],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096255477,0.00081677124,0.005953212,0.0002426684,0.000102045546,0.00001802881,0.00015093051,0.00020394521,0.000010238772],"category_scores_gemma":[0.0012080034,0.00052049523,0.0005386616,0.00037948036,0.00080234045,0.00007505281,0.00012986227,0.0005234674,0.000011951598],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014458125,0.00055115944,0.0005675254,0.6766884,0.01674504,0.0007127952,0.009592682,5.6968537e-7,0.0000013063785,0.00003553797,0.0006163475,0.28003058],"study_design_scores_gemma":[0.022598606,0.030834064,0.001110013,0.2719131,0.030625928,0.00036546864,0.0009515966,0.0000043046375,0.000036316065,0.000022245718,0.6403219,0.0012164441],"about_ca_topic_score_codex":0.000012835596,"about_ca_topic_score_gemma":0.000033167624,"teacher_disagreement_score":0.63970554,"about_ca_system_score_codex":0.0011082295,"about_ca_system_score_gemma":0.0007757089,"threshold_uncertainty_score":0.9997247},"labels":[],"label_agreement":null},{"id":"W4399199106","doi":"10.1016/j.euo.2024.05.007","title":"Prostate Magnetic Resonance Imaging Using the Prostate Imaging for Recurrence Reporting (PI-RR) Scoring System to Detect Recurrent Prostate Cancer: A Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sinai Health System; Women's College Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Magnetic resonance imaging; Meta-analysis; Prostate; Radiology; Oncology; Cancer; Internal medicine","score_opus":0.0962896154507982,"score_gpt":0.39811055240029514,"score_spread":0.30182093694949697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399199106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022780145,0.971773,0.000088180044,0.0031052202,0.00067342765,0.023329064,0.00063733844,0.00022927856,0.00014167436],"genre_scores_gemma":[0.00031671478,0.9819145,0.0011709651,0.0018273297,0.00019269112,0.013791295,0.00011051166,0.00030991572,0.00036607255],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9874534,0.0029891885,0.0052381153,0.0025431297,0.0004218485,0.0013543066],"domain_scores_gemma":[0.9916948,0.00083540456,0.004922907,0.0015787167,0.00055237924,0.00041579906],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.007122179,0.0014271855,0.011504626,0.0007759632,0.0004659364,0.00020280192,0.0005320739,0.00012854532,0.000017871067],"category_scores_gemma":[0.0013454058,0.00084178534,0.002409354,0.0018283008,0.0003248307,0.000117708376,0.00068379095,0.001125366,0.000042367803],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007661689,0.00006291202,0.000091366615,0.7224753,0.023054691,0.0025711807,0.0007079421,0.000018151,0.0000010045961,0.000019641153,0.00062757474,0.2502936],"study_design_scores_gemma":[0.0004190016,0.00071507145,0.000011163165,0.08158538,0.67921567,0.002758441,0.00009555908,0.00040750418,6.7413004e-7,0.0000056722834,0.23420732,0.0005785588],"about_ca_topic_score_codex":0.00008531577,"about_ca_topic_score_gemma":0.000053356034,"teacher_disagreement_score":0.65616095,"about_ca_system_score_codex":0.0015868748,"about_ca_system_score_gemma":0.0010764335,"threshold_uncertainty_score":0.9998478},"labels":[],"label_agreement":null},{"id":"W4399597402","doi":"10.1016/j.euo.2024.05.011","title":"Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health; Movember Foundation; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Castration; Cancer; Prostate; Hormone","score_opus":0.021770141579877285,"score_gpt":0.3371124047456912,"score_spread":0.31534226316581393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399597402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963503,0.0019221271,0.000018069662,0.000542781,0.000038643877,0.00056005985,0.000076427474,0.000018706616,0.00047288256],"genre_scores_gemma":[0.99897987,0.00049814925,0.00017527911,0.000058889655,0.000019618978,0.000033206517,0.000037278995,0.000028618713,0.00016906313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986623,0.00042137914,0.00029175193,0.00027754993,0.00010346362,0.00024355354],"domain_scores_gemma":[0.9994556,0.00017141225,0.00012236749,0.000098224926,0.00009277419,0.000059634378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003504429,0.0001312216,0.0004410265,0.00023773278,0.000022890594,0.00000517362,0.00004264014,0.000059754442,0.000016780425],"category_scores_gemma":[0.000031816042,0.00008875674,0.00002953077,0.00016328828,0.0002846156,0.000047633766,0.00004812987,0.00021996557,0.000002707708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040324996,0.00083547976,0.74646497,0.0009307519,0.0011690359,0.010358944,0.009185012,0.00022086226,0.11389766,0.00009007843,0.000055750497,0.11275895],"study_design_scores_gemma":[0.006077236,0.009560054,0.9664894,0.0006141202,0.0005545114,0.000350816,0.0005953243,0.0022748304,0.01299386,0.000032194657,0.00029032194,0.0001673816],"about_ca_topic_score_codex":0.000055600158,"about_ca_topic_score_gemma":0.00066980004,"teacher_disagreement_score":0.22002438,"about_ca_system_score_codex":0.00011830962,"about_ca_system_score_gemma":0.00035723738,"threshold_uncertainty_score":0.3619395},"labels":[],"label_agreement":null},{"id":"W4400019582","doi":"10.1016/j.euo.2024.05.013","title":"Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Sunnybrook Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Prednisone; Internal medicine; Pembrolizumab; Clinical endpoint; Oncology; Interquartile range; Cohort; Urology; Cancer; Clinical trial; Surgery; Androgen deprivation therapy","score_opus":0.017376358492093395,"score_gpt":0.2946632417206965,"score_spread":0.2772868832286031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400019582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854437,0.0032246083,0.00001783583,0.0059225657,0.00022811804,0.0015593622,0.00042155685,0.00010883534,0.0030733834],"genre_scores_gemma":[0.99500513,0.0012404236,0.00034571413,0.0006873473,0.00010685032,0.00011473047,0.0006132985,0.00008815299,0.001798348],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99723333,0.0005431203,0.000542668,0.0008510633,0.00026161107,0.00056821597],"domain_scores_gemma":[0.99900913,0.0002236189,0.00012729883,0.00031876826,0.000121475096,0.00019972044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048185352,0.00032094837,0.00062802446,0.00024754266,0.00008836895,0.000049060647,0.000115946445,0.00009309214,0.00008918525],"category_scores_gemma":[0.000046032175,0.00022963365,0.00004287469,0.0002822815,0.00045629195,0.00012465689,0.000078313555,0.0005141521,0.00006663224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40741938,0.0030292694,0.33766708,0.00080044154,0.0062979995,0.0253415,0.03281772,0.0009419764,0.010630693,0.00019843713,0.0062443623,0.16861114],"study_design_scores_gemma":[0.052347906,0.008061105,0.926034,0.00013752862,0.00046870922,0.00006116886,0.0001506928,0.000758531,0.0002918826,0.00009296151,0.011297455,0.00029811042],"about_ca_topic_score_codex":0.0006840601,"about_ca_topic_score_gemma":0.0005891262,"teacher_disagreement_score":0.58836687,"about_ca_system_score_codex":0.00045842235,"about_ca_system_score_gemma":0.00064409897,"threshold_uncertainty_score":0.93641883},"labels":[],"label_agreement":null},{"id":"W4400443896","doi":"10.1016/j.euo.2024.06.012","title":"Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Juravinski Cancer Centre; McGill University Health Centre; Ottawa Hospital; McMaster University; London Health Sciences Centre","funders":"","keywords":"Medicine; Radiosurgery; Ablative case; Renal cell carcinoma; Renal function; Internal medicine; Oncology; Kidney; Kidney cancer; Radiation therapy; Clear cell renal cell carcinoma; Term (time); Radiology","score_opus":0.018680012198882545,"score_gpt":0.2707078697871421,"score_spread":0.2520278575882596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400443896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977005,0.0010214997,0.0008707291,0.010868085,0.0025929585,0.0015790577,0.00020658904,0.000071149145,0.0057849116],"genre_scores_gemma":[0.9833279,0.00003087708,0.00054704974,0.01342969,0.0006432528,0.00018057215,0.0006287449,0.00010728988,0.0011045861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961492,0.0011690808,0.0009636595,0.0008286891,0.0004090465,0.00048033602],"domain_scores_gemma":[0.9963719,0.0017386872,0.0006228304,0.0007278001,0.00027364917,0.00026513045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009055479,0.0004276951,0.00084773626,0.0002187334,0.00015353515,0.000024658246,0.00035726195,0.00020940449,0.00029254533],"category_scores_gemma":[0.00036189667,0.00023898395,0.00040905632,0.00018739876,0.00064635795,0.00013267809,0.00026010192,0.0006728817,0.00001930395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0117006665,0.0007926191,0.95881796,0.00008336638,0.002336378,0.0045001674,0.0012012309,0.0000058148626,0.0054842373,0.000014859016,0.012832819,0.0022298773],"study_design_scores_gemma":[0.005999242,0.0040528295,0.9370706,0.00007640717,0.001470551,0.0009623631,0.00002721563,0.000053901786,0.0004065266,0.000028022705,0.049650546,0.0002018047],"about_ca_topic_score_codex":0.000050727405,"about_ca_topic_score_gemma":0.000020939238,"teacher_disagreement_score":0.036817726,"about_ca_system_score_codex":0.001031703,"about_ca_system_score_gemma":0.001623498,"threshold_uncertainty_score":0.9745482},"labels":[],"label_agreement":null},{"id":"W4400613267","doi":"10.1016/j.euo.2024.05.016","title":"Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Vlaamse regering; Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Urology; Gynecology; Internal medicine; Cancer","score_opus":0.013337358796774782,"score_gpt":0.34969508765784457,"score_spread":0.3363577288610698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400613267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051344,0.00047467137,0.000102060854,0.0014924929,0.00046028913,0.0057865465,0.0003818222,0.00018475771,0.0006039323],"genre_scores_gemma":[0.99717486,0.00013075951,0.00042798265,0.00037026394,0.00027683226,0.0011632263,0.00014957282,0.00014663406,0.0001598593],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99559486,0.0021775537,0.00045077756,0.00090450264,0.00024645758,0.00062582],"domain_scores_gemma":[0.9977303,0.0012402851,0.00016461185,0.00038810846,0.00016089606,0.00031579306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014716921,0.00043466612,0.0010593063,0.0003202489,0.00012535624,0.00004117328,0.0001596563,0.00008295953,0.000057462585],"category_scores_gemma":[0.00026843898,0.0002784544,0.000089889465,0.00045791743,0.00017337313,0.00008201679,0.000071205475,0.0004636471,0.00002212988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17060953,0.010440798,0.45516133,0.0018831955,0.009886618,0.011287512,0.019984055,0.0017555382,0.014808827,0.00019370468,0.01209345,0.29189542],"study_design_scores_gemma":[0.028049592,0.51125157,0.43368042,0.0002808644,0.0044350433,0.00021343569,0.00083991257,0.00027437412,0.012149772,0.000030596915,0.0082236,0.00057082594],"about_ca_topic_score_codex":0.0002840377,"about_ca_topic_score_gemma":0.00019838149,"teacher_disagreement_score":0.50081074,"about_ca_system_score_codex":0.00033349477,"about_ca_system_score_gemma":0.000391809,"threshold_uncertainty_score":0.99996674},"labels":[],"label_agreement":null},{"id":"W4400720534","doi":"10.1016/j.euo.2024.07.003","title":"Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of British Columbia; Health Sciences Centre; BC Cancer Agency; University of Toronto","funders":"Movember Foundation","keywords":"SAFER; Medicine; Prostate cancer; Medical physics; Cancer; Internal medicine; Computer security; Computer science","score_opus":0.12654041648727882,"score_gpt":0.4275346217680749,"score_spread":0.30099420528079607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400720534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6192844,0.018144265,0.0004604405,0.32981786,0.005345501,0.0018975076,0.0041903136,0.0005071391,0.020352598],"genre_scores_gemma":[0.985046,0.0055038026,0.0004885326,0.0057118786,0.0013220996,0.0003093846,0.0004416476,0.000074560514,0.0011020635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970955,0.0006725576,0.0005626741,0.0010096768,0.000111306355,0.00054825825],"domain_scores_gemma":[0.9980321,0.0009797231,0.00017382496,0.00043893204,0.0001241329,0.00025130287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065165135,0.00028274936,0.00075641624,0.00005101998,0.0001273513,0.000038618215,0.00017974532,0.00021755444,0.00023497507],"category_scores_gemma":[0.00029200455,0.0002359937,0.00027048553,0.00016440343,0.000537145,0.000051670282,0.00013521829,0.0004932053,0.00029333468],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006399172,0.00092962227,0.12473041,0.00009925901,0.0019017984,0.0039932583,0.000636954,0.000033000448,0.0002012585,0.0009939006,0.07905205,0.7810293],"study_design_scores_gemma":[0.004088465,0.003384653,0.26627523,0.00004566861,0.0003370371,0.00008795062,0.000039050075,0.0001624214,0.000047617305,0.0010763401,0.7242813,0.00017429717],"about_ca_topic_score_codex":0.0002469636,"about_ca_topic_score_gemma":0.0006686994,"teacher_disagreement_score":0.780855,"about_ca_system_score_codex":0.00058102614,"about_ca_system_score_gemma":0.0010646721,"threshold_uncertainty_score":0.96235436},"labels":[],"label_agreement":null},{"id":"W4401180930","doi":"10.1016/j.euo.2024.07.006","title":"De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; De-escalation; Active monitoring; Oncology; Gynecology; Internal medicine; Cancer","score_opus":0.029248663105080203,"score_gpt":0.3298719499419391,"score_spread":0.3006232868368589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401180930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97409475,0.005212754,0.00006513731,0.014669768,0.00084522145,0.00077125034,0.0004862337,0.000045172816,0.003809734],"genre_scores_gemma":[0.99676675,0.0018910447,0.00016084823,0.0003976489,0.00039212705,0.00014591412,0.00008291451,0.000025413705,0.00013735172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987178,0.0003414812,0.00033619453,0.00031337835,0.00005650468,0.00023465982],"domain_scores_gemma":[0.9981575,0.0014460122,0.000112850066,0.00017228395,0.00006691033,0.000044462548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005565453,0.000107587686,0.00026997726,0.0000535796,0.000033158332,0.0000071323298,0.000071772025,0.00006483001,0.0000136082235],"category_scores_gemma":[0.00023030292,0.00007653503,0.000056973644,0.00011818335,0.00013699195,0.000028877026,0.000035759713,0.00020763122,0.0000094176185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007736948,0.0003515468,0.6267506,0.000077315606,0.000463056,0.000609465,0.0083356695,0.00067098095,0.0050791125,0.00035682102,0.003803074,0.3457654],"study_design_scores_gemma":[0.0035238804,0.0014492837,0.90796113,0.00008702812,0.00010156904,0.000016135984,0.0001419908,0.00049191137,0.0026355116,0.00022327524,0.083296284,0.0000720261],"about_ca_topic_score_codex":0.00035851542,"about_ca_topic_score_gemma":0.00022088723,"teacher_disagreement_score":0.34569338,"about_ca_system_score_codex":0.00026627723,"about_ca_system_score_gemma":0.00026941556,"threshold_uncertainty_score":0.31210077},"labels":[],"label_agreement":null},{"id":"W4402087631","doi":"10.1016/j.euo.2024.08.001","title":"Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG)","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; European Association of Urology","keywords":"Medicine; Bladder cancer; Urology; Cancer; Oncology; Internal medicine","score_opus":0.06929239183369176,"score_gpt":0.4047866575280217,"score_spread":0.33549426569432994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402087631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000070613864,0.978792,0.000039949147,0.007439524,0.0013186595,0.0045893085,0.0014390291,0.000069907874,0.0063045425],"genre_scores_gemma":[0.00007466937,0.985429,0.00011662386,0.005549657,0.00088939106,0.002382215,0.0015044898,0.0001731107,0.0038808507],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964157,0.0009000368,0.0011872911,0.0008819679,0.00020593517,0.00040910108],"domain_scores_gemma":[0.9976009,0.00046449137,0.00079699815,0.0006171568,0.00038795418,0.00013248112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005266741,0.00066537777,0.0024073154,0.00018493828,0.00008692465,0.000016858688,0.0004610598,0.0002703519,0.00039698565],"category_scores_gemma":[0.00016421579,0.00038006445,0.0007552306,0.0003923,0.00041820234,0.000036992406,0.00011973227,0.0004689228,0.00024452206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027141528,0.00075682456,0.000004965442,0.007641717,0.007044032,0.00013680877,0.0003628787,4.1958162e-7,0.000029420287,0.0002610672,0.29694083,0.6865496],"study_design_scores_gemma":[0.0016978423,0.003663119,0.000006639394,0.0051616756,0.016051827,0.00042267103,0.000041084233,0.000008116121,0.000007924237,0.00002430606,0.9726741,0.00024071746],"about_ca_topic_score_codex":0.000060152863,"about_ca_topic_score_gemma":0.000053504198,"teacher_disagreement_score":0.6863089,"about_ca_system_score_codex":0.00092742615,"about_ca_system_score_gemma":0.001634003,"threshold_uncertainty_score":0.9998651},"labels":[],"label_agreement":null},{"id":"W4402883766","doi":"10.1016/j.euo.2024.09.010","title":"Lights and Shadows of Bacillus Calmette-Guérin (BCG)-exposed and BCG-unresponsive Definitions: A Practical Overview","year":2024,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Association of Urology","keywords":"Medicine; Bacillus (shape); BCG vaccine; Tuberculosis; Microbiology; Pathology; Biology","score_opus":0.061467679491246124,"score_gpt":0.3512845803886108,"score_spread":0.28981690089736467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402883766","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018235032,0.0957301,0.00006193058,0.019255776,0.70588136,0.003333303,0.0023491115,0.00042640854,0.15472697],"genre_scores_gemma":[0.07238994,0.08915226,0.0036013098,0.01188316,0.8123178,0.0004261503,0.002084388,0.00092617184,0.007218833],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956238,0.0016597665,0.00079563196,0.001045773,0.000372791,0.0005022166],"domain_scores_gemma":[0.995244,0.003282826,0.0003456647,0.0005101703,0.0002857476,0.00033155803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007773127,0.0005648068,0.0014907791,0.00039685427,0.00010472552,0.000025659869,0.00014708111,0.0010127343,0.00027907686],"category_scores_gemma":[0.002214528,0.00047161532,0.00018488825,0.0001989867,0.0008461674,0.00006299566,0.00039149186,0.0017252389,0.00034399508],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035059168,0.0006195717,0.00011678171,0.00078148866,0.001355688,0.008995745,0.0008984226,2.760703e-7,0.00025495442,0.0014565134,0.9747195,0.0072951056],"study_design_scores_gemma":[0.005409266,0.011574055,0.0008818184,0.0001874846,0.0028359252,0.0016537736,0.000059705548,0.0000073311353,0.00002828646,0.0008413826,0.97620595,0.00031502856],"about_ca_topic_score_codex":0.000066557404,"about_ca_topic_score_gemma":0.00009291313,"teacher_disagreement_score":0.14750813,"about_ca_system_score_codex":0.00017701638,"about_ca_system_score_gemma":0.0014812353,"threshold_uncertainty_score":0.99977356},"labels":[],"label_agreement":null},{"id":"W4402947065","doi":"10.1016/j.euo.2024.09.009","title":"Room for improvement when approaching RCC in the solitary kidney: surgery is not the only choice","year":2024,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"Pharmaceuticals Bayer; Varian Medical Systems","keywords":"Medicine; Kidney; General surgery; Surgery; Medical physics; Internal medicine","score_opus":0.04625114927445017,"score_gpt":0.35284315541850464,"score_spread":0.30659200614405446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402947065","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008629043,0.003852277,0.00039981923,0.18476301,0.7116061,0.006244495,0.00078312453,0.00022521407,0.08349696],"genre_scores_gemma":[0.0065712025,0.0011533471,0.0006561365,0.07208392,0.89664626,0.0010718075,0.001739967,0.0003562739,0.01972107],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99184644,0.0034983072,0.0012762984,0.0012546249,0.0007743627,0.001349963],"domain_scores_gemma":[0.9739068,0.0239047,0.00039667293,0.0012731842,0.00024557507,0.00027307097],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011616,0.00063109276,0.001853692,0.00047427337,0.000353026,0.00005452124,0.0012328662,0.0012747152,0.00020152243],"category_scores_gemma":[0.009477569,0.0003676232,0.0005517803,0.00025541233,0.0007384292,0.000053776406,0.00059104,0.0050790156,0.00041780292],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001344987,0.00046405217,0.001265428,0.00047284304,0.0007320094,0.0009901741,0.00293518,7.4269275e-7,0.00003930719,0.00015758442,0.98058,0.011017722],"study_design_scores_gemma":[0.0024975059,0.003374998,0.0018489043,0.00008876659,0.0014533137,0.00019766032,0.00028610826,0.00027114508,0.0000022523045,0.0005376312,0.98914456,0.00029715092],"about_ca_topic_score_codex":0.00054192654,"about_ca_topic_score_gemma":0.00036914964,"teacher_disagreement_score":0.1850402,"about_ca_system_score_codex":0.00051709136,"about_ca_system_score_gemma":0.0052902536,"threshold_uncertainty_score":0.9998776},"labels":[],"label_agreement":null},{"id":"W4403213466","doi":"10.1016/j.euo.2024.09.013","title":"Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Abiraterone; Prostate cancer; Abiraterone acetate; Olaparib; Asymptomatic; Placebo; Internal medicine; Oncology; Urology; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.06115839959823703,"score_gpt":0.3709653573860134,"score_spread":0.30980695778777634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403213466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663396,0.0055047856,0.000027078708,0.0024167236,0.00017829993,0.0047319494,0.0002608054,0.00003618463,0.00021023184],"genre_scores_gemma":[0.9978355,0.0011431153,0.0001634837,0.00011484181,0.00008170534,0.00031043903,0.00023445241,0.000046536654,0.00006990383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99667656,0.0011706846,0.0009110387,0.0005010719,0.00034360122,0.000397049],"domain_scores_gemma":[0.99714154,0.0019030784,0.0003259569,0.00041624575,0.00010851344,0.000104641476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000632962,0.00036950625,0.0009778821,0.0001961559,0.0001434247,0.00004275414,0.00017622011,0.00007120162,0.000046756108],"category_scores_gemma":[0.000102028505,0.00017636188,0.0000691019,0.00037481092,0.0008303196,0.000095179916,0.00006864672,0.00022824947,0.000007046338],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8848756,0.006244117,0.00796964,0.0013071776,0.0067352336,0.0014205113,0.04160585,0.0010519668,0.0020571663,0.000100985024,0.00028050158,0.046351247],"study_design_scores_gemma":[0.7284094,0.09770995,0.155013,0.000657414,0.0060787457,0.00006233542,0.0012763712,0.008149227,0.00052100286,0.00005542931,0.0016436776,0.00042344697],"about_ca_topic_score_codex":0.000351538,"about_ca_topic_score_gemma":0.0006798616,"teacher_disagreement_score":0.1564662,"about_ca_system_score_codex":0.00033945506,"about_ca_system_score_gemma":0.0005815984,"threshold_uncertainty_score":0.7191829},"labels":[],"label_agreement":null},{"id":"W4403731062","doi":"10.1016/j.euo.2024.10.008","title":"Oncological Outcomes of Active Surveillance versus Surgery or Ablation for Patients with Small Renal Masses: A Systematic Review and Quantitative Analysis","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"Agencja Badań Medycznych; European Association of Urology","keywords":"Medicine; Ablation; Renal mass; Radiology; Medical physics; Internal medicine; Kidney; Nephrectomy","score_opus":0.13097529584533918,"score_gpt":0.3802293122406022,"score_spread":0.249254016395263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403731062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010429651,0.9914912,0.000120276374,0.00016743972,0.00020928332,0.005942962,0.00025378336,0.000052413365,0.00071969104],"genre_scores_gemma":[0.00083541835,0.99536973,0.0015571028,0.0002066173,0.000037592854,0.0005889865,0.0010080786,0.00009452375,0.00030194988],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9935855,0.0033316128,0.0016283299,0.00087772025,0.00020760528,0.00036919667],"domain_scores_gemma":[0.9854018,0.011847211,0.0017166435,0.00051628763,0.00036749625,0.00015055419],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001467544,0.0006422167,0.008970197,0.0006699651,0.000051463136,0.000010091189,0.00016836711,0.00029991454,0.00003913208],"category_scores_gemma":[0.0030459356,0.00032969197,0.0010075571,0.0008440336,0.00030444685,0.000031881787,0.00012604444,0.00041466093,0.000038741196],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042602313,0.00081366004,0.002256381,0.9308514,0.038022976,0.0014037577,0.00012978792,0.0000013368729,6.4227045e-8,0.00008145981,0.00042282286,0.021756107],"study_design_scores_gemma":[0.006170916,0.043780006,0.026966812,0.09680327,0.65515846,0.00040385587,0.00007775606,0.000017149554,1.2315536e-7,0.000008529437,0.1695086,0.0011044915],"about_ca_topic_score_codex":0.0000065713502,"about_ca_topic_score_gemma":0.00012424447,"teacher_disagreement_score":0.83404815,"about_ca_system_score_codex":0.00041477763,"about_ca_system_score_gemma":0.0007008338,"threshold_uncertainty_score":0.99991554},"labels":[],"label_agreement":null},{"id":"W4404316580","doi":"10.1016/j.euo.2024.10.017","title":"Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; Division of Cancer Prevention, National Cancer Institute; National Institutes of Health; Pfizer; Bristol-Myers Squibb","keywords":"Subtyping; Medicine; Oncology; Internal medicine; Prostate cancer; Prostate; Biopsy; Pathology; Cancer","score_opus":0.03929479077338504,"score_gpt":0.35905274845038837,"score_spread":0.3197579576770033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404316580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97227037,0.005692689,0.000087442095,0.017872559,0.0012034606,0.0011864556,0.00038381154,0.00007165916,0.0012315669],"genre_scores_gemma":[0.9942274,0.0023997785,0.0002680689,0.002328426,0.00020193482,0.00022773138,0.00011622199,0.000054601478,0.00017581208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99440163,0.0028852157,0.0012364344,0.0007851878,0.0001803631,0.0005111836],"domain_scores_gemma":[0.996697,0.0019362641,0.00059461023,0.000478114,0.00011603721,0.0001779853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031799679,0.00033969383,0.0017263809,0.00075260847,0.000109051696,0.000020615716,0.00019233784,0.00022215837,0.00024720465],"category_scores_gemma":[0.00062690536,0.00022910483,0.0003701897,0.0013353142,0.00073548494,0.00005026289,0.00014472115,0.00067678734,0.000021844764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01628406,0.004860474,0.64147764,0.00035775223,0.009406717,0.006611526,0.0031648385,0.0008662951,0.0074298405,0.00096721016,0.005770009,0.30280367],"study_design_scores_gemma":[0.039096907,0.015306319,0.75561804,0.00024771327,0.019855479,0.000098941004,0.00022094986,0.007666065,0.001585056,0.0003360335,0.1595122,0.00045629538],"about_ca_topic_score_codex":0.00046555776,"about_ca_topic_score_gemma":0.0007591458,"teacher_disagreement_score":0.30234736,"about_ca_system_score_codex":0.00052761927,"about_ca_system_score_gemma":0.000880403,"threshold_uncertainty_score":0.93426234},"labels":[],"label_agreement":null},{"id":"W4404868817","doi":"10.1016/j.euo.2024.11.007","title":"Frailty in Older Adults with Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Gerontology; Cancer; Oncology; Internal medicine","score_opus":0.037113717786421585,"score_gpt":0.36195392486886746,"score_spread":0.3248402070824459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404868817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022511637,0.9573901,0.0000030813487,0.0023593025,0.0012542586,0.0027740004,0.00009537548,0.00027596674,0.035622783],"genre_scores_gemma":[0.00026107993,0.9839048,0.00020084738,0.0019790907,0.00080146256,0.0005113891,0.0003038197,0.00039151535,0.011646029],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99489635,0.0013292143,0.0011350176,0.0014606344,0.0002436367,0.0009351328],"domain_scores_gemma":[0.9980598,0.00029884034,0.0004111574,0.00084174133,0.000110872235,0.00027755485],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059781736,0.00087784015,0.0031202277,0.0007427601,0.000043756445,0.00001848095,0.00044376534,0.00067489455,0.0006123277],"category_scores_gemma":[0.00015069303,0.0005960209,0.0003358919,0.00075489405,0.0005148856,0.00005054058,0.00033591772,0.0030032417,0.0033828444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051073765,0.00033903838,0.00011367998,0.015381495,0.0004592421,0.01864588,0.0012520056,0.0000016731118,1.6811369e-7,0.00002271073,0.02348804,0.9397853],"study_design_scores_gemma":[0.0033203408,0.0022644668,0.0007845782,0.016168816,0.0028977203,0.0038510654,0.00003646924,0.0000073254614,1.03852614e-7,0.00000549928,0.9701712,0.00049240375],"about_ca_topic_score_codex":0.00007810592,"about_ca_topic_score_gemma":0.00064990215,"teacher_disagreement_score":0.94668317,"about_ca_system_score_codex":0.00057453325,"about_ca_system_score_gemma":0.0015278102,"threshold_uncertainty_score":0.9996491},"labels":[],"label_agreement":null},{"id":"W4405465549","doi":"10.1016/j.euo.2024.12.005","title":"Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Docetaxel; Gemcitabine; Bladder cancer; Bacillus (shape); Urology; Oncology; Internal medicine; Cancer; Microbiology","score_opus":0.01886197048488084,"score_gpt":0.2837807346246937,"score_spread":0.26491876413981286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405465549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870751,0.00067063636,0.00012597827,0.003650177,0.00049963436,0.0014087381,0.00021774242,0.000100252706,0.0062517407],"genre_scores_gemma":[0.99495775,0.00015133628,0.00059774634,0.003243877,0.00019239378,0.00011703384,0.00010494692,0.000112014735,0.0005229039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960895,0.00088173937,0.00077019696,0.0010555739,0.00040310386,0.0007998552],"domain_scores_gemma":[0.9980244,0.0006514397,0.00024254838,0.00046852563,0.0002739158,0.00033918532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004177957,0.0006078048,0.0014859607,0.00050425617,0.00009854408,0.000025100662,0.00024914017,0.0002710856,0.000457656],"category_scores_gemma":[0.00015431776,0.00041381558,0.00012451061,0.00052524864,0.001163356,0.00014106685,0.0002418256,0.0008758176,0.00008207692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021774083,0.0033766737,0.89803433,0.0003956873,0.004095047,0.013539728,0.00536331,0.0004771213,0.002681592,0.00020474273,0.002801533,0.047256142],"study_design_scores_gemma":[0.02235229,0.018314632,0.9482923,0.000094957104,0.0010786622,0.00023831653,0.00019987531,0.00011249358,0.0002497707,0.000025882771,0.008604335,0.00043647052],"about_ca_topic_score_codex":0.0005129074,"about_ca_topic_score_gemma":0.0016535756,"teacher_disagreement_score":0.050257973,"about_ca_system_score_codex":0.00046850226,"about_ca_system_score_gemma":0.001024194,"threshold_uncertainty_score":0.9998314},"labels":[],"label_agreement":null},{"id":"W4405945558","doi":"10.1016/j.euo.2024.12.011","title":"Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta; BC Cancer Agency; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Carcinoma; Internal medicine; Cancer research","score_opus":0.04675184849823367,"score_gpt":0.31053943928657235,"score_spread":0.2637875907883387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405945558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722246,0.0059926854,0.0046473923,0.003428434,0.001153155,0.0013730577,0.001567408,0.0001998734,0.0094133755],"genre_scores_gemma":[0.98280025,0.00019217194,0.008062975,0.00078088674,0.00071604544,0.00037974166,0.0029926235,0.0001841141,0.003891183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942788,0.0016148443,0.0011352763,0.0015920554,0.00045225967,0.0009267501],"domain_scores_gemma":[0.99601513,0.0012941288,0.0003234156,0.0015792901,0.0002738874,0.0005141171],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010102482,0.000802348,0.0014566414,0.0011175852,0.00018557707,0.00008725024,0.00063933077,0.00013295136,0.0013423061],"category_scores_gemma":[0.00013482409,0.00062792137,0.0008487394,0.00058837055,0.0004934331,0.00026882256,0.00029481167,0.0004692361,0.00028757998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059994094,0.029952174,0.44227734,0.0024995217,0.04491967,0.2766934,0.01981383,0.0039996686,0.07517952,0.0022971232,0.013974241,0.02839943],"study_design_scores_gemma":[0.05415397,0.07409303,0.45315418,0.000042066076,0.086684935,0.0039494913,0.0011231137,0.02218988,0.016999884,0.0004989795,0.2846675,0.002442967],"about_ca_topic_score_codex":0.00022435674,"about_ca_topic_score_gemma":0.00093232613,"teacher_disagreement_score":0.2727439,"about_ca_system_score_codex":0.00060414075,"about_ca_system_score_gemma":0.00051748863,"threshold_uncertainty_score":0.9996172},"labels":[],"label_agreement":null},{"id":"W4406136944","doi":"10.1016/j.euo.2024.12.009","title":"Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Urothelial carcinoma; Lymph node metastasis; Multimodal therapy; Lymph node; Metastasis; Oncology; General surgery; Urology; Internal medicine; Cancer; Bladder cancer","score_opus":0.16649947699337558,"score_gpt":0.42395589411950907,"score_spread":0.2574564171261335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406136944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014052461,0.99213815,0.000071955175,0.0009951215,0.0000538642,0.0043011033,0.0007688181,0.000010544149,0.00025517496],"genre_scores_gemma":[0.022067994,0.975266,0.0005495524,0.0010483142,0.000084095416,0.00035586837,0.00023740732,0.00006961281,0.00032115972],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9875845,0.007450021,0.003486822,0.0007807587,0.00034463932,0.00035327865],"domain_scores_gemma":[0.98985547,0.0043278574,0.0042767213,0.0006616123,0.00075299066,0.00012532297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036762548,0.0005839379,0.008856187,0.00026946454,0.000061457926,0.0000063779084,0.00033265635,0.00027069583,0.00004283524],"category_scores_gemma":[0.0017065258,0.00031426107,0.0019180003,0.00034003626,0.00055386417,0.00004894934,0.00014082492,0.00027258988,0.0000012534434],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026902077,0.004244066,0.01894242,0.436046,0.47591522,0.00011106746,0.0004723361,0.00002388664,0.000004772292,0.000067277775,0.001477734,0.060005005],"study_design_scores_gemma":[0.0045606545,0.0076639336,0.0025059409,0.0040943213,0.95906156,0.0001529877,0.000017380382,0.000019341864,0.0000027429328,0.0000074320747,0.021683166,0.00023056396],"about_ca_topic_score_codex":0.00014476111,"about_ca_topic_score_gemma":0.000016179216,"teacher_disagreement_score":0.4831463,"about_ca_system_score_codex":0.000092794646,"about_ca_system_score_gemma":0.0006175095,"threshold_uncertainty_score":0.9999309},"labels":[],"label_agreement":null},{"id":"W4406885123","doi":"10.1016/j.euo.2024.12.013","title":"A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic Quinolones with Adjuvant Bacillus Calmette-Guérin Instillation for Non–muscle-invasive Bladder Cancer","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Bladder cancer; Adjuvant; Meta-analysis; Bacillus (shape); Oncology; Urology; Cancer; Internal medicine; Surgery; Microbiology","score_opus":0.11001338861337835,"score_gpt":0.43894441216388796,"score_spread":0.3289310235505096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406885123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016168377,0.9901053,0.00003896713,0.0004578115,0.00011821541,0.007938989,0.0005823152,0.000014011734,0.0005827504],"genre_scores_gemma":[0.0066349437,0.99063,0.00009610375,0.0010812802,0.0000560335,0.0008877682,0.00007454275,0.000060408598,0.00047892597],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9936468,0.0030754409,0.0020926,0.0006920011,0.00019434055,0.00029880716],"domain_scores_gemma":[0.9941061,0.0018937745,0.0025198306,0.0009478032,0.0004230452,0.00010940806],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011139073,0.00056379347,0.012072109,0.00038962436,0.000060105962,0.0000043856335,0.00030371954,0.00030541726,0.000116095456],"category_scores_gemma":[0.0009929934,0.0002556457,0.0036138357,0.0008991797,0.00049951905,0.000028187796,0.00014943934,0.00044817093,0.0000040959208],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021916463,0.00032727973,0.00019356546,0.5753916,0.40412265,0.000051126022,0.000099757664,0.000011661836,6.4624385e-7,0.000007963976,0.000199116,0.019375505],"study_design_scores_gemma":[0.0012408108,0.004775392,0.0017131009,0.00968827,0.976414,0.000100643054,0.0000061590636,0.0000049365162,3.349188e-7,0.0000020660334,0.0058723926,0.0001818447],"about_ca_topic_score_codex":0.00010614846,"about_ca_topic_score_gemma":0.00023919965,"teacher_disagreement_score":0.57229143,"about_ca_system_score_codex":0.000174367,"about_ca_system_score_gemma":0.002381155,"threshold_uncertainty_score":0.99998957},"labels":[],"label_agreement":null},{"id":"W4407090068","doi":"10.1016/j.euo.2024.12.015","title":"Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Fraction (chemistry); Meta-analysis; Radiation therapy; Prostate; Oncology; Prospective cohort study; Cancer; Internal medicine","score_opus":0.20613283951657208,"score_gpt":0.4449259458388961,"score_spread":0.23879310632232403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407090068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051579584,0.9702042,0.00019028447,0.0009330487,0.0025293005,0.007983305,0.01725338,0.000054444947,0.0003362424],"genre_scores_gemma":[0.0014894485,0.98632437,0.00029576317,0.00068496866,0.000674855,0.003079439,0.007218469,0.00009719097,0.00013550166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882055,0.0072596855,0.0022589322,0.001461673,0.00034616273,0.0004680816],"domain_scores_gemma":[0.9780109,0.0150702745,0.0047551836,0.0017324592,0.00030593565,0.00012525046],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035525383,0.000740278,0.008144321,0.00065609626,0.00018439595,0.000044510187,0.0007564214,0.00031723644,0.0004547996],"category_scores_gemma":[0.0025141328,0.00044063633,0.0024764454,0.00068363367,0.0002620466,0.00014014146,0.00041268664,0.00093312893,0.000018366083],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004036198,0.0006056853,0.000274167,0.00049153087,0.4087667,0.00008279605,0.00034671513,0.00003014043,7.179089e-7,0.000009391734,0.0043215896,0.58103436],"study_design_scores_gemma":[0.0041414583,0.003888557,0.000766012,0.00009587569,0.4885572,0.0000061294427,0.000050612693,0.00004704279,0.0000020739847,0.000014934995,0.5022573,0.00017279894],"about_ca_topic_score_codex":0.0004826222,"about_ca_topic_score_gemma":0.0005210759,"teacher_disagreement_score":0.58086157,"about_ca_system_score_codex":0.0010305229,"about_ca_system_score_gemma":0.0012234297,"threshold_uncertainty_score":0.99980456},"labels":[],"label_agreement":null},{"id":"W4408476470","doi":"10.1016/j.euo.2025.02.008","title":"Treatment of Metastatic Renal Cell Carcinoma: Lack of Consensus Urges the Need for a Well-organized Multidisciplinary Team","year":2025,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Multidisciplinary approach; Multidisciplinary team; Intensive care medicine; Oncology; MEDLINE; Internal medicine; Nursing","score_opus":0.035304713824297264,"score_gpt":0.32354127302980945,"score_spread":0.28823655920551217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408476470","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3394208,0.016293645,0.00013987036,0.007934172,0.49277782,0.012018364,0.0023205543,0.00020513572,0.12888962],"genre_scores_gemma":[0.7482664,0.0010571177,0.0074268156,0.00033249316,0.19875081,0.000562889,0.003290856,0.00049201335,0.039820638],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942823,0.0021886756,0.0015492819,0.0009307054,0.0003981493,0.00065086765],"domain_scores_gemma":[0.9880106,0.008506865,0.001378808,0.0011954737,0.00072235626,0.00018588558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008359438,0.00077340205,0.002750485,0.0004455632,0.00014329386,0.000005847347,0.00044906596,0.0006096253,0.000100039535],"category_scores_gemma":[0.00088350335,0.00050581986,0.00079558924,0.00027848163,0.001052651,0.00001174596,0.00027460468,0.0006342841,0.000051897674],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0150882425,0.003999782,0.00080768263,0.0010095823,0.0020141543,0.0020087478,0.0015667203,0.00004203923,0.0087909885,0.000037913178,0.9634105,0.0012236498],"study_design_scores_gemma":[0.029852618,0.044573616,0.002083356,0.00004971441,0.010327993,0.0002490768,0.00044834433,0.00009221852,0.008414351,0.00005439075,0.9034851,0.000369183],"about_ca_topic_score_codex":0.00013530534,"about_ca_topic_score_gemma":0.000038795763,"teacher_disagreement_score":0.40884557,"about_ca_system_score_codex":0.0005411046,"about_ca_system_score_gemma":0.0024964847,"threshold_uncertainty_score":0.99973935},"labels":[],"label_agreement":null},{"id":"W4409833020","doi":"10.1016/j.euo.2025.03.011","title":"Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; BC Cancer Agency; CancerCare Manitoba; Sunnybrook Health Science Centre","funders":"Prostate Cancer Canada","keywords":"Medicine; Ablative case; Prostate; Radiosurgery; Radiation therapy; Term (time); Oncology; Medical physics; Internal medicine; Radiology; Cancer","score_opus":0.042587242600463045,"score_gpt":0.38245616294540197,"score_spread":0.33986892034493893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409833020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974586,0.0009800115,0.00010736954,0.010282802,0.00066552754,0.0029070966,0.00003622212,0.000043791235,0.010391145],"genre_scores_gemma":[0.98596734,0.0007739191,0.00011516375,0.011154387,0.0001541478,0.0002566825,0.00002172733,0.000032872493,0.0015237649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954417,0.0026280924,0.0007775963,0.00052553543,0.00017093681,0.00045615324],"domain_scores_gemma":[0.99685717,0.0021280318,0.00036154588,0.000502132,0.000072653216,0.000078496276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013661667,0.00030411352,0.0010270745,0.00023263553,0.000075779324,0.0000132953055,0.00029305465,0.00016148348,0.00028483794],"category_scores_gemma":[0.00038018727,0.00016847085,0.00018366327,0.0003310244,0.00045994663,0.00006164799,0.0000865847,0.00050820573,0.000025836733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2413855,0.028626261,0.6041085,0.00010667044,0.0017628506,0.010823279,0.0058737407,0.000018010094,0.0006488178,0.0004537353,0.0036792285,0.10251338],"study_design_scores_gemma":[0.22749858,0.063284166,0.63553214,0.000072263196,0.00059881684,0.00016848973,0.00016286033,0.000044541182,0.00015935602,0.00006753685,0.072182715,0.0002285275],"about_ca_topic_score_codex":0.000027411998,"about_ca_topic_score_gemma":0.00008852666,"teacher_disagreement_score":0.102284856,"about_ca_system_score_codex":0.00037102905,"about_ca_system_score_gemma":0.0005295276,"threshold_uncertainty_score":0.6870042},"labels":[],"label_agreement":null},{"id":"W4410014449","doi":"10.1016/j.euo.2025.03.001","title":"Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Pharmaceuticals Bayer","keywords":"Medicine; Prostate cancer; Oncology; Prostate-specific antigen; Internal medicine; Prostate; Cancer; Clinical trial; Hormone","score_opus":0.030688283063919717,"score_gpt":0.33577459456679093,"score_spread":0.3050863115028712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410014449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969276,0.010121661,0.0000253613,0.0074123973,0.00010910445,0.0012605455,0.000110605775,0.000026936576,0.0012406021],"genre_scores_gemma":[0.98610824,0.011345281,0.00038656502,0.00049451634,0.000028594253,0.00005048287,0.00006024525,0.00002433567,0.0015017398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960671,0.0023871455,0.00058726687,0.0004629685,0.00015698203,0.00033850313],"domain_scores_gemma":[0.99710596,0.0020996549,0.00034544335,0.00018244066,0.00017797215,0.000088505636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011718181,0.0002153015,0.0011550285,0.0004032817,0.00008545313,0.000015150926,0.000054155957,0.00009516148,0.000011934179],"category_scores_gemma":[0.00056404533,0.00014674131,0.000045920773,0.00027599753,0.0003676187,0.00007152618,0.00007344938,0.00031488386,0.0000052024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07221141,0.000708087,0.81395197,0.00010120268,0.0026583609,0.0033909027,0.009872043,0.000048206624,0.07827566,0.0001624405,0.00076470425,0.017854989],"study_design_scores_gemma":[0.017318305,0.003173708,0.96735847,0.000053759977,0.00042531537,0.000018702976,0.00067459303,0.000081460785,0.0035818648,0.0002943282,0.006876363,0.00014310057],"about_ca_topic_score_codex":0.00022420831,"about_ca_topic_score_gemma":0.000647662,"teacher_disagreement_score":0.1534065,"about_ca_system_score_codex":0.00021057243,"about_ca_system_score_gemma":0.0002951263,"threshold_uncertainty_score":0.59839374},"labels":[],"label_agreement":null},{"id":"W4410038448","doi":"10.1016/j.euo.2025.02.007","title":"Variation in Prostate Magnetic Resonance Imaging Performance: Data from the Prostate Biopsy Collaborative Group","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Prostate; Magnetic resonance imaging; Prostate biopsy; Prostate cancer; Radiology; Internal medicine","score_opus":0.015590260090161713,"score_gpt":0.2857436566102127,"score_spread":0.270153396520051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410038448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90469754,0.030609688,0.000062558895,0.035420265,0.0009565757,0.002127773,0.00040995594,0.00010402102,0.025611598],"genre_scores_gemma":[0.9862482,0.00362724,0.0007907259,0.007848069,0.00015107363,0.00016609611,0.0005766167,0.000032931628,0.0005590255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754554,0.0007869651,0.0004521064,0.0007069436,0.00011029083,0.00039812515],"domain_scores_gemma":[0.99843746,0.00041404853,0.00015116071,0.0008318862,0.00010855721,0.00005688058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008458752,0.00021464066,0.00036196914,0.00011790591,0.00014494038,0.000026465572,0.00035978723,0.000052102267,0.00007987869],"category_scores_gemma":[0.00018317164,0.00015509322,0.000025481479,0.00054547016,0.00031341732,0.00014157737,0.0004013407,0.0003852103,0.0001258781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002449842,0.00072560133,0.785246,0.000030493742,0.0000820052,0.0015208599,0.0029059711,0.000026306321,0.0011006519,0.0004530323,0.012211808,0.19324741],"study_design_scores_gemma":[0.004157385,0.0008753421,0.75101155,0.000057816742,0.00012139913,0.000037175778,0.00013500213,0.0014878856,0.000023791043,0.00012350561,0.2418756,0.000093574155],"about_ca_topic_score_codex":0.00013340813,"about_ca_topic_score_gemma":0.00015847862,"teacher_disagreement_score":0.22966379,"about_ca_system_score_codex":0.00023852028,"about_ca_system_score_gemma":0.00038402918,"threshold_uncertainty_score":0.6324518},"labels":[],"label_agreement":null},{"id":"W4410038451","doi":"10.1016/j.euo.2025.04.004","title":"Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck; Pfizer; Merck Healthcare KGaA","keywords":"Medicine; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Avelumab; Javelin; Oncology; Toxicity; Internal medicine; Urology; Bladder cancer; Immunotherapy; Cancer; Pembrolizumab","score_opus":0.06087568181395224,"score_gpt":0.3749091265974353,"score_spread":0.31403344478348305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410038451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946387,0.0005996622,0.0010478935,0.0035172086,0.00072964706,0.002512754,0.00024198774,0.00008242296,0.0018045661],"genre_scores_gemma":[0.99098885,0.000083207546,0.00054617337,0.0048622605,0.0002613715,0.00014226454,0.00014488446,0.000057198875,0.002913771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964854,0.00089054275,0.0012086969,0.00074344577,0.00019786888,0.00047402692],"domain_scores_gemma":[0.99672496,0.0015557505,0.0006194406,0.0006984384,0.0002705405,0.00013085066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051733945,0.0004057667,0.0013353272,0.00014524539,0.00019028076,0.000012495639,0.00026248122,0.00021595511,0.00025871227],"category_scores_gemma":[0.0011987764,0.00024895958,0.0002695687,0.00022740338,0.0005709808,0.000053162043,0.00018547586,0.00031684223,0.00001939989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37527218,0.0033501931,0.54754806,0.00016631575,0.0061210045,0.00059151,0.0018627541,0.000050108585,0.0080934195,0.00014524904,0.0017463929,0.055052817],"study_design_scores_gemma":[0.19369902,0.014304576,0.7801109,0.0000659869,0.0034669118,0.000080082216,0.000109104774,0.00013996151,0.002541747,0.00012006726,0.005000776,0.000360892],"about_ca_topic_score_codex":0.0002846208,"about_ca_topic_score_gemma":0.0005149625,"teacher_disagreement_score":0.23256283,"about_ca_system_score_codex":0.00011929886,"about_ca_system_score_gemma":0.0004911564,"threshold_uncertainty_score":0.99999624},"labels":[],"label_agreement":null},{"id":"W4410085374","doi":"10.1016/j.euo.2025.04.012","title":"Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development; Johnson and Johnson","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Abiraterone; Oncology; Castration; Internal medicine; Urology; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor","score_opus":0.08226572202178561,"score_gpt":0.40670531651909064,"score_spread":0.32443959449730503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410085374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746462,0.005152519,0.0006504553,0.01414953,0.0004238574,0.0029806732,0.0001604639,0.000036909267,0.0017993812],"genre_scores_gemma":[0.9912588,0.0015413905,0.00032602245,0.0008872151,0.00011990403,0.00054190535,0.00016675472,0.000025137477,0.0051328437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974335,0.00084364455,0.0005532144,0.00051010336,0.00014740242,0.0005121486],"domain_scores_gemma":[0.9986454,0.0006806363,0.00015789809,0.0002809167,0.00013375338,0.00010136839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012913689,0.00022755502,0.0007504828,0.00038543477,0.00019051011,0.00003564339,0.00015499262,0.0000683866,0.00008113769],"category_scores_gemma":[0.0001532589,0.00015394429,0.00013233084,0.00048725124,0.00042827113,0.000057495618,0.000098142424,0.0003408307,0.0000062181803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8822148,0.003183578,0.024188815,0.00038113323,0.010705153,0.0024025592,0.0034255174,0.003240578,0.010444147,0.0013094918,0.0030199534,0.055484317],"study_design_scores_gemma":[0.6706325,0.021946944,0.21196932,0.000041033054,0.008480398,0.000047539223,0.00054330047,0.010225518,0.00039187554,0.00047854072,0.07481298,0.00043007007],"about_ca_topic_score_codex":0.00031698664,"about_ca_topic_score_gemma":0.0022357195,"teacher_disagreement_score":0.21158227,"about_ca_system_score_codex":0.00024122791,"about_ca_system_score_gemma":0.00091408537,"threshold_uncertainty_score":0.62776655},"labels":[],"label_agreement":null},{"id":"W4410116981","doi":"10.1016/j.euo.2025.03.017","title":"Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Saint-Boniface; CancerCare Manitoba; St. Boniface Hospital; London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network; Western University; Sunnybrook Health Science Centre; McGill University Health Centre; Juravinski Cancer Centre","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Prostate cancer; Radiation therapy; Randomized controlled trial; Clinical trial; Quality of life (healthcare); Medical physics; Oncology; Prostate; Internal medicine; Cancer; Nursing","score_opus":0.11764613250169513,"score_gpt":0.49173306586966686,"score_spread":0.3740869333679717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410116981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829215,0.0028528357,0.0007235335,0.0034027826,0.0017589839,0.007574756,0.00008175361,0.000056131317,0.00062776846],"genre_scores_gemma":[0.9894412,0.0029905261,0.0010877469,0.003661957,0.00021476141,0.0023007211,0.00012793406,0.00003943006,0.000135698],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894836,0.006386953,0.0029585909,0.0006447499,0.00015650244,0.0003695952],"domain_scores_gemma":[0.99235004,0.005045992,0.0017270265,0.0003277151,0.0004146656,0.00013453669],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007883764,0.00025482042,0.0019973053,0.00025634826,0.000070293616,0.000007765057,0.00009447167,0.00019185158,0.00007470796],"category_scores_gemma":[0.010489732,0.00020111319,0.00037732028,0.00023137649,0.00038826748,0.000062374565,0.00005357133,0.0004717377,0.0000028567383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78389114,0.0027567663,0.034393754,0.000060956747,0.0014950577,0.000059107562,0.0005284739,0.00013942113,0.00026004954,0.00008730271,0.0007086333,0.17561935],"study_design_scores_gemma":[0.94208825,0.01840918,0.027348772,0.000053942193,0.00074828934,0.0000052202636,0.00006704478,0.0068452875,0.00014453461,0.00030079673,0.0038388434,0.00014981539],"about_ca_topic_score_codex":0.00023650711,"about_ca_topic_score_gemma":0.000082083505,"teacher_disagreement_score":0.17546953,"about_ca_system_score_codex":0.0002955573,"about_ca_system_score_gemma":0.0016721622,"threshold_uncertainty_score":0.99784535},"labels":[],"label_agreement":null},{"id":"W4410338114","doi":"10.1016/j.euo.2025.02.015","title":"Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"Bayer; Astellas Pharma US","keywords":"Medicine; Docetaxel; Pembrolizumab; Prostate cancer; Prednisone; Oncology; Internal medicine; Abiraterone; Enzalutamide; Cancer; Immunotherapy","score_opus":0.017536134480207105,"score_gpt":0.3190061985177405,"score_spread":0.3014700640375334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410338114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99025184,0.00064925686,0.00005672992,0.0035293289,0.00010494785,0.0025923946,0.00007589979,0.00004340498,0.0026961872],"genre_scores_gemma":[0.9957172,0.00010933024,0.00095973205,0.00082932436,0.000014672794,0.00043865532,0.00013410447,0.000040216353,0.0017567523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809027,0.00027620993,0.000443701,0.0005305027,0.00017223893,0.00048707693],"domain_scores_gemma":[0.9989315,0.0002316225,0.00019885346,0.00025015807,0.0002667271,0.00012111219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021610301,0.00025507575,0.0005929867,0.00028626065,0.00011774788,0.000017335937,0.00006999901,0.000060382456,0.00002502194],"category_scores_gemma":[0.00010615444,0.00016101162,0.000038207927,0.00025604462,0.0003643494,0.00007674751,0.000058687037,0.00024981122,0.000003017726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04372539,0.0015873468,0.93566346,0.00020479367,0.0010259039,0.0010707779,0.0011629815,0.00007145365,0.00034102314,0.0001312745,0.00040284937,0.014612747],"study_design_scores_gemma":[0.045846827,0.0134724,0.9319726,0.00006731837,0.0005544066,0.0000420587,0.00015667167,0.000070173985,0.000098621866,0.00007194131,0.00746732,0.00017963188],"about_ca_topic_score_codex":0.000100637764,"about_ca_topic_score_gemma":0.0005806677,"teacher_disagreement_score":0.014433116,"about_ca_system_score_codex":0.00020788415,"about_ca_system_score_gemma":0.0006661122,"threshold_uncertainty_score":0.6565863},"labels":[],"label_agreement":null},{"id":"W4410573706","doi":"10.1016/j.euo.2025.04.010","title":"Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non–muscle-invasive Bladder Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"European Association of Urology","keywords":"Medicine; Bladder cancer; Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.011843675398855743,"score_gpt":0.28240497704873446,"score_spread":0.27056130164987874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410573706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8673228,0.00075801427,0.0017836884,0.0013085688,0.0020967792,0.0014079771,0.00022133655,0.00014631412,0.12495451],"genre_scores_gemma":[0.98772806,0.0002952697,0.0010128657,0.008789071,0.0002486605,0.00029490027,0.00023119034,0.000081450584,0.0013185198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997943,0.000297813,0.00040907235,0.0006352235,0.00014636971,0.0005685376],"domain_scores_gemma":[0.998661,0.00031409835,0.00022859068,0.0003603618,0.00029405413,0.00014188475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023366003,0.000348291,0.000668929,0.00021307432,0.00018231118,0.000021835276,0.00022011093,0.00018015468,0.00014959452],"category_scores_gemma":[0.00014112765,0.00026959184,0.00015162084,0.00019339914,0.00033594595,0.00010084714,0.00013776874,0.00040591735,0.00006852059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017187025,0.0020283842,0.5607606,0.00039678102,0.0042908504,0.00050994835,0.004565086,0.00009849506,0.0004213873,0.0009986648,0.038824484,0.3699183],"study_design_scores_gemma":[0.025030192,0.01171865,0.89985,0.000078368685,0.0018098501,0.000012793194,0.00037158115,0.000017823142,0.00007944016,0.0003943774,0.06034473,0.00029218898],"about_ca_topic_score_codex":0.00013045575,"about_ca_topic_score_gemma":0.00042040888,"teacher_disagreement_score":0.3696261,"about_ca_system_score_codex":0.0002703705,"about_ca_system_score_gemma":0.0020366148,"threshold_uncertainty_score":0.9999756},"labels":[],"label_agreement":null},{"id":"W4410873763","doi":"10.1016/j.euo.2025.05.006","title":"Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostatectomy; Medicine; Androgen deprivation therapy; Concomitant; Meta-analysis; Urology; Radiation therapy; Androgen; Duration (music); Prostate cancer; Oncology; Internal medicine; Hormone; Cancer","score_opus":0.095004380636919,"score_gpt":0.37583951501623175,"score_spread":0.28083513437931273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410873763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004160705,0.9866858,0.00016695776,0.0014965133,0.000044138185,0.0107824495,0.00034309187,0.000026353619,0.00003858801],"genre_scores_gemma":[0.004065214,0.9880439,0.00040104438,0.0035384286,0.000058664682,0.00263965,0.001193389,0.00003772485,0.000021998872],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99529725,0.0018360557,0.0015731703,0.0008942935,0.00012498755,0.0002742463],"domain_scores_gemma":[0.9962568,0.0014346576,0.0011283539,0.00082783843,0.00021307434,0.00013925495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026694124,0.00039518383,0.00600141,0.00035308968,0.00006679384,0.00003136904,0.00024954465,0.00018891794,0.000017363069],"category_scores_gemma":[0.001729558,0.0002647689,0.00042089826,0.00071935717,0.000075061784,0.00015825496,0.000262999,0.00021185547,0.0000033104684],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048657708,0.000274933,0.00059469993,0.7700474,0.15957636,0.00015977271,0.00016097563,0.00003868731,0.0000018032778,0.00026168782,0.0011665776,0.067230515],"study_design_scores_gemma":[0.0017969046,0.0018619214,0.000725419,0.015777728,0.8459691,0.00012405636,0.000005501339,0.00007084436,0.0000015729513,0.00002257478,0.133309,0.000335371],"about_ca_topic_score_codex":0.0000028930492,"about_ca_topic_score_gemma":0.0000080515765,"teacher_disagreement_score":0.7542697,"about_ca_system_score_codex":0.000110439185,"about_ca_system_score_gemma":0.00034162987,"threshold_uncertainty_score":0.99998045},"labels":[],"label_agreement":null},{"id":"W4410879240","doi":"10.1016/j.euo.2025.05.008","title":"The Burden of Genitourinary Malignancies in Southeast Asia from 1990 to 2021","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Prostate Cancer Foundation","keywords":"Medicine; Genitourinary system; Southeast asia; Oncology; Intensive care medicine; Internal medicine; Ancient history","score_opus":0.01420437330433892,"score_gpt":0.2891482787989355,"score_spread":0.2749439054945966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410879240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6539982,0.0023467408,0.00009156352,0.028067691,0.0007906211,0.00051908987,0.000038167902,0.000028174187,0.31411976],"genre_scores_gemma":[0.99453896,0.000096692864,0.00025773485,0.0010641409,0.00039466535,0.000025732792,0.000012584529,0.000019915677,0.0035895526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984596,0.0005275186,0.00034687444,0.00029284772,0.00008179269,0.000291376],"domain_scores_gemma":[0.9991607,0.00026395384,0.00006891055,0.0003789764,0.00005450033,0.000072949944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029138473,0.00013900975,0.00035877683,0.00013902177,0.000071764,0.000004580598,0.00022180597,0.00008550498,0.00017991672],"category_scores_gemma":[0.00011870675,0.000100628706,0.000072345705,0.00022237436,0.00020595305,0.000013570188,0.00017823657,0.00022576866,0.00028823563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027947113,0.0033430955,0.22109252,0.00013471814,0.0029006933,0.012698,0.018958159,0.0006689676,0.09227831,0.010937353,0.12174215,0.48729894],"study_design_scores_gemma":[0.004564488,0.0030207187,0.35630468,0.000048251954,0.00025537284,0.00007749128,0.0024383867,0.000030290383,0.0008406078,0.00063689804,0.63165087,0.00013195514],"about_ca_topic_score_codex":0.00051601406,"about_ca_topic_score_gemma":0.0001498967,"teacher_disagreement_score":0.5099087,"about_ca_system_score_codex":0.000071428716,"about_ca_system_score_gemma":0.00024492238,"threshold_uncertainty_score":0.41035193},"labels":[],"label_agreement":null},{"id":"W4411094435","doi":"10.1016/j.euo.2025.05.012","title":"Quality Indicators for Renal Cancer Care: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality (philosophy); Intensive care medicine; Kidney cancer; Cancer; Internal medicine","score_opus":0.06814733408136993,"score_gpt":0.42249111102646647,"score_spread":0.35434377694509656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411094435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012621753,0.95645213,0.00004482995,0.0005927234,0.00068794086,0.011266306,0.00018303936,0.00012458206,0.03064716],"genre_scores_gemma":[0.000008695383,0.9860458,0.00018091736,0.0048998436,0.00039123488,0.0038735315,0.0007271314,0.00013438433,0.003738465],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98980653,0.00585112,0.0023576587,0.0010994311,0.00024759225,0.0006376556],"domain_scores_gemma":[0.99451756,0.0019652848,0.001718598,0.0013052046,0.00021778214,0.0002755411],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019719857,0.0008031675,0.008609042,0.00058818597,0.00011727202,0.000008985254,0.000564977,0.0005471052,0.00014213528],"category_scores_gemma":[0.0015862539,0.0005608327,0.001668034,0.00056113704,0.00023995,0.000018256147,0.0002606046,0.00087247475,0.00031526142],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000522925,0.00011327332,0.0000046969176,0.79341656,0.0012269927,0.0005390909,0.000054017597,6.49438e-8,1.4419044e-7,0.00010199011,0.0071658357,0.19732505],"study_design_scores_gemma":[0.00080288935,0.0011266099,0.000012621307,0.2412281,0.02787357,0.00043601816,0.0000058680794,7.6103106e-8,2.0191126e-7,0.0000026593184,0.7282525,0.00025891318],"about_ca_topic_score_codex":0.000011083563,"about_ca_topic_score_gemma":0.000016154732,"teacher_disagreement_score":0.7210866,"about_ca_system_score_codex":0.0013222988,"about_ca_system_score_gemma":0.0027219465,"threshold_uncertainty_score":0.99968433},"labels":[],"label_agreement":null},{"id":"W4411192142","doi":"10.1016/j.euo.2025.05.013","title":"Long Noncoding RNAs Identify a Subgroup of Patients with Low-grade Non–muscle-invasive Bladder Cancer with Less Favorable Outcomes","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Oncology; Cancer; Long non-coding RNA; Subgroup analysis; Internal medicine; Bioinformatics; RNA; Gene; Genetics; Biology","score_opus":0.009344993534375973,"score_gpt":0.2855987190947529,"score_spread":0.2762537255603769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411192142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970599,0.00048933254,0.021233266,0.00060116086,0.0004000675,0.000720314,0.00004637475,0.000029410456,0.0058810585],"genre_scores_gemma":[0.9963246,0.00021758857,0.00038613053,0.001443516,0.00008873883,0.00007856983,0.00013633115,0.00009232802,0.0012322003],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99709994,0.00060626416,0.00045416495,0.00085569033,0.0002809549,0.00070300244],"domain_scores_gemma":[0.9983274,0.0000970109,0.00031652156,0.00068982324,0.00042825897,0.00014102679],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040626695,0.00037255575,0.0005586242,0.00027324585,0.0001599395,0.00002440268,0.000607682,0.00030191123,0.0000659972],"category_scores_gemma":[0.00012476169,0.00031023033,0.00012694516,0.00038756971,0.00050912687,0.000012434112,0.0004614558,0.0004940993,0.000018502691],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061203614,0.0026467775,0.3337168,0.00047321088,0.0049780095,0.001204978,0.00076340453,0.007816953,0.6132214,0.00045731117,0.005798969,0.022801837],"study_design_scores_gemma":[0.017065372,0.008138363,0.74891555,0.00018221953,0.00070006424,0.00004447426,0.00032271925,0.0001033877,0.19782516,0.00004772205,0.02558664,0.0010683055],"about_ca_topic_score_codex":0.00013945161,"about_ca_topic_score_gemma":0.0018597326,"teacher_disagreement_score":0.4153962,"about_ca_system_score_codex":0.0001182488,"about_ca_system_score_gemma":0.0007666608,"threshold_uncertainty_score":0.999935},"labels":[],"label_agreement":null},{"id":"W4411638092","doi":"10.1016/j.euo.2025.05.028","title":"Radiation Therapy in the Management of Muscle-invasive Bladder Cancer with Carcinoma in Situ: Still a No Go?","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System","funders":"","keywords":"Medicine; Bladder cancer; Radiation therapy; Carcinoma in situ; Cancer therapy; Cancer; Oncology; General surgery; Internal medicine","score_opus":0.035201486465901315,"score_gpt":0.3372665991929558,"score_spread":0.3020651127270545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411638092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002031491,0.9021303,0.000002797654,0.00060281897,0.00033370598,0.0026233932,0.000036222107,0.000018132238,0.09222112],"genre_scores_gemma":[0.015518229,0.9805947,0.000055327637,0.0021545135,0.00019531907,0.0005113747,0.00009792507,0.00005776099,0.00081483845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965639,0.0016446905,0.00065970473,0.00058004365,0.00016946976,0.00038215428],"domain_scores_gemma":[0.99860054,0.00038929543,0.00035893908,0.00053397357,0.00006780607,0.000049467042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004723056,0.0004154725,0.0015392216,0.00041642206,0.000026026602,0.0000048334805,0.0003570041,0.0002301738,0.0001662322],"category_scores_gemma":[0.0000209917,0.00025147488,0.00018775692,0.00056062645,0.0001829201,0.000025399895,0.00008071108,0.00060372456,0.00006675801],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005279027,0.0006220275,0.0012160953,0.003744292,0.0008706443,0.0030686324,0.0010066241,0.00000625488,0.0000012819081,0.000069786634,0.0007830758,0.98808336],"study_design_scores_gemma":[0.00595673,0.0036123407,0.038396973,0.0018448301,0.0017519167,0.0000994917,0.00007378399,7.962905e-7,0.0000010729253,0.00000725937,0.94806,0.00019485588],"about_ca_topic_score_codex":0.00015570033,"about_ca_topic_score_gemma":0.0005060153,"teacher_disagreement_score":0.9878885,"about_ca_system_score_codex":0.0003311002,"about_ca_system_score_gemma":0.0009376423,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W4411638096","doi":"10.1016/j.euo.2025.04.025","title":"PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Manchester Biomedical Research Centre; Merck Sharp and Dohme; Institute of Cancer Research; Prostate Cancer UK; Cancer Research UK; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Movember Foundation","keywords":"Medicine; Pembrolizumab; Prostate cancer; Open label; Oncology; Internal medicine; Castration; Clinical trial; Immune system; Immunotherapy; Cancer; Immunology; Hormone","score_opus":0.07294500427301906,"score_gpt":0.3603880609852758,"score_spread":0.2874430567122568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411638096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910343,0.00064093224,0.0000074207205,0.00087902584,0.00005149162,0.0023377487,0.0000368515,0.00003534964,0.00497683],"genre_scores_gemma":[0.9979701,0.000012704013,0.00079037185,0.00097295217,0.0000151868135,0.000076405566,0.000040059665,0.00003557618,0.00008663213],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973046,0.0012388078,0.00043248225,0.00047867125,0.00017730567,0.00036809334],"domain_scores_gemma":[0.9986331,0.00039900778,0.00023872998,0.00031417116,0.00029599434,0.00011898808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006333555,0.00022348139,0.0004904855,0.00017802195,0.00015491806,0.000025565701,0.00016731715,0.00005085764,0.000012794095],"category_scores_gemma":[0.00039961826,0.00013402705,0.000020377867,0.00048663717,0.00088492926,0.00008491261,0.000106555766,0.0003097175,0.0000017596019],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7988142,0.029047653,0.07905803,0.00032385188,0.0015449489,0.004155347,0.009656498,0.00034882038,0.06513342,0.000943939,0.00016717581,0.010806118],"study_design_scores_gemma":[0.6455635,0.1710769,0.17340292,0.00038780013,0.0015275672,0.00013245488,0.0017439175,0.0005215253,0.003842903,0.00008884869,0.0012328514,0.00047884777],"about_ca_topic_score_codex":0.0003531208,"about_ca_topic_score_gemma":0.00018699231,"teacher_disagreement_score":0.15325072,"about_ca_system_score_codex":0.00013094449,"about_ca_system_score_gemma":0.001152479,"threshold_uncertainty_score":0.54654646},"labels":[],"label_agreement":null},{"id":"W4412492574","doi":"10.1016/j.euo.2025.04.008","title":"Years of Life Lost in Metastatic and Locally Advanced Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Prostate; Internal medicine","score_opus":0.012057575497284784,"score_gpt":0.3004577217629125,"score_spread":0.2884001462656277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612767,0.005433661,0.0000570168,0.0043878783,0.00043316375,0.00031041115,0.000011679303,0.000019460014,0.02807003],"genre_scores_gemma":[0.99115217,0.0008104453,0.0001409885,0.0065093776,0.000028865687,0.000016107955,0.000005811232,0.000016719501,0.0013195041],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988164,0.00035059458,0.0003101528,0.00025431442,0.0000587898,0.00020977373],"domain_scores_gemma":[0.99944353,0.00016448059,0.00008744285,0.00016912658,0.0000601402,0.00007530457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033098468,0.00009753308,0.00041239962,0.00019114299,0.000012513844,0.0000020374775,0.00007541856,0.000048877413,0.00009747072],"category_scores_gemma":[0.00017978204,0.00009789347,0.00003434243,0.00023830937,0.00026105432,0.00002266129,0.000087737724,0.00023984707,0.000020161784],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007851449,0.00057142304,0.3343159,0.00054775376,0.00039706245,0.0018098085,0.006042092,0.00035721983,0.0058441698,0.0019185478,0.0034984741,0.63684607],"study_design_scores_gemma":[0.007855992,0.0019163027,0.7273379,0.00008341578,0.00019819746,0.000043166863,0.00062775693,0.00009389879,0.00011907373,0.00020885353,0.26136667,0.00014878558],"about_ca_topic_score_codex":0.00018921639,"about_ca_topic_score_gemma":0.0022553776,"teacher_disagreement_score":0.6366973,"about_ca_system_score_codex":0.00005330638,"about_ca_system_score_gemma":0.0003867844,"threshold_uncertainty_score":0.39919797},"labels":[],"label_agreement":null},{"id":"W4412492827","doi":"10.1016/j.euo.2025.04.009","title":"Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; Movember Foundation; Sanofi; Veracyte; U.S. Department of Defense","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Hazard ratio; Radiation therapy; Metastasis; Chemotherapy; Cancer; Confidence interval","score_opus":0.01989595292806918,"score_gpt":0.3533734733597566,"score_spread":0.33347752043168744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879873,0.0035870997,0.00031096386,0.0047066384,0.0001806779,0.0022606356,0.00029085716,0.00002618319,0.000649666],"genre_scores_gemma":[0.9942123,0.00328069,0.00054374384,0.0010495534,0.00007596407,0.00038347475,0.000278583,0.000023033625,0.00015264908],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715203,0.0012249151,0.0005456438,0.0005615413,0.000165139,0.00035070258],"domain_scores_gemma":[0.9981926,0.0010327514,0.00024598849,0.00029173007,0.00014571566,0.000091228314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008288337,0.00021798744,0.00083041616,0.0006260069,0.00012323912,0.000020078847,0.00018819717,0.00013718124,0.00006786676],"category_scores_gemma":[0.00018158428,0.00013516404,0.000093319686,0.00085589866,0.00047768254,0.00006275029,0.00005152733,0.00037312444,0.000002451594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55098474,0.00353091,0.0972785,0.00008813357,0.008714937,0.000697026,0.02369741,0.00028256158,0.0686592,0.0003394671,0.0008220145,0.24490511],"study_design_scores_gemma":[0.46087533,0.04364829,0.42446002,0.00024221162,0.01755507,0.000036690813,0.003268473,0.0022267557,0.013975003,0.0006197757,0.032528847,0.0005635318],"about_ca_topic_score_codex":0.00084580964,"about_ca_topic_score_gemma":0.0014638369,"teacher_disagreement_score":0.32718152,"about_ca_system_score_codex":0.00019544347,"about_ca_system_score_gemma":0.00035815945,"threshold_uncertainty_score":0.551183},"labels":[],"label_agreement":null},{"id":"W4412521995","doi":"10.1016/j.euo.2025.06.009","title":"Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Mount Sinai Hospital; Ottawa Hospital; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Medicine; Radiation therapy; Prostate cancer; Hazard ratio; Cumulative incidence; Prostatectomy; Androgen deprivation therapy; Interquartile range; Internal medicine; Relative risk; Randomized controlled trial; Docetaxel; Oncology; Surgery; Confidence interval; Cancer; Urology; Cohort","score_opus":0.026251544192120835,"score_gpt":0.3216585503992758,"score_spread":0.295407006207155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412521995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959972,0.00861072,0.000042667503,0.017914353,0.0012011323,0.0009269236,0.00006961519,0.000108821434,0.0111537585],"genre_scores_gemma":[0.9840089,0.010874336,0.00017934287,0.003073258,0.00015750252,0.00036762675,0.00009592906,0.00004578562,0.0011972861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974534,0.00081880135,0.0004957727,0.000574605,0.00008129374,0.00057610933],"domain_scores_gemma":[0.99837583,0.0008810705,0.00018570964,0.0003741654,0.000058682006,0.0001245611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042170365,0.00029274065,0.000733846,0.00034618212,0.00008443539,0.000011988291,0.000088290304,0.00012683711,0.00027037034],"category_scores_gemma":[0.00007619099,0.00023683056,0.00014436786,0.0003211289,0.00020718556,0.000032374242,0.00002828188,0.0002520058,0.00005781911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009463386,0.0019893197,0.5540904,0.000035636825,0.00076172943,0.002799789,0.0002540771,0.0030589795,0.00016994891,0.00033356296,0.0054858103,0.42155737],"study_design_scores_gemma":[0.033800434,0.011600628,0.5827029,0.000054709242,0.0005995747,0.000013788408,0.00005641866,0.00037442613,0.0007543811,0.00008053501,0.36970004,0.0002621795],"about_ca_topic_score_codex":0.0020915316,"about_ca_topic_score_gemma":0.0022392876,"teacher_disagreement_score":0.4212952,"about_ca_system_score_codex":0.0013411423,"about_ca_system_score_gemma":0.001147274,"threshold_uncertainty_score":0.96576697},"labels":[],"label_agreement":null},{"id":"W4413408517","doi":"10.1016/j.euo.2025.06.010","title":"A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pharmaceuticals Bayer","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Clinical trial; Hormone therapy; Prostate; Androgen; Hormone; Cancer; Breast cancer","score_opus":0.044188780447867254,"score_gpt":0.37906314171303823,"score_spread":0.334874361265171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413408517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796168,0.0003323959,0.00006185704,0.014293913,0.00012319854,0.005259271,0.000062078805,0.00003330542,0.00021714703],"genre_scores_gemma":[0.9876611,0.00033684605,0.00014903084,0.011064383,0.00003712498,0.00032944416,0.00014370144,0.000045438614,0.00023290757],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99354416,0.004132901,0.0007102448,0.00067090924,0.00032884983,0.00061291247],"domain_scores_gemma":[0.99787223,0.0011585095,0.00023050235,0.00039703428,0.00023569698,0.000106040585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025528292,0.0003055827,0.0008730791,0.0004725496,0.0001104673,0.000025315332,0.00020595077,0.00011312418,0.00001741835],"category_scores_gemma":[0.00035649267,0.00017250924,0.000081558275,0.0008173313,0.00039182443,0.00008010474,0.00007343573,0.0006697855,0.00002080967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57114494,0.0020311575,0.40613753,0.0000035537348,0.0005462961,0.0014797738,0.0057536275,0.000047231246,0.00012878882,0.0000018905645,0.00035395878,0.012371256],"study_design_scores_gemma":[0.22836265,0.022586174,0.7437983,0.000027533222,0.00009413503,0.0000048153374,0.00015880067,0.00005793008,0.000042094216,0.000014060143,0.0047126743,0.00014082566],"about_ca_topic_score_codex":0.000051097417,"about_ca_topic_score_gemma":0.00026740675,"teacher_disagreement_score":0.3427823,"about_ca_system_score_codex":0.00045612198,"about_ca_system_score_gemma":0.00067503867,"threshold_uncertainty_score":0.7034723},"labels":[],"label_agreement":null},{"id":"W4413734039","doi":"10.1016/j.euo.2025.07.011","title":"Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma—An Observational Prospective Multicentre Diagnostic Test Cohort Study","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"NIHR Cambridge Biomedical Research Centre; Medical Research Council; Lunds Universitet; European Commission; Horizon 2020; National Institute for Health and Care Research; Cancer Research UK; Scottish Government","keywords":"Medicine; Renal cell carcinoma; Observational study; Internal medicine; Urine; Prospective cohort study; Cohort study; Oncology; Cohort","score_opus":0.02074644367003278,"score_gpt":0.2816981245404117,"score_spread":0.26095168087037895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413734039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945066,0.00047217894,0.000110252084,0.00020907856,0.00026527117,0.0033060699,0.000121066565,0.000028763412,0.0009807391],"genre_scores_gemma":[0.9977883,0.00011074876,0.0012135293,0.000195116,0.00008183947,0.00020145763,0.00016616013,0.000040464012,0.00020237359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665475,0.0011473185,0.0007714135,0.0008315168,0.00017221976,0.00042277752],"domain_scores_gemma":[0.99390155,0.0048664473,0.00040162104,0.0004389523,0.00024186996,0.0001495671],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010035753,0.00031716327,0.0008385177,0.00030106926,0.00008048375,0.000009265493,0.00021468374,0.00009113116,0.000026988339],"category_scores_gemma":[0.0022417593,0.000286459,0.00006773117,0.00027207955,0.0003965916,0.000060606326,0.00019061968,0.00041482828,0.000012589339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025276297,0.003942033,0.9889541,0.00015625132,0.00008281318,0.0006268045,0.00096211856,0.00009864655,0.00079750345,0.000023025188,0.00014178647,0.0016872704],"study_design_scores_gemma":[0.012117385,0.019616874,0.965746,0.000023125105,0.00042322505,0.000025987816,0.0002751116,0.000735368,0.0006793994,0.000058385835,0.00012856643,0.00017060345],"about_ca_topic_score_codex":0.00034965502,"about_ca_topic_score_gemma":0.0012337138,"teacher_disagreement_score":0.02320815,"about_ca_system_score_codex":0.0002431852,"about_ca_system_score_gemma":0.000275708,"threshold_uncertainty_score":0.99995875},"labels":[],"label_agreement":null},{"id":"W4414422734","doi":"10.1016/j.euo.2025.07.007","title":"Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"McMaster University; Movember Foundation; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Foundation for the National Institutes of Health; U.S. Department of Defense","keywords":"Androgen deprivation therapy; Prostate cancer; Predictive testing; Personalized medicine; Personalization; Precision medicine; Androgen","score_opus":0.03536143272135039,"score_gpt":0.35896742767318646,"score_spread":0.32360599495183606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414422734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98222405,0.001482271,0.00024750273,0.0073991427,0.00017125836,0.0013110652,0.000012044513,0.00017482469,0.0069778357],"genre_scores_gemma":[0.99103445,0.0009115274,0.0013483368,0.00467759,0.00010186332,0.000087912085,0.000011353564,0.000049489394,0.0017774897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967172,0.00186516,0.00038402982,0.00045792994,0.00019126177,0.000384418],"domain_scores_gemma":[0.99838233,0.0005760626,0.00013963495,0.0004975456,0.0002798952,0.00012454245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013673615,0.00021529691,0.00066775386,0.00047337532,0.00009530939,0.0000058556748,0.0002525063,0.00008257696,0.00012588638],"category_scores_gemma":[0.00055465446,0.00013849403,0.000062812265,0.0006081811,0.00040167943,0.00003167188,0.000142461,0.00027558426,0.000035621564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.270816,0.0007583339,0.48844925,0.000040321123,0.0029965206,0.00047064197,0.0030186914,0.000053618718,0.17646284,0.000033478664,0.009669884,0.047230404],"study_design_scores_gemma":[0.009655622,0.016659463,0.6472668,0.000020798425,0.0001225046,0.000092736605,0.00010287265,0.000021178894,0.0064133443,0.000010080744,0.31951532,0.00011929672],"about_ca_topic_score_codex":0.000029804174,"about_ca_topic_score_gemma":0.0000793587,"teacher_disagreement_score":0.30984545,"about_ca_system_score_codex":0.00019378518,"about_ca_system_score_gemma":0.0008014808,"threshold_uncertainty_score":0.5647623},"labels":[],"label_agreement":null},{"id":"W4414517593","doi":"10.1016/j.euo.2025.08.004","title":"MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Michael's Hospital; University Health Network; University of British Columbia; Princess Margaret Cancer Centre","funders":"University of Toronto; Fundação para a Ciência e a Tecnologia; Princess Margaret Cancer Foundation","keywords":"Malignancy; microRNA; Biomarker; Diagnostic biomarker; Testicular cancer","score_opus":0.018829348508647026,"score_gpt":0.3074765358319598,"score_spread":0.28864718732331274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414517593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94020957,0.0037538419,0.0005212896,0.006634342,0.00032704786,0.0006902028,0.0000068948475,0.00013136346,0.04772545],"genre_scores_gemma":[0.9825012,0.000051613355,0.003283053,0.012895195,0.000051495,0.000051409104,0.000020348443,0.000040860043,0.0011047971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979901,0.0005347335,0.00037585082,0.000561126,0.000060850663,0.00047735331],"domain_scores_gemma":[0.9989417,0.0002430529,0.00007922371,0.0004326047,0.00007238785,0.00023099371],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026647092,0.0002419055,0.0004482732,0.00040498137,0.000055907192,0.00000921515,0.00017924672,0.00013000944,0.00015214054],"category_scores_gemma":[0.0009813093,0.00021610275,0.000120870376,0.00044307826,0.00012226094,0.000017342532,0.00021225368,0.00020534437,0.0011502272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016713446,0.0058673164,0.43239772,0.00040863242,0.0019582221,0.16155231,0.00058834074,0.00012305268,0.15527947,0.0026753964,0.010164355,0.21227174],"study_design_scores_gemma":[0.0064871632,0.007365876,0.80443776,0.00012632461,0.00065738027,0.0010929296,0.00003218098,0.00002845392,0.0011205846,0.00040607262,0.17798406,0.00026120548],"about_ca_topic_score_codex":0.00007272759,"about_ca_topic_score_gemma":0.00009546324,"teacher_disagreement_score":0.37204003,"about_ca_system_score_codex":0.00014851779,"about_ca_system_score_gemma":0.00033952115,"threshold_uncertainty_score":0.9996275},"labels":[],"label_agreement":null},{"id":"W4414564476","doi":"10.1016/j.euo.2025.07.014","title":"Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; University Health Network; Prostate Cancer Canada; McGill University Health Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate cancer; Biomarker; Disease; Androgen; Prostate; Tumor progression; PCA3; Androgen receptor","score_opus":0.018948851700828263,"score_gpt":0.29512109710868834,"score_spread":0.27617224540786006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414564476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97115564,0.015496332,0.00002726853,0.008419131,0.00048378066,0.0031629365,0.00022879893,0.000019361809,0.0010067408],"genre_scores_gemma":[0.99555856,0.0022902656,0.00011294341,0.0010938678,0.0000653374,0.00040780308,0.00006583715,0.000024989884,0.0003804054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972275,0.0010570358,0.00053212175,0.0005032023,0.00019026738,0.00048990635],"domain_scores_gemma":[0.9987277,0.00041150412,0.00018221508,0.00033435863,0.00019558339,0.00014868531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004029683,0.00025659183,0.0005583866,0.0001474698,0.0002933561,0.000010469554,0.0002636718,0.00015885803,0.000042386815],"category_scores_gemma":[0.00015748644,0.0001407392,0.00007322804,0.0005357091,0.0015459076,0.00005184837,0.00012501476,0.00053449074,0.000002308018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035073508,0.00028700975,0.9665972,0.00016506147,0.00024455163,0.00030724885,0.0020245255,0.0011074244,0.016883943,0.00013967138,0.0014653584,0.0072706277],"study_design_scores_gemma":[0.0076414878,0.00043282867,0.95297104,0.0005858736,0.00025557255,0.000014876289,0.00008454573,0.000646382,0.004512059,0.00016051035,0.032546338,0.00014850996],"about_ca_topic_score_codex":0.027159598,"about_ca_topic_score_gemma":0.20598888,"teacher_disagreement_score":0.1788293,"about_ca_system_score_codex":0.00035370307,"about_ca_system_score_gemma":0.003698184,"threshold_uncertainty_score":0.9793186},"labels":[],"label_agreement":null},{"id":"W4414695231","doi":"10.1016/j.euo.2025.07.006","title":"Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Terry Fox Research Institute","keywords":"Cabazitaxel; Enzalutamide; Abiraterone; Prostate cancer; Phases of clinical research; PTEN; Clinical endpoint; Circulating tumor cell","score_opus":0.06026926909396508,"score_gpt":0.4007988400723302,"score_spread":0.3405295709783651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414695231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98793346,0.0013581213,0.00047279074,0.0044421377,0.00040743774,0.0034540691,0.000274615,0.0001046697,0.0015526935],"genre_scores_gemma":[0.9915134,0.00008409921,0.0019179272,0.0013441703,0.0002118262,0.0022920636,0.00021525437,0.000065686116,0.0023556305],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99670184,0.0007121343,0.00071631995,0.00083182304,0.0002479336,0.0007899269],"domain_scores_gemma":[0.99812686,0.0006554853,0.00029971072,0.00034639504,0.0003531306,0.00021842025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076786266,0.00038084044,0.0010140208,0.0005322351,0.000237389,0.000050102823,0.00016746912,0.000080298894,0.0003192125],"category_scores_gemma":[0.0003021064,0.0002572924,0.0002559139,0.0010787273,0.0004225583,0.00010002963,0.00008020059,0.00034734883,0.000020145404],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95269144,0.0019262969,0.003933679,0.0002921547,0.011111738,0.007070523,0.0010767562,0.00020165322,0.010443483,0.000086159576,0.0007410841,0.010425015],"study_design_scores_gemma":[0.8167205,0.08280835,0.025898773,0.00016569588,0.036070883,0.00020180747,0.0011504943,0.0027050201,0.0030969116,0.00009094978,0.030164512,0.0009260977],"about_ca_topic_score_codex":0.00012587821,"about_ca_topic_score_gemma":0.0015521433,"teacher_disagreement_score":0.13597095,"about_ca_system_score_codex":0.00042931188,"about_ca_system_score_gemma":0.0015077967,"threshold_uncertainty_score":0.9999879},"labels":[],"label_agreement":null},{"id":"W4415082452","doi":"10.1016/j.euo.2025.08.003","title":"Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; North York General Hospital","funders":"","keywords":"Clinical trial; Bladder cancer; Research design; Clinical study design; MEDLINE; Clinical research; Standard of care","score_opus":0.09042560362667153,"score_gpt":0.38350139166491815,"score_spread":0.29307578803824663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415082452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50203145,0.00965118,0.17660676,0.17753582,0.03136511,0.019623436,0.0072203516,0.0005852721,0.07538066],"genre_scores_gemma":[0.91633034,0.053368814,0.00786612,0.015752487,0.0024308811,0.0022572514,0.0011218399,0.00008035651,0.0007919411],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967551,0.0012594663,0.00082053145,0.0007178708,0.00012832104,0.00031869975],"domain_scores_gemma":[0.9965395,0.0022829259,0.00044621804,0.00042714385,0.0001902698,0.00011399495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010276578,0.0002689492,0.0004298683,0.00012692263,0.00038260722,0.00007740264,0.00035572887,0.00018034366,0.0005652801],"category_scores_gemma":[0.0003012334,0.00020860575,0.0001616743,0.00014602033,0.0004253689,0.00011602856,0.00015191452,0.0005543244,0.00003732299],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03799913,0.0025919715,0.034725342,0.00003502261,0.011880358,0.00010202904,0.0015024489,0.00012594523,0.00010573744,0.00670712,0.3155899,0.58863497],"study_design_scores_gemma":[0.09956678,0.0071719484,0.48998678,0.000087421075,0.007967545,0.000011758432,0.002820601,0.000643964,0.000032221862,0.011792997,0.37949198,0.00042602004],"about_ca_topic_score_codex":0.00072060677,"about_ca_topic_score_gemma":0.0028894325,"teacher_disagreement_score":0.588209,"about_ca_system_score_codex":0.00018888478,"about_ca_system_score_gemma":0.0007869647,"threshold_uncertainty_score":0.85066956},"labels":[],"label_agreement":null},{"id":"W4415899361","doi":"10.1016/j.euo.2025.10.010","title":"Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Abiraterone; Prostate cancer; Placebo; Olaparib; Prostate-specific antigen; Biomarker; Population","score_opus":0.09922039059211404,"score_gpt":0.41549668792859473,"score_spread":0.31627629733648066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415899361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699649,0.013074377,0.00007862672,0.009167605,0.00047709217,0.005368272,0.00014146804,0.00009557176,0.0016320739],"genre_scores_gemma":[0.98589694,0.006759535,0.00046327608,0.000787962,0.0001101557,0.0011158842,0.00018129525,0.00008966176,0.0045952895],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99553657,0.0015746431,0.0007724518,0.001017654,0.00022537966,0.0008733179],"domain_scores_gemma":[0.9977816,0.0009840033,0.00025336104,0.00042500035,0.0003545229,0.00020155252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014150895,0.00047247848,0.0010099101,0.0006478121,0.0003163723,0.00006330387,0.00020564697,0.00015575794,0.00009602248],"category_scores_gemma":[0.0002802233,0.00036360818,0.00010346895,0.0006138616,0.0007408286,0.00014567272,0.0001367269,0.00052173977,0.00004070887],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8570793,0.00097595126,0.0030966573,0.0002539322,0.001537118,0.0029090939,0.008130124,0.0012580865,0.10663017,0.000138153,0.0017732398,0.016218172],"study_design_scores_gemma":[0.33528942,0.088599436,0.3416659,0.0003895684,0.0010898686,0.00021233897,0.0040480522,0.002708804,0.026999466,0.00056321174,0.19700423,0.0014296909],"about_ca_topic_score_codex":0.0003392497,"about_ca_topic_score_gemma":0.001221555,"teacher_disagreement_score":0.52178985,"about_ca_system_score_codex":0.0010249057,"about_ca_system_score_gemma":0.0020232003,"threshold_uncertainty_score":0.99988157},"labels":[],"label_agreement":null},{"id":"W4415899403","doi":"10.1016/j.euo.2025.10.001","title":"Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer HealthCare; Bayer Corporation; Bayer","keywords":"Docetaxel; Subgroup analysis; Placebo; Prostate cancer; Clinical trial; Prostate","score_opus":0.019614739825982806,"score_gpt":0.3182689564540624,"score_spread":0.29865421662807956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415899403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952733,0.001472522,0.000014546333,0.0009175776,0.000049425184,0.001765045,0.00007384447,0.000009929269,0.00042383806],"genre_scores_gemma":[0.9980318,0.0014944596,0.000041542957,0.00019950648,0.0000069638545,0.000020782663,0.00009506645,0.000013578299,0.00009629363],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99798584,0.00087129616,0.00046690373,0.00032157893,0.00013657569,0.00021778178],"domain_scores_gemma":[0.9990217,0.0003082566,0.00026874623,0.00021974373,0.00012812938,0.000053427026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050511165,0.00015308788,0.0007271638,0.00042370896,0.000060813916,0.000003857555,0.00006695894,0.000059130685,0.0000072832563],"category_scores_gemma":[0.000100252124,0.0000931115,0.00006130077,0.0008597785,0.00074903993,0.000032532997,0.0000752317,0.00023870652,2.9941728e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6592672,0.0029790762,0.27181777,0.0000644331,0.008996727,0.00037044074,0.006077908,0.0005421223,0.0043911804,0.00019722503,0.000054195705,0.04524172],"study_design_scores_gemma":[0.21331513,0.0060943514,0.77793175,0.000022406874,0.0015826583,0.0000038099677,0.000074247444,0.0004128539,0.00024918222,0.000019809344,0.00022846626,0.000065352884],"about_ca_topic_score_codex":0.00008897989,"about_ca_topic_score_gemma":0.0001077232,"teacher_disagreement_score":0.50611395,"about_ca_system_score_codex":0.000105225976,"about_ca_system_score_gemma":0.00024212565,"threshold_uncertainty_score":0.37969765},"labels":[],"label_agreement":null},{"id":"W4415901316","doi":"10.1016/j.euo.2025.09.018","title":"Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"University of Texas MD Anderson Cancer Center; National Institutes of Health","keywords":"Epigenomics; Renal cell carcinoma; Chromophobe cell; Renal oncocytoma; Clear cell; Oncocytoma","score_opus":0.028362661116922934,"score_gpt":0.2982851752699084,"score_spread":0.26992251415298546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415901316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702351,0.01232548,0.000018807532,0.0019243337,0.0005874751,0.0007967483,0.00006426547,0.00007311423,0.013974687],"genre_scores_gemma":[0.9944144,0.0005254484,0.000750249,0.0029154774,0.0006055209,0.00003564941,0.00016867979,0.00008099059,0.0005036223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940647,0.002329603,0.0013500914,0.0012941259,0.00017106713,0.0007904411],"domain_scores_gemma":[0.99669844,0.0014375079,0.00070924964,0.00071325473,0.000070963244,0.0003705628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082246715,0.00052887446,0.0013423034,0.00047395044,0.0001535384,0.000023111168,0.00038573274,0.00037101965,0.000120065575],"category_scores_gemma":[0.0005347848,0.00048010837,0.00023444508,0.00024484232,0.00083652994,0.00002884675,0.00050244684,0.0013917112,0.000086115695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031064416,0.0018729881,0.86178124,0.0001555849,0.00048328552,0.04655325,0.0028171549,0.00020091842,0.061254393,0.00019159596,0.0033091968,0.018273925],"study_design_scores_gemma":[0.008876971,0.0035747655,0.974434,0.000096698524,0.00050121476,0.000290895,0.00011150164,0.00014536444,0.0020479965,0.00023445593,0.009359008,0.00032709262],"about_ca_topic_score_codex":0.0008634159,"about_ca_topic_score_gemma":0.0008204546,"teacher_disagreement_score":0.11265277,"about_ca_system_score_codex":0.0008339029,"about_ca_system_score_gemma":0.0006816248,"threshold_uncertainty_score":0.99976504},"labels":[],"label_agreement":null},{"id":"W4416275632","doi":"10.1016/j.euo.2025.09.002","title":"A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Urothelial carcinoma; Urothelial cancer; Disease; Mitomycin C; MEDLINE; Carcinoma","score_opus":0.015169956557332038,"score_gpt":0.31247897854828194,"score_spread":0.2973090219909499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416275632","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13291337,0.535482,0.0025607364,0.049510345,0.0029430469,0.01636229,0.00029132466,0.00034030477,0.25959662],"genre_scores_gemma":[0.9528981,0.00521704,0.0008252101,0.03772749,0.00023307352,0.00033811518,0.000064733955,0.000057837016,0.0026384126],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796134,0.00068046286,0.0006881418,0.00030882884,0.00009168501,0.00026951046],"domain_scores_gemma":[0.9987375,0.00042767497,0.00020676453,0.0004113058,0.00015151702,0.00006523969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006754847,0.00020143154,0.0010940842,0.00015524805,0.000055728095,0.000002700953,0.00018398438,0.000103752354,0.00013853506],"category_scores_gemma":[0.00038894953,0.00015031376,0.00028260774,0.00013832268,0.00018415198,0.000027802516,0.000043697968,0.00018982012,0.000043917415],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005006053,0.0045074876,0.01962678,0.8956399,0.004911831,0.0011117428,0.002570123,0.0000016969558,0.0063333274,0.0067652347,0.035210274,0.018315539],"study_design_scores_gemma":[0.06361389,0.06139904,0.24155179,0.15454273,0.045564454,0.0049342937,0.0010360981,0.00013928814,0.004160917,0.0033486544,0.41786772,0.001841141],"about_ca_topic_score_codex":0.000011053871,"about_ca_topic_score_gemma":0.0000023307891,"teacher_disagreement_score":0.81998473,"about_ca_system_score_codex":0.00007736772,"about_ca_system_score_gemma":0.0003385199,"threshold_uncertainty_score":0.6129617},"labels":[],"label_agreement":null},{"id":"W4416405197","doi":"10.1016/j.euo.2025.09.010","title":"Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Abiraterone; Olaparib; Placebo; Prostate cancer; Clinical trial","score_opus":0.061145733419048894,"score_gpt":0.38868008007266386,"score_spread":0.32753434665361497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416405197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729337,0.0005607548,0.00005735044,0.008722485,0.0003430406,0.009707599,0.00006692357,0.000071456045,0.00753666],"genre_scores_gemma":[0.9910542,0.0000864748,0.00020173052,0.0010773146,0.000052268086,0.002395998,0.00015877432,0.000060745126,0.0049125417],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957726,0.0015779356,0.0008268081,0.00076119386,0.00031627086,0.0007451756],"domain_scores_gemma":[0.9981194,0.00056194904,0.00033315504,0.0005571054,0.00030285513,0.0001255213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012498532,0.0004030144,0.00093000673,0.00031323946,0.00026623058,0.0000485563,0.00025908288,0.000081379985,0.000055582834],"category_scores_gemma":[0.00020802785,0.0002322174,0.00007690226,0.00045858274,0.00041489565,0.0001048661,0.000101196856,0.00051604206,0.000017574954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77249074,0.01344068,0.057645634,0.00056975696,0.009204771,0.019137535,0.0591634,0.0017644925,0.009494511,0.00019566574,0.015134322,0.041758474],"study_design_scores_gemma":[0.5932741,0.11551268,0.2234197,0.00017107287,0.004381264,0.00017462642,0.020404909,0.0022445966,0.0008897143,0.00007364006,0.038568385,0.00088530564],"about_ca_topic_score_codex":0.00036081744,"about_ca_topic_score_gemma":0.002207151,"teacher_disagreement_score":0.17921664,"about_ca_system_score_codex":0.0007317801,"about_ca_system_score_gemma":0.0016000374,"threshold_uncertainty_score":0.9469551},"labels":[],"label_agreement":null}]}